Methods and kits for inducing immune tolerance to gene delivery target agents
By administering nucleic acid vectors encoding immunosuppressants into gene therapy, immune tolerance is induced, solving the problem of immune response in recombinant viral vectors and enabling effective repeated administration of gene therapy and therapeutic efficacy.
Patent Information
- Application Number
- CN202180093128.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-12-07
- Filing Date
- 2021-12-06
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2041-12-06
AI Technical Summary
In existing gene therapies, the immunogenicity of recombinant viral vectors such as AAV vectors leads to an immune response in the host, which limits the effectiveness of the therapy. In particular, when repeated gene delivery therapy is used, it is necessary to suppress the immune response against AAV in order to improve rAAV transduction.
Immune tolerance can be induced by administering an inducer nucleic acid vector encoding an immunosuppressant to the subject, thereby suppressing the immune response to the target agent. This includes using an inducer nucleic acid vector encoding a CTLA-4 or CD40 derivative to modulate the immune stimulation and inhibition pathways and reduce the immune response to the target agent.
It induced immune tolerance to the target agent in subjects, reduced the immune response to the target agent, improved the effectiveness of gene therapy, and allowed for repeated administration of the target agent for treatment.
Smart Images

Figure CN117642173B_ABST
Abstract
Description
Technical Field
[0001] This disclosure generally relates to the field of gene therapy, and more specifically to methods and kits for inducing immune tolerance to a target agent for gene therapy in subjects of need. More specifically, this disclosure relates to methods and kits for inducing immune tolerance to a viral vector carrying a transgene. Background Technology
[0002] Recombinant vectors, such as recombinant viral vectors, have been widely used as powerful tools for delivering exogenous genes in animals and / or humans, and have achieved some success in treating human diseases such as Duchenne muscular dystrophy (DMD), hemophilia B, Parkinson's disease, and α1-antitrypsin deficiency.
[0003] However, an undesirable problem exists in subjects receiving gene therapy using these target gene delivery vectors: the host produces pre-existing or induced immune responses against these potentially immunogenic gene delivery vectors, most notably neutralizing antibodies (NAbs) against certain viral packaging proteins (e.g., capsid) and / or transgenic products. This severely limits the effectiveness of these therapies, especially repeated gene delivery therapy using the same target gene delivery vector.
[0004] In the case of adeno-associated virus (AAV), although naturally occurring AAV is considered nonpathogenic and capable of infecting a wide range of human tissues and organs, infection can induce humoral and cellular immunity. AAV neutralizing antibodies have been shown to be present in nearly half of all human populations. Furthermore, AAV NAbs are frequently induced during the first treatment with AAV gene therapy. These antibodies against the AAV capsid and / or transgenic product limit the efficacy of recombinant AAV (rAAV) as a drug delivery medium. Previous studies have shown that NAbs generated from the first administration significantly inhibit transgenic expression in rabbit lungs following re-administration of rAAV. However, given the limited tropism, seropositivity rate, and serotype vector production, repeated administration of rAAV gene therapy may be essential for some genetic diseases requiring long-term treatment. Therefore, there is a strong need to suppress the immune response against AAV to improve rAAV transduction and enable repeated administration of rAAV during gene therapy. Similar observations have been made regarding other non-AAV vectors. Summary of the Invention
[0005] In view of the aforementioned problems with pre-existing or induced host immunity against these gene delivery vectors, this disclosure provides methods and kits for inducing host immune tolerance against immunogenic gene delivery target agents, or more specifically, reducing unwanted host immunity against said immunogenic gene delivery target agents containing a target vector that expresses and encodes a target therapeutic protein or nucleic acid.
[0006] In a first aspect, a method is provided for inducing immune tolerance to an immunogenic target agent for gene delivery in a subject. The method includes the steps of: a) administering the immunogenicity inducer agent to the subject.
[0007] In this document, the subject administered the immunogenic target agent can be any animal with an immune response to a foreign immunogen, such as an immunogenic target agent used for gene delivery, including innate and / or adaptive immune responses. Optionally, the subject can be an antibody-producing animal, such as a vertebrate. Further optionally, the subject can be a warm-blooded mammal such as a primate, dog, cat, cattle, horse, sheep, goat, rabbit, rat, and mouse. Further optionally, the subject can be a primate. In some embodiments, the subject can be a human.
[0008] In the methods disclosed herein, the immunogenicity inducer mediator comprises an inducer nucleic acid vector encoding at least one immunosuppressant, thereby allowing the at least one immunosuppressant to be expressed in a subject, which inhibits the immune response in the subject against the inducer mediator. Furthermore, the immune response is cross-reactive to the target mediator.
[0009] In some embodiments of the method, the immune response includes a host innate immune response and / or a host adaptive immune response. Optionally, the immune response includes generating at least one antibody capable of binding to the inducer mediator. More optionally, the immune response includes generating at least one antibody capable of binding to and neutralizing the inducer mediator. More optionally, the at least one antibody includes one or more antibodies that are cross-reactive to the target mediator.
[0010] In some embodiments of the method, the inducer medium comprises inducer virus particles, and the target medium comprises target virus particles. Further optionally, each of the inducer virus particles and the target virus particles may include a capsid. Further optionally, the subject's immune response comprises generating at least one antibody capable of binding to the capsid of the inducer virus particles, and further optionally, the at least one antibody is cross-reactive to the capsid of the target virus particles.
[0011] In each embodiment of the method comprising viral particles, including the inducer and target viral particles, optionally, both the inducer and target viral particles may have the same type of virus, and said type of virus may be selected from the group consisting of adenovirus, adeno-associated virus (AAV), lentivirus, retrovirus, and oncolytic virus. In some embodiments, said type of virus is adeno-associated virus (AAV).
[0012] In this study, the inducer virus particles and the target virus particles may have the same serotype. Alternatively, they may have different serotypes that exhibit cross-reactivity.
[0013] Optionally in this article, each of the inducer virus particles and the target virus particles includes the same capsid protein.
[0014] In any of the embodiments of the methods described above, the at least one immunosuppressant may act by downregulating the immune stimulation pathway and / or by upregulating the immunosuppressive pathway.
[0015] In some embodiments of the method, one or more of the at least one immunosuppressant reduces the expression or activity of one or more immunomodulators in the immune stimulation pathway, and optionally each of the one or more immunomodulators is selected from the group consisting of: CD27, CD70, CD28, CD80 (B7-1), CD86 (B7-2), CD40, CD40L (CD154), CD122, CD137, CD137L, OX40 (CD134), OX40L (CD252), GITR, ICOS (CD278), and ICOSLG (CD275). In this document, the one or more immunomodulators may be in at least one of the B7 / CD28 co-stimulatory signaling pathway or the CD40 / CD40L co-stimulatory signaling pathway. In addition, each of the one or more immunomodulators may be selected from the group consisting of: CD28, CD80 (B7-1), CD86 (B7-2), CD40, and CD40L (CD154).
[0016] In some embodiments of the method, one or more of the at least one immunosuppressant increases the expression or activity of one or more immunosuppressive modulators in the immunosuppressive pathway, and optionally each of the one or more targets is selected from the group consisting of: A2AR, B7-H3 (CD276), B7-H4 (VTCN1), BTLA (CD272), CTLA-4 (CD152), IDO1, IDO2, TDO, KIR, LAG3, NOX2, PD-1, PD-L1, PD-L2, TIM-3, VISTA, SIGLEC7 (CD328), TIGIT, PVR (CD155), and SIGLEC9 (CD329).
[0017] In some embodiments of the method, the at least one immunosuppressant regulates the expression or activity of at least one of TLR2, TLR9, MyD88, IFN-1, IRF-7, NF-κB, mTOR, CD3, CD4, CD278, CD19, CD20, CD79, IL-4, IL-2R, IL-5, IL-6R, TNF-α, or LFA-1.
[0018] In some embodiments of the method, the at least one immunosuppressant downregulates the B7-CD28 immune stimulation pathway and / or downregulates the CD40 and CD40L immune stimulation pathways. In this document, the at least one immunosuppressant may inhibit the binding or signaling of CTLA-4 and CD80 (B7-1) or CD86 (B7-2); and / or may inhibit the binding or signaling of CD40 and CD40L (CD154).
[0019] Furthermore, in some embodiments, the at least one immunosuppressant may compete with CD28 for binding to B7, or compete with B7 for binding to CD28. In other embodiments, the at least one immunosuppressant may compete with CD40 for binding to CD40L, or compete with CD40L for binding to CD40.
[0020] In the above embodiments of the method, the at least one immunosuppressant may include at least one immunosuppressive protein.
[0021] In this document, according to certain embodiments, the at least one immunosuppressive protein includes a CTLA-4 derivative and / or a CD40 derivative. Furthermore, the at least one immunosuppressive protein may optionally include: an extracellular domain of CTLA-4 or a fragment thereof capable of binding to at least one of CD80 (B7-1) or CD86 (B7-2); and / or an extracellular domain of CD40 or a fragment thereof capable of binding to CD40L (CD154).
[0022] Additionally, according to certain embodiments, each of the at least one immunosuppressive protein further includes a half-life-extending peptide portion. In this document, according to certain embodiments, the half-life-extending peptide portion may include Fc.
[0023] In any implementation of the methods described above, the at least one immunosuppressant may include at least one immunosuppressive nucleic acid.
[0024] In some embodiments of the method, step a) further comprises administering to the subject at least one additional inducer medium, wherein each of the at least one additional inducer medium comprises an inducer nucleic acid vector encoding at least one additional immunosuppressant. Optionally herein, each of the at least one immunosuppressant and the at least one additional immunosuppressant acts on a different immunomodulator.
[0025] In some embodiments of the method, step a) further comprises: administering to the subject at least one immunosuppressive agent, each immunosuppressive agent capable of inhibiting the activity of a target in an immune stimulation pathway or enhancing the activity of a target in an immunosuppressive pathway. In this document, each of the at least one immunosuppressive agent may be a compound, a nucleic acid, a peptide, or a combination thereof. Further optionally, each of the at least one immunosuppressive agent and the at least one immunosuppressive agent has a different target.
[0026] In any embodiment of the claims described above, the target agent may include a target nucleic acid vector encoding at least one target gene, each target gene encoding a therapeutic protein or a therapeutic nucleic acid.
[0027] In any embodiment of the claims described above, the subject may not have a pre-existing immune response to the inducer medium or the target medium, or both. Optionally herein, the pre-existing immune response may include an immune response to the capsid of the inducer virus particles of the inducer medium or to the capsid of the target virus particles of the target medium, or both.
[0028] Optionally, the pre-existing immune response may be characterized prior to step a) by the subject's serum having an antibody titer of at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 against the anti-mediator antibody, wherein the antibody titer is defined as the dilution factor by which the subject's serum produces threshold-specific binding to the inducer mediator or the target particle. Binding to the inducer mediator or target mediator may optionally be measured by enzyme-linked immunosorbent assay (ELISA). In some embodiments, threshold-specific binding is determined based on antibody binding in the presence of a given amount of mediator, wherein threshold-specific binding is considered sufficient to indicate an antibody binding level specifically binding to the mediator.
[0029] Further optionally, the pre-existing immune response may be characterized by, prior to step a), the subject's serum having a neutralizing antibody titer of at least 2, 4, 6, 8, 18, or 32, wherein the antibody titer is defined as the dilution factor by which the subject's serum produces a maximum neutralization of 50% of the inducer or target agent. Neutralization of the inducer or target agent may optionally be measured by a reporting assay.
[0030] In any embodiment of the method described above, the immune tolerance may be characterized by, after step a), the antibody titer of the anti-mediator antibody in the subject's serum not exceeding 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200, and wherein the antibody titer is defined as the dilution factor by which the subject's serum produces threshold-specific binding to the inducer mediator or the target mediator. Binding to the inducer mediator or target mediator may optionally be measured by ELISA. In some embodiments, threshold-specific binding is determined based on a given amount of mediator, wherein threshold-specific binding is considered sufficient to indicate the level of antibody binding specifically to the mediator.
[0031] In any embodiment of the method described above, the immune tolerance may be characterized by, after step a), the antibody titer of neutralizing antibodies in the subject's serum not exceeding 2, 4, 6, 8, 18, or 32, and wherein the antibody titer is defined as the dilution factor by which the subject's serum produces a maximum neutralization of 50% of the inducer or target agent. Neutralization of the inducer or target agent may optionally be measured by reporter gene assay.
[0032] In a second aspect, this disclosure further provides a method for expressing a target gene in a subject using an immunogenic target agent comprising a target vector encoding the target gene, wherein the subject exhibits pre-existing immune tolerance to the immunogenic target agent. The method comprises the steps of: a) administering the immunogenic target agent to the subject. Prior to step a), the pre-existing immune tolerance has been induced by exposing the subject to an immunogenic inducer agent comprising an inducer nucleic acid vector encoding at least one immunosuppressant, thereby allowing the expression of the at least one immunosuppressant in the subject to allow suppression of an immune response that is cross-reactive against the inducer agent and to a target viral agent.
[0033] In a third aspect, this disclosure further provides a method for expressing a target gene in a subject using an immunogenic target agent, said immunogenic target agent comprising a target vector encoding said target gene. The method comprises the following two steps:
[0034] a) Administering an immunogenicity inducer mediated to the subject, thereby allowing the expression of the at least one immunosuppressant in the subject, the immunogenicity inducer mediated comprising an inducer nucleic acid vector encoding at least one immunosuppressant, the at least one immunosuppressant inhibiting an immune response against the inducer mediated and cross-reactive to the target mediated, thereby inducing immune tolerance to the target mediated in the subject; and
[0035] b) Administer the target agent to the subject who has induced immune tolerance, thereby expressing the target gene in the subject.
[0036] In a fourth aspect, this disclosure further provides a method for treating a subject's condition with an immunogenic target agent comprising a target vector encoding a target gene capable of treating the condition, wherein the subject has pre-existing immune tolerance to the target agent. The method comprises the steps of: a) administering the target agent to the subject, thereby expressing the target gene in the subject to treat the condition. In this document, prior to step a), the pre-existing immune tolerance has been induced by exposing the subject to an immunogenic inducer agent comprising an inducer nucleic acid vector encoding at least one immunosuppressant, thereby allowing suppression of an immune response against the inducer agent and cross-reactive to the target agent.
[0037] In a fifth aspect, this disclosure further provides a method for treating a subject's condition using an immunogenic target agent, said immunogenic target agent comprising a target vector encoding a target gene capable of treating said condition. The method comprises the following two steps:
[0038] a) Administering an immunogenicity inducer mediator to the subject, the immunogenicity inducer mediator comprising an inducer nucleic acid vector encoding at least one immunosuppressant, thereby allowing the expression of the at least one immunosuppressant in the subject, the immunogenicity inducer mediator comprising an inducer nucleic acid vector encoding at least one immunosuppressant, the at least one immunosuppressant inhibiting an immune response against the inducer mediator and cross-reactive to the target mediator, thereby inducing immune tolerance to the target mediator in the subject; and
[0039] b) Administer the target agent to the subject who has induced immune tolerance, thereby expressing the target gene in the subject to treat the condition.
[0040] In any of the methods provided in the second, third, fourth, and fifth aspects of this disclosure as described above, step a) of administering the target agent to the subject includes repeatedly administering the target agent to the subject.
[0041] Furthermore, in any of the methods provided in the second, third, fourth, and fifth aspects of this disclosure as described above, various embodiments of the inducer, the at least one immunosuppressant, the target agent, the immune response, and the immune tolerance can be referenced to various embodiments of the methods provided in the first aspect of this disclosure, the description of which is omitted here for the sake of brevity.
[0042] In a sixth aspect, this disclosure further provides a kit for inducing immune tolerance to an immunogenic target agent to be administered in a subject.
[0043] The kit includes a first pharmaceutical composition comprising a therapeutically effective amount of an inducer medium, and the inducer medium comprising at least one inducer nucleic acid vector. Each of the at least one inducer nucleic acid vector encodes and is configured to allow expression of at least one immunosuppressant in a subject. Each of the at least one immunosuppressant is configured to suppress an immune response in a subject against the inducer medium when expressed in the subject, and the immune response is cross-reactive to the target medium.
[0044] In some embodiments of the kit, the inducer medium comprises inducer virus particles, and the target medium comprises target virus particles. Optionally herein, each of the inducer virus particles and the target virus particles comprises a capsid. The immune response may include generating at least one antibody capable of binding to the capsid of the inducer virus particles. The at least one antibody may be cross-reactive to the capsid of the target virus particles.
[0045] In some embodiments of the kit, both the inducer virus particles and the target virus particles have the same type of virus. In this document, the type of virus can be selected from the group consisting of adenoviruses, adeno-associated viruses (AAVs), lentiviruses, retroviruses, and oncolytic viruses. Further, according to some embodiments, the type of virus is adeno-associated virus (AAV).
[0046] Optionally, the inducer virus particles and the target virus particles may have the same serotype or may have different serotypes.
[0047] In some implementations, each of the inducer virus particles and the target virus particles includes the same capsid protein.
[0048] In any of the embodiments of the kit described above, the at least one immunosuppressant works by downregulating the immune stimulation pathway and / or by upregulating the immunosuppressive pathway.
[0049] In some embodiments of the kit, one or more of the at least one immunosuppressant reduces the expression or activity of one or more targets in the immune stimulation pathway, and optionally each of the one or more targets is selected from the group consisting of: CD27, CD70, CD28, CD80 (B7-1), CD86 (B7-2), CD40, CD40L (CD154), CD122, CD137, CD137L, OX40 (CD134), OX40L (CD252), GITR, ICOS (CD278), and ICOSLG (CD275). In some embodiments, the one or more targets are in at least one of the B7 / CD28 co-stimulatory signaling pathway or the CD40 / CD40L co-stimulatory signaling pathway. Optionally herein, each of the one or more targets is selected from the group consisting of: CD28, CD80 (B7-1), CD86 (B7-2), CD40, or CD40L (CD154).
[0050] In some embodiments of the kit, one or more of the at least one immunosuppressant increases the expression or activity of one or more targets in the immunosuppressive pathway, and optionally each of the one or more targets is selected from the group consisting of: A2AR, B7-H3 (CD276), B7-H4 (VTCN1), BTLA (CD272), CTLA-4 (CD152), IDO1, IDO2, TDO, KIR, LAG3, NOX2, PD-1, PD-L1, PD-L2, TIM-3, VISTA, SIGLEC7 (CD328), TIGIT, PVR (CD155), and SIGLEC9 (CD329).
[0051] In some embodiments of the kit, the at least one immunosuppressant regulates the expression or activity of at least one of TLR2, TLR9, MyD88, IFN-1, IRF-7, NF-κB, mTOR, CD3, CD4, CD278, CD19, CD20, CD79, IL-4, IL-2R, IL-5, IL-6R, TNF-α, or LFA-1.
[0052] In any embodiment of the kit described above, the at least one immunosuppressant comprises at least one immunosuppressive protein. Optionally herein, the at least one immunosuppressive protein comprises: an extracellular domain of CTLA-4 or a fragment thereof capable of binding to at least one of CD80 (B7-1) or CD86 (B7-2); and / or an extracellular domain of CD40 or a fragment thereof capable of binding to CD40L (CD154). Further optionally, each of the at least one immunosuppressive protein further comprises a half-life-extending peptide moiety. In some embodiments, the half-life-extending peptide moiety comprises Fc.
[0053] In any of the embodiments of the kit described above, the at least one immunosuppressant comprises at least one immunosuppressive nucleic acid.
[0054] In any of the embodiments of the kit described above, each of the inducer and the target agent may include viral particles. In some embodiments, the viral particles are derived from adeno-associated virus (AAV). In some embodiments, AAV is generated in a suitable cell line, including but not limited to HeLa, HEK293, or variants thereof.
[0055] In any of the embodiments described above, the kit may further include a first instruction manual for administering the first pharmaceutical composition to a subject.
[0056] In any of the embodiments described above, the kit may further include a first detection kit for determining whether immune tolerance has been induced in the subject after administration of the first pharmaceutical composition. Hereinafter, the immune response may optionally include generating at least one anti-mediator antibody and / or at least one neutralizing antibody capable of binding to the inducing mediator and having cross-reactivity with the target mediator, and the first detection kit may include at least one first reagent configured to allow determination of titers of one or more anti-mediator antibodies and / or one or more neutralizing antibodies in the subject's serum.
[0057] In some embodiments, the kit further includes a second detection kit comprising at least one second reagent configured to allow detection of the expression of each of the at least one immunosuppressant in the subject.
[0058] In any of the embodiments described above, the kit may further include a second pharmaceutical composition comprising a therapeutically effective amount of the target agent.
[0059] In this document, the kit may further include a second instruction manual for administering the second pharmaceutical composition to the subject. The second instruction manual further includes a first sub-instruction manual for administering the second pharmaceutical composition to the subject after administration of the first pharmaceutical composition. The second instruction manual may further include a second sub-instruction manual for repeating the administration of the second pharmaceutical composition.
[0060] In some embodiments of the kit, the target agent includes a target vector that encodes a target gene and is configured to allow expression of the target gene in a subject.
[0061] In some embodiments, the kit further includes a third detection kit comprising at least one third reagent configured to allow detection of the expression of the target gene in the subject.
[0062] In a seventh aspect, this disclosure further provides a kit for expressing a target gene in a subject.
[0063] The kit includes a pharmaceutical composition and instructions for administering the pharmaceutical composition. The pharmaceutical composition comprises an immunogenic target medium, the immunogenic target medium comprising a target vector encoding the target gene and configured to allow expression of the target gene in the subject. The instructions for administering the pharmaceutical composition to the subject include a method for inducing immune tolerance to the target medium prior to administration of the pharmaceutical composition to the subject. Hereinafter, the method comprises: a) administering an immunogenic inducer medium to the subject. Hereinafter, the inducer medium comprises an inducer nucleic acid vector encoding at least one immunosuppressant, thereby allowing expression of the at least one immunosuppressant in the subject, the at least one immunosuppressant inhibiting the immune response in the subject against the inducer medium. Furthermore, the immune response is cross-reactive to the target medium.
[0064] The kit may optionally further include a first assay kit for determining whether immune tolerance to the target agent is induced in the subject. In this document, the immune response may include generating at least one anti-target agent antibody or at least one neutralizing antibody capable of binding to the inducing agent and having cross-reactivity with the target agent, and the first assay kit includes at least one first reagent configured to allow determination of the titer of one or more of the anti-target agent antibodies and / or neutralizing antibodies in the subject's serum.
[0065] In any embodiment of the kit in the seventh aspect, the kit further includes a second detection kit comprising at least one second reagent configured to allow detection of the expression of each of the at least one immunosuppressant in the subject.
[0066] In any embodiment of the kit in the seventh aspect, the kit may further include a third detection kit, wherein the third detection kit includes at least one third reagent configured to allow detection of the expression of the target gene in the subject.
[0067] In any embodiment of the kit in the seventh aspect, the kit may further include instructions for use, and further include a sub-instructions for use of the pharmaceutical composition for repeated administration.
[0068] In an eighth aspect, this disclosure further provides a kit for expressing a target gene in a subject using an immunogenic target agent that encodes the target gene.
[0069] The kit comprises a first pharmaceutical composition and a second pharmaceutical composition, the first pharmaceutical composition being used to induce immune tolerance to the target agent in the subject, and the second pharmaceutical composition comprising a target agent including a target vector encoding a target gene. The first pharmaceutical composition comprises an inducer agent, the inducer agent including at least one inducer nucleic acid vector, each inducer nucleic acid vector encoding and configured to allow expression of at least one immunosuppressant in the subject. Each of the at least one immunosuppressant is configured to suppress the immune response against the inducer agent in the subject when expressed. In this document, the immune response is cross-reactive to the target agent.
[0070] The kit may further include a first detection kit for determining whether immune tolerance has been induced in the subject after administration of the first pharmaceutical composition. In this document, an immune response includes the production of at least one antibody capable of binding to an inducer and cross-reactive to a target agent, and the first detection kit includes at least one first reagent configured to allow determination of the titer of one or more of the at least one antibody in the subject's serum.
[0071] In any embodiment of the kit in the eighth aspect, the kit further includes a second detection kit comprising at least one second reagent configured to allow detection of the expression of each of the at least one immunosuppressant in the subject.
[0072] In any embodiment of the kit in the eighth aspect, the kit may further include a third detection kit comprising at least one third reagent configured to allow detection of the expression of the target gene in the subject.
[0073] In any embodiment of the kit in the seventh aspect, the kit may further include a first instruction for administering the first pharmaceutical composition; and a second instruction for administering the second pharmaceutical composition. Optionally herein, the second instruction may further include a first sub-instruction for administering the second pharmaceutical composition to the subject after administering the first pharmaceutical composition. Further optionally, the second sub-instruction may further include a second sub-instruction for repeating the administration of the second pharmaceutical composition.
[0074] In any embodiment of the kit described in aspects six, seven, and eight, the kit may further comprise a third pharmaceutical composition comprising at least one immunosuppressive agent, each immunosuppressive agent capable of inhibiting the activity of a target in an immune stimulation pathway or enhancing the activity of a target in an immunosuppressive pathway. In this document, each of the at least one immunosuppressive agent may comprise a compound, a nucleic acid, a peptide, or a combination thereof. In some embodiments, each of the at least one immunosuppressive agent and each of the at least one immunosuppressive agent has a different target.
[0075] The foregoing overview is illustrative only and is not intended to be limiting in any way. In addition to the illustrative aspects, embodiments, and features described above, further aspects, embodiments, and features will become apparent from the accompanying drawings and the following detailed description. Attached Figure Description
[0076] Figure 1A-1E The transgenic expression of AAV8 mediated in vitro and in vivo is shown, in which Figure 1A The AAV vector plasmids pAAV-CTLA4-Ig and pAAV-CD40-Ig were demonstrated; Figure 1B Western blot results for the proteins CTLA4-Ig or CD40-Ig with a molecular weight of 56 kDa are shown. pAAV-CTLA4-Ig or pAAV-CD40-Ig were transiently transfected into HEK293 cells with PEI, and the culture medium and cells were collected for Western blotting 72 hours later. GAPDH was used as a reference protein for quantification, and untransfected cells were used as negative controls (NC). Figure 1C Western blot results for proteins CTLA4-Ig or CD40-Ig are shown, in which HUH-7 cells were infected with AAV8-CTLA4-Ig or AAV8-CD40-Ig virus, and after 72 hours, the culture medium and cells were collected for Western blot, in which untransfected cells were used as NC; Figure 1D or Figure 1E Serum CTLA4-Ig or CD40-Ig levels, determined by ELISA, were shown in 6-8 week old C57BL / 6J WT male mice administered two doses of 4 × 10⁻⁶ intravenously. 12 vg / kg (high dose, HD) and 4×10 11 vg / kg (medium dose, MD) of AAV8-CTLA4-Ig or AAV8-CD40-Ig, where each value represents the mean ± SD (n = 5); and Figure 1FThe AAV8 vector was demonstrated to be delivered to the muscle and liver via intravenous (iv) or intramuscular (im) injection, with C57BL / 6J mice receiving 4 × 10⁴ lbs via hindlimb iv or im injection. 12 vg / kg AAV8-GFP, and after two weeks, muscle and liver tissues were obtained for GFP fluorescence expression, where frozen muscle sections are shown in sagittal and cross shapes, where FITC represents GFP and DAPI represents cell nuclei, untreated mice serve as the control group, and the scale bar is 100 μm.
[0077] Figure 2A-2D This indicates that CTLA4-Ig and CD40-Ig treatments effectively inhibit antibody responses against the AAV8 vector, among which... Figure 2A The study design outline is shown, in which, in the first administration, C57BL / 6J mice (n=5, per group) were intravenously injected with two doses of AAV8-CTLA4-Ig, AAV8-CD40-Ig, AAV8-GFP, or AAV8-CTLA4-Ig + AAV8-CD40-Ig, as described in the table, 4 × 10⁻⁶. 12 vg / kg (high dose, HD) and 4×10 11 Mice were administered 6 × 10⁶ vg / kg (medium dose, MD) intravenously, with mice receiving AAV8-GFP as the control group and mice without the AAV vector as the untreated control. In the second and third administration experiments at 8 and 15 weeks, respectively, mice in all groups were injected intravenously with 6 × 10⁶ vg / kg. 11 Mice were exposed to vg / kg of AAV8-GFP, and then bled weekly after exposure to the AAV vector to collect serum for antibody assays for 19 weeks. Figure 2B The results of weekly AAV8 neutralizing antibody (NAb) titers are shown; Figure 2C The results of the anti-AAV8 IgG antibody assay are shown, which was performed by ELISA, with repeated testing of each serum sample; and Figure 2D The correlation between NAb titer and anti-AAV8 IgG antibody was shown (linear regression: n=5, R=0.8451, p<0.0001), where crossover refers to the AAV injection time point.
[0078] Figures 3A-3D This indicates that AAV8-CTLA4-Ig or AAV8-CD40-Ig immunomodulatory therapy does not impair humoral immunity in mice. Figure 3A The ELISA results for total mouse IgG in serum are shown, with serum samples collected weekly from mice (n=5 per group) starting from the second administration of the AAV vector, and each serum sample was tested repeatedly (n=2). Figure 3B ,3C The results of the assays for cytokines including TNF-α, IL-4, and IL-10 in mouse plasma, as shown in Figures 2 and 3D, were obtained using Luminex, with plasma samples obtained on days 4 and 7 after the third administration of the AAV vector. Each value represents mean ± SD, and each serum sample was tested repeatedly (n = 2).
[0079] Figure 4A , 4B 4C, 4D, and 4E illustrate transgene expression in the liver and muscle via repeated administration of the AAV8 vector at high or moderate doses via intravenous injection (iv). Figure 4A and 4B The transgene expressing GFP is shown, in mice such as Figure 2A The mice were injected as described in the study. At the end of the study, all mice in all groups died. Mouse livers and muscles were obtained for GFP fluorescence expression. GFP (shown in green) and cell nuclei were stained with DAPI (blue). Untreated mice served as an untreated control group. Scale bar, 100 μm. Figure 4D and 4E The expression transgene of GLUC is shown, in mice such as Figure 4C The mice were injected as described in the study, and plasma was collected during the study to measure GLUC expression.
[0080] Figures 5A-5C This indicates that AAV8-CTLA4-Ig or AAV8-CTLA4-Ig + AAV8-CD40-Ig treatment provides antigen-selective tolerance to the AAV8 vector, and long-term expression of CTLA4-Ig and CD40-Ig inhibits antibodies against other serotypes of AAV (AAV843). Figure 5A The study design outline is shown, in which mice were intravenously injected with 4 × 10⁴ AAV at week 20 of AAV administration. 12 Mice were expressed at vg / kg with AAV843 (AAV843-GLUC) containing Gaussian luciferase, and blood was expelled weekly to obtain plasma or serum. Figure 5B The results of NAb titer determinations for the AAV8 and AAV843 vectors are shown (*P<0.05, **P<0.01); and Figure 5C The results of relative optical units (RLU) of GLUC expression in mouse plasma are shown. Each serum sample was tested repeatedly. Each value represents the mean ± SD (n = 5).
[0081] Figures 6A-6EThis study demonstrates the effects of CTLA4-Ig and CD40-Ig immunomodulatory therapy on cellular immunity in mice, with flow cytometry used to explore CD40-Ig. + T cells, B220 + CD19 + B cells, CD4 + GL7 + T cells and CD25 + FoxP3 + Regulates the frequency of T cells (Tregs), which are monocytes from the peripheral blood (PBMCs) or spleen of mice immunomodulated by treated AAV8-CTLA4-Ig or AAV8-CD40-Ig: Figure 6A CD4 is shown + T cells and B220 + CD19 + The percentage of B cells was determined 2 weeks after AAV administration; Figure 6B The results of Treg cell percentage determination are shown, which were measured at 2 and 7 weeks after AAV administration (**P<0.01); Figure 6C CD4 is shown + GL7 + The percentage of T cells was determined at 17 weeks after AAV administration; Figure 6D-6F CD4 is shown + T cells, B220 + CD19 + The results of the B cell and Treg percentage measurements were obtained 25 weeks after AAV administration; and Figure 6G The B220 values in the AAV8-CTLA4-Ig HD group and the AAV8-CTLA4-Ig+AAV8-CD40-Ig HD group are shown respectively. + CD19 + Changes in B cells between 2 and 25 weeks. (n = 3–5). *P < 0.05, **P < 0.01.
[0082] Figures 7A-7B The sequence disclosed in this disclosure is shown. Detailed Implementation
[0083] In the following detailed description, reference is made to the accompanying drawings, which are intended to accompany the various embodiments provided herein and are intended to form a part of the description of the embodiments. Unless the context otherwise indicates or specifies, similar symbols in the drawings generally identify similar components in the description.
[0084] All descriptions provided herein are intended to illustrate various embodiments of the invention and are not intended to be limiting. It will be apparent to those skilled in the art that various equivalents, changes, and modifications can be made without departing from the scope of this disclosure, and it should be understood that such equivalent embodiments are included herein.
[0085] It should be understood that certain features of this disclosure described in the context of individual embodiments for clarity may also be provided in combination in a single embodiment. Conversely, various features of this disclosure described in the context of individual embodiments for brevity may also be provided individually or in any suitable sub-combination. For illustration, if a particular embodiment disclosed herein includes components A, B, and C, it should be understood that this disclosure is also intended to include embodiments containing only A, B, or C, or any combination of A, B, or C.
[0086] All references cited in this disclosure, including patent applications, granted patents, published articles, or other publications, are incorporated herein by reference in their entirety, with the aim of providing methods that can be used in conjunction with the descriptions provided herein. Any terminology presented in one or more publications that is similar to or identical to the terminology expressly defined in this disclosure shall, in all respects, be subject to the terminology definitions expressly provided in this disclosure.
[0087] Unless otherwise expressly defined, all technical and scientific terms used in this disclosure are generally considered to have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains.
[0088] I. definition
[0089] Before providing a detailed description of the invention in this disclosure, note and define the following.
[0090] As used herein, and throughout this publication, unless otherwise stated, the articles “a,” “an,” and “the” will be interpreted as meaning “one or more” or “at least one.” For example, “a gene” can mean one gene or more than one gene.
[0091] As used herein, unless otherwise expressly stated, any range of numbers described herein may include the range and each number within each subrange.
[0092] As used herein, the terms “about,” “approximately,” “around,” etc., refer to a quantity, level, value, number, frequency, percentage, size, volume, weight, or length that varies relative to a reference quantity, level, value, number, frequency, percentage, size, volume, weight, or length by as much as 30%, 25%, 20%, 25%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%. In certain embodiments, the terms “about” or “approximately” preceding a numerical value indicate a range of said value plus or minus 15%, 10%, 5%, or 1%.
[0093] As used herein, the term "polypeptide" is used interchangeably with "peptide," "protein," etc., and refers to a polymer of amino acid residues or an assembly of polymers of multiple amino acid residues. The term is applicable to both naturally occurring and non-naturally occurring amino acid polymers, and is interpreted to also cover amino acid polymers in which one or more amino acid residues are artificial or synthetic chemical mimics of their corresponding naturally occurring amino acids. The term "protein" generally refers to a large polypeptide. The term "peptide" generally refers to a short polypeptide. A polypeptide sequence is generally described as having an amino-terminal (N-terminus) on the left and a carboxyl-terminus (C-terminus) on the right.
[0094] As used herein, the term "nucleic acid" refers to oligonucleotides or polynucleotides such as deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), and further should be interpreted to include equivalents, derivatives, variants, and analogs of RNA or DNA made of nucleotide analogs, single-stranded (sense or antisense), and double-stranded polynucleotides. It should be understood that the term "nucleic acid" does not refer to or infer a specific length of polynucleotide chain; therefore, nucleotides, polynucleotides, and oligonucleotides are also included in the definition.
[0095] The "percentage of sequence identity (%)" for an amino acid sequence (or nucleic acid sequence) is defined as the percentage of amino acid (or nucleic acid) residues in a candidate sequence that are identical to those in a reference sequence after alignment, and, where necessary, the introduction of vacancies to achieve the maximum number of identical amino acids (or nucleic acids). Conservative substitutions of amino acid residues may or may not be considered identical residues. Alignments performed for the purpose of determining the percentage of amino acid (or nucleic acid) sequence identity can be performed, for example, using publicly available tools such as BLASTN, BLASTp (available on the website of the US National Center for Biotechnology Information (NCBI), see also Altschul SF et al., 1990 and Altschul SF et al., 1997), ClustalW2 (available on the website of the European Bioinformatics Institute; see also Higgins DG et al., 1996 and Larkin MA et al., 2007), and ALIGN or Megalign (DNASTAR) software. Those skilled in the art can use the default parameters provided by the tool or can appropriately customize the parameters as needed for comparison, for example by selecting a suitable algorithm.
[0096] As used herein, the terms “comprise”, “comprises”, “comprising”, “include”, “includes”, “including”, “contain”, “containing”, “have”, “has”, “having”, etc., are synonyms and are used in an open-ended manner, without excluding other elements, features, steps, actions, operations, etc.
[0097] As used herein, the term “or” is used in its inclusive sense (rather than in its exclusive sense), so when used, for example, to connect lists of elements, the term “or” means one, some, or all of the elements in the list.
[0098] As used herein, the phrase “at least one / a kind” means one or more, i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more. A phrase referring to “at least one / a kind” of a series of items is interpreted as referring to any combination of those items, including a single member. For example, “at least one of A, B or C” is intended to cover: A, B, C, A and B, A and C, B and C, and A, B and C. Unless otherwise specifically stated, connective language such as the phrase “at least one of X, Y and Z” is otherwise understood through the context in which items, terms, etc., can be at least one of X, Y or Z. Therefore, such connective language is not generally intended to imply that a particular implementation requires the presence of at least one of X, at least one of Y, and at least one of Z, respectively.
[0099] As used herein, references to “one embodiment,” “an embodiment,” “a particular embodiment,” “related embodiment,” “a certain embodiment,” “an additional embodiment,” or “another embodiment,” or combinations thereof, are understood to mean that a particular feature, structure, or characteristic described in connection with that particular embodiment is included in at least one embodiment of this disclosure. Therefore, the foregoing phrases present or appearing throughout this disclosure do not necessarily all refer to the same embodiment. Furthermore, a particular feature, structure, or characteristic may be combined in any suitable manner in one or more embodiments.
[0100] The conditional language used herein, such as "can / could / might / may" and "e.g.," is generally intended to convey that some implementations include certain features, elements, and / or steps, while other implementations do not. Therefore, such conditional language is not generally intended to imply that a feature, element, and / or step is necessary in any way for one or more implementations.
[0101] II. Methods for inducing immune tolerance to gene delivery target agents
[0102] This disclosure provides methods and kits for inducing immune tolerance to a gene delivery target agent to be administered to a subject.
[0103] While gene delivery can be used to express target genes in subjects, the delivery medium (e.g., a recombinant viral vector) can induce an immune response against the medium, thus significantly inhibiting target gene expression with repeated administration of the delivery medium. However, repeated administration of the delivery medium may be essential, for example, for treating some genetic diseases requiring long-term treatment. Therefore, this article provides methods and compositions for inhibiting immune responses against gene delivery media to enable repeated administration of the delivery medium and significantly enhance target gene expression in subjects.
[0104] In some aspects, this disclosure provides a method for inducing immune tolerance to an immunogenic target agent for gene delivery in a subject. The method includes the steps of: a) administering an immunogenicity inducer to the subject. In other words, administering an immunogenicity inducer to induce immune tolerance to a target agent that is otherwise immunogenic.
[0105] As used herein, the term “immunotolerance” or “immunological tolerance” is defined as the suppressive immunity of a subject to an antigen such that the subject’s immune system no longer produces a significant level of immune response to the antigen; that is, the subject’s immune system produces only an acceptable low level of immune response to the antigen, or even a zero immune response.
[0106] The terms "immune response" and "immunity" generally refer to the reaction that occurs within a subject's body to defend against any invading foreign organism or any substance that the host body perceives as foreign. Typically, an immune response can include the host's innate immune response and / or adaptive immune response. The adaptive immune response can further include responses from dendritic cells, T cells, and B cells, and the B cell response can further include antibody production.
[0107] As used in this article, "T cell" refers to a type of immune cell that contributes to cellular immunity against antigens. Several types of T cells are known, such as CD4 T cells, CD8 T cells, and regulatory T cells. "B cell" refers to a second type of immune cell that can also promote an immune response against specific antigens, usually by expressing immunoglobulins that bind to the antigen. Other forms of B cells, namely regulatory B cells, can play a suppressive role in the immune system (Goode I et al., 2014).
[0108] In the methods provided herein, both the inducer and the target are immunogenic. As used herein, the terms "immunogenicity" refer to the ability of a particular substance to elicit a host immune response in a subject in the absence of immune tolerance. In some embodiments, the host immune response includes innate and / or adaptive immune responses.
[0109] i. mediator
[0110] The term "mediator" generally refers to a device used to deliver a target cargo into a subject. In this document, the term "target cargo" can include any suitable bioactive agent intended to be delivered to a subject for the purposes of this disclosure. Examples of target cargo contained in a mediator can include nucleic acid vectors encoding transgenes, certain macromolecular entities (e.g., proteins, peptides, polynucleotides, etc.), or certain small molecule compounds. Upon delivery into a subject, the target cargo can be expressed (if it includes a nucleic acid vector) and / or perform its intended function (if it includes a macromolecular entity or a small molecule compound).
[0111] Any suitable medium for delivering the target cargo can be used. In some embodiments, the medium is configured to deliver a nucleic acid vector and may include, for example, a viral medium or a non-viral medium. Suitable media in this disclosure are immunogenic.
[0112] In some embodiments, the medium (i.e., inducer medium and / or target medium) is a viral medium. The viral medium is based on a viral delivery system, which may, for example, include recombinant viral particles. In some embodiments, the medium may include viral particles for delivering a target gene. As used herein, the terms "virus particle" or "viral particle," etc., refer to a recombinant viral genome or recombinant viral vector packaged within a viral capsid. The viral genome in the viral particle may be a modified viral genome, such that it may lack some natural viral sequences or have altered certain viral sequences and / or may contain sequences heterologous to the natural viral genome. Depending on the embodiment, the viral genome may be a complete or partial viral genome. Non-limiting examples of viral particles used for gene delivery include adenoviruses, adeno-associated viruses (AAVs), lentiviruses, retroviruses, herpes simplex virus (HSV), and oncolytic viruses, etc.
[0113] In some embodiments, the medium (i.e., inducer medium and / or target medium) is a nonviral medium. Nonviral mediums are based on nonviral delivery systems, which may, for example, include synthetic nanocarriers. Recent years have witnessed significant advancements in gene delivery using nanocarriers (see, for example, Xu H et al., 2014 and Riley MK et al., 2017). As used herein, the term "synthetic nanocarrier" refers to a carrier for target cargo (i.e., polynucleotide agents such as nucleic acid carriers, peptide agents, antibodies, small molecule agents, etc.) to be delivered to a subject, said carrier not found in nature and having at least one dimension less than or equal to 5 micrometers. In some embodiments, the nanocarrier or nanoparticle has a diameter less than 1000 nm.
[0114] Synthetic nanocarriers may include, but are not limited to, lipid-based nanoparticles (i.e., nanoparticles whose structure is largely composed of lipids), polymer nanoparticles, microparticles, microcapsules, metal nanoparticles, synthetic liposomes, surfactant-based emulsions, dendritic structures, buckyballs, nanowires, virus-like particles (i.e., particles that are mainly composed of viral structural proteins but are not infectious or have low infectivity), peptide or protein-based particles (also referred to herein as protein particles, i.e., particles whose structure is largely composed of peptides or proteins) (such as albumin nanoparticles), and / or nanoparticles developed using combinations of nanomaterials such as lipid-polymer nanoparticles. Examples of such nanocarriers or nanoparticles may include liposomes (see, for example, WO 2012 / 149255; WO 2012 / 149252) or dextran particles (see, for example, U.S. Patent Publications 2005 / 0281781 and 2010 / 0040656, and WO 2006 / 007372 and WO 2007 / 050643).
[0115] Synthetic nanocarriers can take on a variety of shapes, including but not limited to spheres, cubes, pyramids, ellipses, cylinders, and rings. Synthetic nanocarriers may include one or more surfaces. They may be solid or hollow and may comprise one or more layers. In some embodiments, each layer has a unique composition and properties relative to the other layers. As just one example, a synthetic nanocarrier may have a core / shell structure, where the core is a single layer (e.g., a polymer core) and the shell is a second layer (e.g., a lipid bilayer or monolayer). Synthetic nanocarriers may include multiple distinct layers.
[0116] Various compositions are available for synthesizing nanocarriers, which are well known to those skilled in the art and can be referenced in the following literature: U.S. Patent No. 5,543,158, U.S. Patent Application Nos. US20060002852, US20090028910, US20020086049, US20080145441, US20090226525, US20060222652 and US20060251677, and International Patent Application Nos. WO 2010047839A1, WO2009 / 051837 and WO 2009106999A2, and publications such as Paolicelli P et al., 2010 and Look M et al., 2013. Typically, synthetic nanocarriers may include one or more lipids (e.g., liposomes, lipid bilayers, lipid monolayers, micelles, etc.), certain particles (e.g., metal particles, quantum dots, ceramic particles, etc.), one or more amphiphilic entities, polymers, and / or one or more carbohydrates.
[0117] ii. Cross-reactivity
[0118] In some embodiments, the immune response to the inducer mediator is cross-reactive to the target mediator. The terms "cross-reactive" and "cross-reactivity" generally refer to a situation where an initial immune response against a first entity is also reactive to a second entity. In this document, the first and second entities can be the inducer mediator and the target mediator. Therefore, the subject's immune response to the inducer mediator (e.g., antibodies produced in the host body) can be "cross-reactive" because it can also recognize and bind to the target mediator. In some embodiments, the inducer mediator and the target mediator share at least one common or similar immunogenic antigen or epitope, such that upon administration of the inducer mediator, antibodies against one or more of the at least one common or similar immunogenic antigen or epitope found in the target mediator are generated in the subject. Upon administration of the target mediator, these antibodies in the subject should also be able to recognize and target the shared immunogenic antigen or epitope, thereby generating cross-reactivity. However, it should be noted that for cross-reactivity of the host immune response, the immunogenic antigens from the inducer and the target agent do not necessarily have to be identical. According to some implementations, this cross-reactivity may be caused by common or similar epitopes of different immunogenic antigens from the inducer and target agents.
[0119] In a specific embodiment further detailed in Example 1 below, both the inducer and the target agent are based on adeno-associated virus (AAV), and they at least share the capsid protein of AAV or epitopes within the capsid protein as common immunogenic antigens or epitopes. Therefore, the host immune response against the capsid protein or epitope of the inducer agent developed in the subject after administration of the inducer agent is also cross-reactive to the subsequently administered target agent.
[0120] Without being bound by any theoretical framework, it is believed that by administering to a subject an inducer mediator that delivers at least one immunosuppressant, the subject's host immune response to the inducer mediator is suppressed, resulting in immune tolerance not only to the inducer mediator but also to the target mediator. Therefore, the effectiveness and efficiency of target mediator delivery in the same subject can be improved.
[0121] In some embodiments, each of the inducer and the target agent comprises a viral particle. In some embodiments, the viral particle is in the form of an infectious virion. The viral particle can be based on any virus that is therapeutically suitable for gene delivery, and non-limiting examples include adenovirus, adeno-associated virus (AAV), lentivirus, retrovirus, and oncolytic virus, etc. The viral particle comprises a nucleic acid vector that includes a sequence encoding one or more target genes (i.e., transgenes or immunosuppressants).
[0122] In some embodiments, the inducer virus particles and the target virus particles may have the same type of virus. For example, the same type of virus may be adenovirus, adeno-associated virus (AAV), lentivirus, retrovirus, or oncolytic virus. In some embodiments, both the inducer virus particles and the target virus particles are adeno-associated virus (AAV).
[0123] In some implementations, the inducer virus particles and the target virus particles may have the same serotype. As used herein, the term "serotype" with respect to virus particles refers to reactivity with a defined antiserum. Serotype can be used to subhistologize virus particles at the subspecies level and generally indicates that virus particles with the same serotype may share the same surface antigen or share surface antigen epitopes.
[0124] In some implementations, the inducer virus particles and the target virus particles may have different serotypes, but cross-reactivity is still observed.
[0125] In some embodiments, both the inducer viral particle and the target viral particle include a capsid. As used herein, the term "capsid" refers to the protein coat of a virus that encapsulates viral nucleic acid. Typically, the capsid comprises several oligomeric subunits (i.e., the original). In this document, the capsid is immunogenic in the subject.
[0126] In some implementations, both the inducer virus particle and the target virus particle include the same capsid protein.
[0127] For more detailed information on the various viruses listed above, please refer to the following sections.
[0128] In some embodiments, the immune response to the inducer mediator includes generating at least one antibody capable of binding to the inducer mediator.
[0129] In some embodiments, the immune response includes the production of at least one antibody capable of binding to and neutralizing the inducer mediator. As used herein, the terms "neutralizing," "neutralizing," "neutralization," etc., refer to the effect of immunoglobulins (including antibodies such as those produced in a host immune response) in reducing the delivery efficiency of the inducer mediator. For example, in embodiments where the inducer mediator comprises viral particles, neutralization can be achieved such that the at least one antibody produced in the subject is directed to the surface of the virion (e.g., capsid proteins), which may lead to virion aggregation, or can be achieved by inhibiting the fusion of the virus and cell membrane after viral particle attachment to the target cell, inhibiting endocytosis, inhibiting progeny viruses from infected cells, etc. Regardless of the mechanism, the at least one antibody that plays a "neutralizing" role produced in the subject's host immune response results in a significant reduction or even complete attenuation of the delivery efficiency of the inducer mediator.
[0130] In some implementations, the immune response includes generating antibodies that bind to and / or neutralize the inducer and target agents.
[0131] In some embodiments, an immune response that is cross-reactive with both the inducer and the target includes the production of at least one antibody capable of binding to the capsid of both the inducer virus particle and the target virus particle.
[0132] iii. Immunosuppressants
[0133] In the methods provided herein, an immune response against the inducer mediator is suppressed. Suppression of the host adaptive immune response may involve suppressing T cell and / or B cell responses, and in some embodiments, may involve the suppression of antibody production. This suppressed immune response is against the inducer mediator but may be cross-reactive to the target mediator.
[0134] The immune response to an inducer can be suppressed by an immunosuppressant. As used herein, the term "immunosuppressant" refers to a bioactive molecule that, upon delivery to a subject, has an immunosuppressive effect, thereby suppressing the host immune response, including innate and / or adaptive immune responses. In some embodiments, immunosuppressants may include proteins, peptides, nucleic acids, or chemical compounds.
[0135] In some implementations, immunosuppressants are delivered via an inducer mediator. As used herein, the phrase "delivered via..." broadly encompasses implementations in which the immunosuppressant or its encoding nucleic acid associates with an inducer mediator and is delivered to the subject in such an associated form. For example, the immunosuppressant may be encapsulated in or conjugated to an inducer mediator and delivered in such an encapsulated or conjugated form, optionally releasing the immunosuppressant after delivery. As another example, the nucleic acid encoding the immunosuppressant may be delivered via an inducer mediator, allowing for the expression or production of the immunosuppressant in the subject after delivery.
[0136] In some embodiments, the inducer medium includes an inducer nucleic acid vector encoding at least one immunosuppressant, which, upon expression in a subject, inhibits the immune response in the subject against the inducer medium. In some embodiments, the inducer medium may include one or more inducer nucleic acid vectors. In some embodiments, depending on practical needs and the capabilities of the inducer nucleic acid vector, the inducer nucleic acid vector may encode one or more immunosuppressants.
[0137] In some embodiments, the inducer medium may include inducer virus particles, wherein the inducer virus particles include the inducer nucleic acid vector.
[0138] In some other embodiments, the inducer medium may include non-viral nanocarriers, such as synthetic nanocarriers capable of delivering immunosuppressants or nucleic acid carriers that deliver inducers.
[0139] In any of the embodiments of the methods described above, the at least one immunosuppressant may act by downregulating the immune stimulation pathway and / or by upregulating the immunosuppressive pathway.
[0140] As used herein, "immunostimulatory pathways" generally refer to signaling pathways that stimulate the host's immune system, positively regulating cytokine secretion, NK cell activation, T cell proliferation, and antibody production. Immunomodulators found in immunostimulatory pathways may include CD27, CD70, CD28, CD80 (B7-1), CD86 (B7-2), CD40, CD40L (CD154), CD122, CD137, CD137L, OX40 (CD134), OX40L (CD252), GITR, ICOS (CD278), and ICOSLG (CD275). Any of these immunostimulators can be inhibited by the immunosuppressants provided herein, such that once the immunosuppressant is delivered to and optionally expressed in the subject by the inducer, the expression or activity of the immunostimulator can be reduced, leading to suppression of the immune response against the inducer, thereby resulting in immune tolerance to the target agent.
[0141] In some embodiments, the at least one immunosuppressant can inhibit the expression and / or function of immunomodulators involved in the B7 / CD28 co-stimulatory signaling pathway and / or the CD40 / CD40L co-stimulatory signaling pathway. According to some embodiments, the immunomodulator can be selected from the group consisting of CD28, CD80 (B7-1), CD86 (B7-2), CD40, and CD40L (CD154).
[0142] As used in this article, "immunosuppressive pathways" generally refer to signaling pathways in the host that suppress the host's immune system, which can reverse cytokine secretion, NK cell activation, T cell proliferation, antibody production, etc. Immunosuppressive modulators in immunosuppressive stimulation pathways may include A2AR, B7-H3 (CD276), B7-H4 (VTCN1), BTLA (CD272), CTLA-4 (CD152), IDO1, IDO2, TDO, KIR, LAG3, NOX2, PD-1, PD-L1, PD-L2, TIM-3, VISTA, SIGLEC7 (CD328), TIGIT, PVR (CD155), or SIGLEC9 (CD329), etc. Any of these immunosuppressive modulators can be stimulated by the immunosuppressant provided herein, such that once the immunosuppressant is delivered to and optionally expressed in the subject by the inducer mediator, the expression of the immunosuppressive modulator can be increased or the activity of the immunosuppressive modulator enhanced, resulting in suppression of the immune response against the inducer mediator, thereby leading to immune tolerance to the target mediator.
[0143] According to certain embodiments, the at least one immunosuppressant can increase the expression and / or activity of an immunosuppressive modulator selected from the group consisting of: TLR2, TLR9, MyD88, IFN-1, IRF-7, NF-κB, mTOR, CD3, CD4, CD278, CD19, CD20, CD79, IL-4, IL-2R, IL-5, IL-6R, TNF-α, and LFA-1.
[0144] Details of these modulators in the immune stimulation and immunosuppression pathways are known in the art, see, for example, WO 97 / 28259; WO 98 / 16247; WO 99 / 11275; Krieg AM et al., 1995; Yamamoto S et al., 1992; Ballas ZK et al., 1996; Klinman DM et al., 1997; Sato Y et al., 1996; Pisetsky DS, 1996; Shimada S et al., 1986; Cowdery JS et al., 1996; Roman H et al., 1997; Lipford GB et al., 1997; WO 98 / 55495 and WO 00 / 61151, etc.
[0145] In some embodiments, the at least one immunosuppressant downregulates the B7-CD28 immune stimulation pathway. In some embodiments, the at least one immunosuppressant inhibits the expression and / or function of CD28, CD80 (B7-1), and CD86 (B7-2). In some embodiments, the at least one immunosuppressant disrupts or blocks B7-CD28 interaction (e.g., binding). In some embodiments, the at least one immunosuppressant competes with CD28 for binding to B7, or competes with B7 for binding to CD28. For example, the at least one immunosuppressant may include a CD80-binding peptide or a CD80-binding fragment of an anti-CD80 antibody, a CD28-binding peptide or a CD28-binding fragment of an anti-CD28 antibody, or a CD86-binding peptide or a CD86-binding fragment of an anti-CD86 antibody.
[0146] In some embodiments, the at least one immunosuppressant comprises a CTLA-4 derivative. CTLA-4, or CTLA4, known as cytotoxic T-lymphocyte-associated antigen 4, is a natural molecule that downregulates the B7-CD28 immunostimulatory pathway. Exemplary sequences of full-length human CTLA-4 are shown in SEQ ID NO:1 (with signal peptide) and SEQ ID NO:15 (without signal peptide), and full-length mouse CTLA-4 is shown in SEQ ID NO:12 (with signal peptide). CTLA-4 is an inhibitory receptor expressed on the cell surface of T cells. CTLA-4 is a homologue of CD28, but it has a 100-fold affinity for B7 compared to CD28; therefore, CTLA-4 expression can induce competitive binding to CD80 and CD86, blocking B7-CD28 interactions and terminating T cell activation (Li W et al., 2009; Dall'Era M et al., 2004; and Slavik JM et al., 1999). As used herein, the term “CTLA-4 derivative” is intended to encompass all analogues, mutants and fragments of CTLA-4, as well as fusion peptides of this class that can bind to B7 and compete with CD28 for binding to B7.
[0147] In some embodiments, the at least one immunosuppressant comprises an extracellular domain of CTLA-4 or its B7-binding fragment. B7 as used herein includes B7-1 and B7-2.
[0148] As used herein, the phrase “extracellular domain (ECD) of CTLA-4” broadly encompasses wild-type ECD CLTA-4 and all its variants, mutants, derivatives, or multimers (e.g., dimers, tetramers, hexamers) provided they are functionally equivalent to wild-type ECD CTLA-4. The term “functionally equivalent” means that variants, mutants, and derivatives of ECD CTLA-4 retain at least some of the functions of their wild-type counterpart, such as the ability to bind to natural ligands like B7. Functionally equivalents may have weaker (but not negative), substantially similar, or even higher functions relative to their wild-type counterpart. The ECD of CTLA-4 described herein may be from mammals such as humans or mice. Exemplary amino acid sequences of the wild-type ECD of human CLTA-4 include SEQ ID NO:11 (full-length human CLTA-4 ECD, no signal peptide, UniProtKB-P16410, amino acids 36-161) and SEQ ID NO:3 (human CLTA-4 ECD, UniProtKB-P16410, amino acids 38-161). Exemplary amino acid sequences of the wild-type ECD of mouse CLTA-4 are shown in SEQ ID NO:13.
[0149] Different mutants have been shown that can be used to retain B7 binding activity. In some embodiments, the ECD of human CLTA-4 in the immunosuppressant includes one or more mutations at positions selected from the group consisting of: A29, L104, K28, T30, R33, T51, Y52, M53, M54, G55, N56, E57, L58, L61, K93, L96, Y99 and any combination thereof, wherein the number is relative to SEQ ID NO:3.
[0150] In some embodiments, the ECD of human CLTA-4 in the immunosuppressant includes one or more mutations selected from the group consisting of: L104E, A29Y, G27A, K28H / T, A29H / T / Y / W / K, T30G / E, R33D, T51Y / N, Y52F, M53F / Y / W, M54R / W / Y, G55P, N56T, E57P, L58G / A / N / Q / E / P / Y / H / K, L61H / Y / A / F / W, D62H, K93M / V / Q / I, L96K / R, L104H / Y / I / M and any substitution at Y99 or any combination thereof, wherein the number is relative to SEQ ID NO:3. These exemplary mutations in the ECD of CTLA-4 have been reported to exhibit B7 binding activity. For details, see Z. Xu et al., Journal of Immunology, November 1, 2012, 189(9)4470-4477; U.S. Patent Nos. 8,148,332, 8,642,557, 5,773,253, 6,090,914, 5,844,095; and PCT Publication No. WO 01 / 92337A2.
[0151] In some embodiments, the at least one immunosuppressant may include the B7-binding fragment of the ECD of CTLA-4, provided that it still allows high affinity binding to B7 (i.e., CD80 and / or CD86).
[0152] In some embodiments, the B7-binding fragment of CTLA-4 can be fused with a fragment of another protein, together enabling such hybrid fusion proteins to exhibit high B7 affinity. For example, the ECD fragment of CTLA-4 can be fused with another fragment of the ECD of CD28 to allow the resulting hybrid fusion polypeptide moiety to have high affinity for B7 (see U.S. Patent No. 6,090,914). An exemplary ECD of the wild-type amino acid sequence of CD28 is shown in SEQ ID NO:2 (UniProtKB, P10747, amino acids 19-220).
[0153] In some embodiments, the extracellular domain of CTLA-4 includes an amino acid sequence as shown in SEQ ID NO:3 or SEQ ID NO:11, or a sequence that has at least 70% (e.g., 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with SEQ ID NO:3 or 11 but retains binding activity or affinity for B7-1 or B7-2.
[0154] In some embodiments, the at least one immunosuppressant downregulates the CD40 / CD40L immune stimulation pathway. In some embodiments, the at least one immunosuppressant inhibits the expression and / or function of CD40 or CD40L. CD40 and CD40L are located on the surface of antigen-presenting cells (APCs) and T cells, respectively. When CD40 and CD40L interact, B7 is strongly expressed in T cells, and then the T cells are activated (Dall'Era M et al., 2004). An exemplary sequence of full-length human CD40 is shown in SEQ ID NO:16 (with signal peptide) and SEQ ID NO:17 (without signal peptide).
[0155] In some embodiments, the at least one immunosuppressant disrupts or blocks the interaction between CD40 and CD40L. In some embodiments, the at least one immunosuppressant competes with CD40L for binding to CD40, or competes with CD40 for binding to CD40L. For example, the at least one immunosuppressant may include a CD40-binding peptide or a CD40-binding fragment of an anti-CD40 antibody, a CD40L-binding peptide or a CD40L-binding fragment of an anti-CD40L antibody.
[0156] In some embodiments, the at least one immunosuppressant comprises a CD40L-binding ligand or a CD40L-binding fragment of an anti-CD40L antibody. Exemplary anti-CD40L antibodies include, but are not limited to, MR1 and BG9588 (see, for example, Noelle RJ et al., 1992 and Boumpas DT et al., 2003). These anti-CD40L antibodies are considered useful for stabilizing transgene expression and improving efficient reapplication via adenoviral vectors (Jiang Z et al., 2004, Chirmule N et al., 2000, Yang Y et al., 1996a and Yang Y et al., 1996b).
[0157] In some embodiments, the at least one immunosuppressant comprises a CD40 derivative. As used herein, the term "CD40 derivative" is intended to encompass all analogues, mutants, and fragments of CD40, as well as fusion peptides of this class that can bind to CD40L and compete with CD40 for binding to CD40L. In some embodiments, the at least one immunosuppressant comprises an extracellular domain of CD40, a CD40L-binding fragment of CD40, or a mutant thereof that retains CD40L binding function or affinity.
[0158] The extracellular domain portion of CD40 may be wild-type or may have other options reported in: U.S. Patent No. 6,376,459 and U.S. Patent Publication No. 20140120091A1; Elgueta R et al., 2009; Clark EA et al., 1986; and Noelle RJ et al., 1992. In some embodiments, the extracellular domain of CD40 includes a sequence as shown in SEQ ID NO:4, or a sequence having at least 70% (e.g., 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with SEQ ID NO:4 but retaining binding activity or affinity for CD40L. An exemplary sequence of the mouse CD40 ECD is shown in SEQ ID NO:14.
[0159] In some embodiments, the at least one immunosuppressant downregulates both the B7-CD28 immune stimulation pathway and the CD40 / CD40L immune stimulation pathway. In some embodiments, the at least one immunosuppressant comprises a first immunosuppressant that downregulates the B7-CD28 immune stimulation pathway and a second immunosuppressant that downregulates the CD40 / CD40L immune stimulation pathway. Downregulation of the B7-CD28 immune stimulation pathway may involve inhibiting the expression and / or function of CD28, CD80 (B7-1), or CD86 (B7-2), or disrupting or blocking B7-CD28 interactions (e.g., binding). Downregulation of the CD40-CD40L immune stimulation pathway may involve inhibiting the expression and / or function of CD40 or CD40L, or disrupting or blocking CD40-CD40L interactions.
[0160] Immune responses, such as the production of neutralizing antibodies (NAb) induced by gene delivery vectors (e.g., AAV), are believed to be associated with T cell and B cell activation (Wang D et al., 2019). The B7 / CD28 and CD40 / CD40L signaling pathways co-stimulate T and B lymphocyte activation and play important roles in transplant rejection and autoimmune diseases (Arima T et al., 1996). These signaling pathways determine the magnitude of T cell responses to antigens and the magnitude of downstream responses to antigens (see, for example, Mueller DL et al., 1989; Bessis N et al., 2004).
[0161] In some embodiments, the at least one immunosuppressant comprises at least one immunosuppressive protein, which may include one of the following, or a combination of two of the following immunosuppressive proteins:
[0162] (1) The extracellular domain of CTLA-4 or a fragment thereof capable of binding to at least one of CD80(B7-1) or CD86(B7-2); and
[0163] (2) The extracellular domain of CD40 or a fragment or antibody fragment that can bind to CD40L (CD154).
[0164] In some embodiments, one or more immunosuppressive proteins further include a half-life extension portion, such as a half-life extension peptide portion.
[0165] In some embodiments, the at least one immunosuppressant includes an extracellular domain of CTLA-4, optionally further linked to a half-life-extending peptide moiety. In some embodiments, the at least one immunosuppressant includes an extracellular domain of CD40, optionally further linked to a half-life-extending peptide moiety.
[0166] As used herein, the term "half-life" refers to the pharmacokinetic property of a particular molecule of interest, which is designed to measure the survival time of the molecule after its administration. Half-life can be expressed as the time required for fifty percent (50%) of a known amount of the molecule to be eliminated from a subject's body or a specific compartment thereof, for example, as measured in serum, i.e., the circulating half-life, or as measured in other tissues. As used herein, a "half-life-extending peptide moiety" refers to a peptide fragment or peptide moiety operatively linked or fused to a target polypeptide moiety of interest, i.e., an immunosuppressant, which can increase or prolong the half-life of the entire fused or chimeric polypeptide expressed in a specific compartment of a subject's body (especially the circulating). In other words, when administered to a subject an inducer mediator containing an inducer nucleic acid carrier encoding such an engineered immunosuppressant, the half-life-extending peptide moiety can increase the half-life of the fused polypeptide in the subject, particularly the in vivo serum or plasma half-life.
[0167] Exemplary half-life-extending peptides include, but are not limited to, the Fc (i.e., the crystallizable region of a fragment, such as the Fc portion of IgG), albumin family members (i.e., albumin (e.g., human serum albumin or HSA), afamin, alpha-fetoprotein, and vitamin D-binding protein, etc.) or their functional (i.e., capable of extending half-life) fragments, serum albumin-binding polypeptides (e.g., serum albumin-binding antibody fragments, domain antibodies, etc.), follicle-stimulating hormone (FSH) and its functional fragments, fibronectin or its functional fragments, fibroblast activating protein (FAP) or its functional fragments, or coagulation factors (e.g., von Willebrand factor, factor V, and prothrombin factor, including factor VII, factor IX, factor X, protein IX, protein S, protein Z, and prothrombin) or their functional fragments, etc. Prior art disclosing the aforementioned half-life extended peptide moiety includes WO2001 / 079271; WO 2005 / 024044; WO 2004 / 101740; WO 2013 / 106787; and WO 2008 / 077616; U.S. Patent Nos. 7,625,564, 8,546,543, and 9,738,707; as well as Beattie et al., 1982; Lichenstein et al., 1994; and Cooke NE et al., 1985.
[0168] According to certain embodiments, the half-life-extending peptide portion includes an Fc portion. In this document, the Fc portion may be derived from any one of IgG1, IgG2, IgG3, and IgG4, and may be wild-type or contain the following variants or combinations thereof, including T250Q / M428L, V308P, M428L, M252Y / S254T / T256E, M428L / N434S, N434A, and N434H (according to the EU index numbering of Kabat et al., 1991, and the EU numbering scheme is used hereinafter). These Fc variants have been reported to enhance the affinity of IgG for neonatal Fc receptors (FcRn), which play a crucial role in regulating IgG homeostasis in vivo (see, for example, Datta-Mannan A et al., 2007; Datta-Mannan A et al., 2012; Hinton PR et al., 2006; Dall'Acqua WF et al., 2006; Zalevsky J et al., 2010; Deng R et al., 2010; Maeda A et al., 2017, etc.). Additionally, the Fc moiety can be an artificial heterodimeric Fc variant, which may include designs such as KiH, KiHS-S, HA-TF, ZW1, DD-KK, EW-RVT, EW-RVTS-S, SEED, and A107. For more details, see the reviews and research articles Ha JH et al., 2016; Wei H et al., 2017; Atwell S et al., 1997; Von Kreudenstein TS et al., 2013; Gunasekaran K et al., 2010; Choi HJ et al., 2013; and Klein C et al., 2012.
[0169] In some embodiments, the at least one immunosuppressant includes a CTLA-4 extracellular domain fused to the Fc, optionally via a linker (e.g., a peptide linker). Alternatively or additionally, in some embodiments, the at least one immunosuppressant includes a CD40 extracellular domain fused to the Fc, optionally via a linker (e.g., a peptide linker).
[0170] These aforementioned fusion proteins, namely CTLA4-Ig or CTLA4-Fc and CD40-Ig or CD40-Fc, are known in the art. See, for example, Najafian N et al., 2000 and Kirk AD et al., 1997. Two commercially available CTLA4-Ig fusion proteins described above include abatacept and belacept, which are approved for the treatment of autoimmune diseases such as rheumatoid arthritis. According to certain embodiments, the Fc portion of the fusion polypeptide of immunosuppressants (i.e., CTLA4-Ig and CD40-Ig) may have a sequence as shown in SEQ ID NO:5.
[0171] CTLA4-Ig, alone or in combination with anti-CD40L antibodies, can prevent acute renal allogeneic transplant rejection (Kirk AD et al., 1997). In 1998, Halbert et al. successfully achieved AAV lung re-administration in mice by using CTLA4-Ig and MR1 to suppress immunity (Halbert CL et al., 1998). Lorain et al. delivered small nuclear RNA via intramuscular injection of AAV1 for the treatment of DMD. In mice treated with CTLA4-Ig and MR1, exogenous gene expression was sustained upon re-administration of AAV1. However, AAV1 re-injection required repeated treatment with CTLA4-Ig and MR1 (Lorain et al., 2008). McIntosh et al. demonstrated that systemic injection of a second AAV vector suppressed the humoral immune response after six injections of non-depleting anti-CD4 (NDCD4) antibody and cyclosporine (CyA) without affecting new transgene expression (Mcintosh JH et al., 2012).
[0172] In some embodiments, immunosuppressant proteins (e.g., the extracellular domain of CTLA-4 or a fragment thereof, or the extracellular domain of CD40 or a fragment thereof, etc.) may be configured to be soluble. Therefore, according to some embodiments, immunosuppressant proteins encoded by inducer nucleic acid vectors may include signal peptides.
[0173] In this document, the signal peptide is configured to cause the polypeptide to be secreted extracellularly by the host cell upon translation and can be cleaved post-secretion. The signal peptide is 10 to 50 amino acid residues in length. According to certain specific embodiments, the signal peptide may have the sequence shown in SEQ ID NO:6 or SEQ ID NO:7. Other options for the signal peptide may include any of the oncogene M signal peptide having the amino acid sequence of SEQ ID NO:10 (see U.S. Patent Application Publication No. 2003 / 0219863A1), CD5 (Jones NH et al., 1986), or a signal peptide derived from any other extracellular protein. It should be noted that the signal peptide described above may have certain sequence variations, such as less than 10%, 20%, 30%, 40%, or 50%, as long as the variant signal peptide retains the functionality of the signal peptide.
[0174] In some embodiments of the method, the at least one immunosuppressant encoded by the inducer nucleic acid vector comprises at least one immunosuppressive nucleic acid, which may be DNA or RNA. In some embodiments, the inducer nucleic acid vector encodes shRNA, siRNA, or microRNA that specifically targets one or more positive regulators in the immune stimulation pathways described above, such that the expression of the positive regulator is downregulated in the subject, resulting in suppression of the immune response against the inducer and the target agent. Other nucleic acids are also possible besides these RNA interference-mediated immunosuppressive nucleic acids.
[0175] In some embodiments, the at least one immunosuppressant provided herein may be used in combination with at least one additional immunosuppressant. Optionally, each immunosuppressant and each additional immunosuppressant may act on different immunomodulators, and more preferably, these different modulators may be configured to have a synergistic effect in the same or different signaling pathways (i.e., any immunostimulatory pathway in the immune stimulation pathway or any immunosuppressive pathway in the immune suppression pathway) to better suppress the immune response against the inducer and the target agent. Any suitable combination of immunosuppressants as disclosed herein may be used. In some embodiments, the at least one immunosuppressant and the at least one additional immunosuppressant inhibit the binding or signaling of CD28 and CD80 (B7-1) and CD86 (B7-2), respectively, and inhibit the binding or signaling of CD40 and CD40L (CD154), respectively.
[0176] In some implementations, the combination of immunosuppressants can be delivered via an inducer medium. For example, the inducer medium may comprise an inducer nucleic acid vector encoding two or more immunosuppressants, which may be in one expression cassette or in different expression cassettes.
[0177] Alternatively, in some other embodiments, the combination of immunosuppressants may be delivered separately via a combination of inducer mediators. For example, the first inducer mediator may include a first inducer nucleic acid vector encoding a first immunosuppressant, while the second inducer mediator may include a second inducer nucleic acid vector encoding a second immunosuppressant. When using two or more inducer mediators, each of the inducer mediators is immunogenic and induces substantially the same immune response. For example, both the first and second inducer mediators may be the same type of viral particles and optionally may be the same serotype or share the same capsid protein.
[0178] In some embodiments of the method, step a) of the method provided herein may further include administering at least one additional inducer medium to the subject. Each additional inducer medium herein may contain an inducer nucleic acid vector encoding at least one additional immunosuppressant.
[0179] In some embodiments, the at least one immunosuppressant encoded by an inducer nucleic acid vector and the at least one additional immunosuppressant encoded by another inducer nucleic acid vector are configured to inhibit the binding or signaling of CD28 and CD80 (B7-1) and CD86 (B7-2), respectively, and to inhibit the binding or signaling of CD40 and CD40L (CD154), respectively. Further optionally, an immunosuppressant includes an extracellular domain of CTLA-4 or a fragment thereof capable of binding to at least one of CD80 (B7-1) or CD86 (B7-2) (e.g., CTLA4-Ig); and / or an additional immunosuppressant includes an extracellular domain of CD40 or a fragment thereof capable of binding to CD40L (CD154) (e.g., CD40-Ig).
[0180] iv. Immunosuppressive agents
[0181] In some embodiments of the method, step a) of the method provided herein further includes administering at least one immunosuppressive agent to the subject, each immunosuppressive agent capable of inhibiting the activity of a target in an immune stimulation pathway or enhancing the activity of a target in an immunosuppressive pathway.
[0182] In some embodiments, the immunosuppressive agent may be a compound, nucleic acid, polypeptide, protein, or a combination thereof, and the immunosuppressive agent does not associate with an inducer mediated. The immunosuppressive agent may be administered in combination with an inducer mediated, for example, before, after, or simultaneously with the inducer mediated, to induce immunosuppression against the inducer mediated.
[0183] Immunosuppressive agents administered in combination with inducer mediators need not be administered concurrently with the inducer mediator or in the same composition as the inducer mediator. When used herein, an immunosuppressive agent administered before or after an inducer mediator is considered to be administered in combination with the inducer mediator, even if administered via a different route. Where possible, immunosuppressive agents administered in combination with the inducer mediators disclosed herein are administered according to the schedule listed in the product information sheet for the immunosuppressive agent or according to the Physicians' Desk Reference 2003 (Physicians' Desk Reference, 57th edition; Medical Economics Company; ISBN: 1563634457; 57th edition (November 2002)) or regimens well known in the art.
[0184] In this article, the administration of immunosuppressive agents may involve the use of certain media such as nanocarriers or nanoparticles, in which immunosuppressive agents are encapsulated.
[0185] According to certain embodiments, the immunosuppressive agent may include a compound, which may include any of the following:
[0186] (1) Glucocorticoids, such as prednisone, prednisolone, methylprednisolone, budesonide, dexamethasone and hydrocortisone, etc.;
[0187] (2) Purine analogues, such as azathioprine and mercaptopurine;
[0188] (3) Pyrimidine analogues, such as fluorouracil, etc.;
[0189] (4) Protein synthesis inhibitors;
[0190] (5) Folic acid analogues, such as methotrexate;
[0191] (6) Alkylating agents, such as nitrogen mustard (cyclophosphamide), nitrosourea, platinum compounds, etc.;
[0192] (7) Cytotoxic antibiotics, such as dactinomycin, anthracycline, mitomycin C, bleomycin, mithramycin, etc.;
[0193] (8) Drugs that act on avidin (e.g., calcineurin, cyclosporin, FKBP1A), such as calcineurin inhibitors (e.g., tacrolimus, cyclosporine), mTOR inhibitors (e.g., sirolimus (i.e., rapamycin), everolimus), etc.);
[0194] (9) Janus kinase inhibitors, such as tofacitinib;
[0195] (10) IMDH inhibitors, such as imidazothiopurine, leflunomide, mycophenolate mofetil, etc.
[0196] (11) Biologics, such as abatacept (Orencia); beracip (Nulojix); adalimumab (Humira); anakinra (Kineret); certolizumab (Cimzia); etanercept (Enbrel); golimumab (Simponi); infliximab (Remicade); ixekizumab (Taltz); and so on. natalizumab (Tysabri); rituximab (Rituxan); secukinumab (Cosentyx); tocilizumab (Actemra); ustekinumab (Stelara); vedolizumab (Entyvio); basiliximab (Simulect); and daclizumab (Zinbryta).
[0197] In some embodiments, the at least one immunosuppressive agent in the above embodiments of the method includes glucocorticoids, calmodulin inhibitors, mTOR inhibitors, nitrogen mustard, Janus kinase inhibitors, or combinations thereof.
[0198] In some embodiments, the at least one immunosuppressive agent in the above embodiments of the method includes tacrolimus, cyclosporine, cyclophosphamide, prednisone, prednisolone, methylprednisolone, budesonide, dexamethasone, hydrocortisone, rapamycin, everolimus, abatacept, berazip, etanercept, or any combination thereof.
[0199] Optionally, each of the at least one immunosuppressant and the at least one immunosuppressive agent acts on a different immunomodulator. In some embodiments, the combination provides a synergistic effect in suppressing the host immune response against both the inducer and the target agent.
[0200] v. Target agent
[0201] In any embodiment of the claims described above, the target agent comprises a target nucleic acid vector encoding at least one target gene. As used herein, a target gene is a transgene. The term "transgene" refers to an exogenous nucleic acid encoding a gene product of interest and introduced into a subject via the target agent. The gene product may be a natural biomolecule, for example, used to treat symptoms characterized by a deficiency of such a natural molecule. Alternatively, the gene product may be non-natural, for example, as an artificial product such as a mutant or fusion molecule, or as a naturally occurring product not naturally found in the subject. The biomolecule may be, for example, polypeptides / proteins and nucleic acids (e.g., polynucleotides, oligonucleotides).
[0202] In some embodiments, the target gene may encode a biomolecule of interest or a functional fragment thereof. In some embodiments, the target gene may encode a protein or peptide or a biologically active fragment thereof.
[0203] In some implementations, the target gene may encode a nucleic acid (polynucleotide) of interest, such as a functional RNA. As used herein, "functional RNA" can be a non-translated RNA, such as a nucleic acid sequence, that acts on a biological target to regulate the expression (increase or decrease) or activity (inhibit or enhance) of the biological target. For example, functional RNA can be antisense oligonucleotides, ribozymes (e.g., as described in U.S. Patent No. 5,877,022), RNAs that affect spliceosome-mediated / primitive splicing (see, for example, Puttaraju M et al., 1999; U.S. Patent Nos. 6,013,487 and 6,083,702), interfering RNAs (RNAi), including small interfering RNAs (siRNAs) that mediate gene silencing (see, for example, Sharp PA et al., 2000), microRNAs or other non-translational functional RNAs, such as guide RNAs (see, for example, Gorman L et al., 1998 and U.S. Patent No. 5,869,248), single guide RNAs used in CRISPR technology (see, for example, US10,266,850; US8,697,359; US20160298134 and Adli M et al., 2018), etc.
[0204] In some implementations, the biomolecule of interest may be a therapeutic molecule (e.g., for medical or veterinary use). The term "therapeutic molecule" refers to a biomolecule (e.g., a polypeptide / protein or nucleic acid) that can be expressed in vivo to provide therapeutic benefits.
[0205] Examples of therapeutic molecules include, but are not limited to, antibodies (e.g., monoclonal, bispecific, or multispecific), insulin, glucagon-like peptide-1, peptide hormones, growth factors, erythropoietin (EPO), cytokines, extracellular domains of cell membrane proteins, coagulation factors, antihemophilic factors, interferon, Fc fusion proteins, and therapeutic enzymes (e.g., lysosomal hydrolases and sulfatases). Such therapeutic molecules also include nucleic acid molecules encoding them.
[0206] Examples of therapeutic molecules also include functional RNAs that target, for example, multiple drug resistance (MDR) protein targets, tumor targets (e.g., VEGF, HER2, EGFR, PD-L1, etc.), pathogen targets such as viral surface antigens (e.g., hepatitis B surface antigen gene), defective gene products (mutated dystrophin) or therapeutic targets as disclosed herein (e.g., myostatin).
[0207] Examples of therapeutic molecules include, but are not limited to, motor neuron survival gene 1 (SMN1), α-N-acetylglucosamine glycosidase (NAGLU), N-sulfoglucosamine sulfonyl hydrolase (SGSH), iduronate 2-sulfatase (IDS), coagulation factor VIII (FVIII), coagulation factor IX (FIX), and Bruton's tyrosine kinase. kinase (BTK), ATP-binding cassette D subfamily member 1 (ABCD1), acyl-CoA dehydrogenase long chain (ACADVL), androgen receptor repeat instability region (AR), hemoglobin subunit β (HBB), sodium voltage-gated channel α subunit 1 (SCN1A), CF transmembrane conduction regulator (CFTR), colony-stimulating factor 2 receptor subunit α (CSF2RA), interleukin 2 receptor subunit α (IL2AG), phenylalanine hydroxylase (PHA), serine / threonine kinase 11 (STK11), phosphatidylinositol polysaccharide anchor biosynthesis class A (PIGA), ornithine carbamoyltransferase (OTC), N-acetylglutamate synthase deficiency (NAGS), DM1 protein kinase (DMPK), CCHC type zinc finger nucleic acid binding protein (CNBP), acyl-CoA dehydrogenase medium chain (ACADM), GNAS complex locus (GNAS), fibrin 1 (FB) N1), lipase A, lysosomal acid form (LIPA), solute carrier family 7 member 7 (SLC7A7), hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit α (HADHA), growth hormone receptor (GHR), isovaleryl-CoA dehydrogenase (IDV), alkaline phosphatase, biomineralization-associated (ALPL), solute carrier family 25 member 15 (SLC25A15), huntingtin (HTT), carboxyl holoenzyme synthase (HCS), notch receptor 3 (NOTCH3), aldolase, fructose diphosphate B (ALDOB), ATPase copper transporter β (ATP7B), acid glucosidase α (GAA), glutaryl-CoA dehydrogenase (GCDH), solute carrier family 12 member 3 (SLC12A3), glucosyl ceramide β (GBA), familial Mediterranean fever Fever (MEFV), galactosidase α (GLA), chloride voltage-gated channel 1 (CLCN1), nuclear receptor subfamily 0 group B member 1 (NR0B1), argininosuccinate synthase 1 (ASS1), solute carrier family 25 member 13 (SLC25A13), solute carrier family 22 member 5 (SLC22A5), sodium voltage-gated channel α subunit 5 (SCN5A), biotinylate (BTD), acetyl-CoA acetyltransferase 1 (ACAT1), arginase (ARG1), cytochrome P450 family 21 subfamily A member 2 (CYP21A2).
[0208] In some embodiments, the biomolecule of interest may be a preventative molecule (e.g., for use in vaccines). In some embodiments, the preventative molecule may be an immunogenic protein, peptide, nucleic acid, or functional RNA encoding said immunogenic protein and peptide. The preventative molecule may be any biomolecule suitable for protecting a subject from disease, including but not limited to infectious diseases such as microbial, bacterial, protozoan, parasitic, fungal, and viral diseases, as well as cancer. For example, the immunogen may be an orthomyxoviral immunogen (e.g., influenza virus immunogen, such as the influenza virus hemagglutinin (HA) surface protein or influenza virus nucleoprotein gene, or equine influenza virus immunogen), or a lentiviral immunogen (e.g., equine infectious anemia virus immunogen, simian immunodeficiency virus (SIV) immunogen, or human immunodeficiency virus (HIV) immunogen, such as the HIV or SIV envelope GP160 protein, HIV or SIV matrix / capsid protein, and HIV or SIV gag, pol, and env gene products). Immunogens can also be arenavirus immunogens (e.g., Lassa fever virus immunogens, such as the Lassa fever virus nucleocapsid protein gene and the Lassa fever envelope glycoprotein gene), poxvirus immunogens (e.g., cowpox, such as the cowpox L1 or L8 gene), flavivirus immunogens (e.g., yellow fever virus immunogens or Japanese encephalitis virus immunogens), filovirus immunogens (e.g., Ebola virus immunogens or Marburg virus immunogens, such as the NP and GP genes), Bunyavirus immunogens (e.g., RVFV, CCHF, and SFS viruses), or coronavirus immunogens (e.g., infectious human coronavirus immunogens, such as the human coronavirus envelope glycoprotein gene, or porcine transmissible gastroenteritis virus immunogens, or avian infectious bronchitis virus immunogens, or severe acute respiratory syndrome (SARS) immunogens, such as S (S1 or S2), M, E, or N proteins or their immunogenic fragments, or COVID-19 immunogens). The immunogen may further be a polio immunogen, a herpes immunogen (e.g., CMV, EBV, HSV immunogen), a mumps immunogen, a measles immunogen, a rubella immunogen, diphtheria toxin or other diphtheria immunogens, pertussis antigen, a hepatitis (e.g., hepatitis A, hepatitis B, or hepatitis C) immunogen, or any other vaccine immunogen known in the art. In another example, the immunogen may be a tumor or cancer antigen expressed on the surface of a tumor or cancer cell. Exemplary tumor or cancer antigens include, but are not limited to, β-catenin, BRCA1 gene product, BRCA2 gene product, EpCAM, EGFR, Her2, VEGFR, CD19, PSMA, etc.
[0209] In some implementations, the biomolecule of interest may be a biomolecule of experimental or research interest, such as a reporter protein (e.g., for use in animal models) and a nuclease (e.g., for use in genetic engineering).
[0210] Reporter proteins can be expressed in animals (e.g., mice, rats, guinea pigs, etc.) to provide engineered animal models. Examples of reporter proteins include, but are not limited to, fluorescent proteins (e.g., EGFP, GFP, RFP, BFP, YFP, or dsRED2), enzymes that produce detectable products, such as luciferases (e.g., from Gaussia, Renilla, or Pho), β-galactosidase, β-glucuronidase, alkaline phosphatase, and chloramphenicol acetyltransferase genes, or proteins that can be directly detected. Almost any protein can be directly detected using, for example, proteins-specific antibodies. Additional markers (and associated antibiotics) suitable for either positive or negative selection in eukaryotic cells are disclosed in Sambrook and Russell, 2001, and Ausubel FM et al., 1992, including periodic updates.
[0211] Nucleases can be used for in vivo gene editing. Examples of nucleases include, but are not limited to, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), or Cas family proteins (such as Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Cas... 11, Cas12, Cas13, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4 or Cpf1).
[0212] vi. Nucleic acid vectors
[0213] In some embodiments, the inducer medium includes an inducer nucleic acid vector encoding the at least one immunosuppressant.
[0214] In some embodiments, the target agent includes a target nucleic acid vector encoding the at least one target gene.
[0215] In this article, the vector may include exogenous nucleic acid, which is typically in the form of a polynucleotide construct and is used to deliver to the host at least one transgene encoding certain polypeptides or certain polynucleotides (RNA or DNA).
[0216] Vectors typically include regulatory elements operatively linked to a coding sequence (e.g., a transgene) to enable and regulate its expression. As used herein, the term "operatively linked" means that the coding sequence is directly or indirectly linked or associated with one or more regulatory sequences in a foreign nucleic acid in a manner that allows expression of the protein of interest from the coding sequence in the cell. The coding sequence, together with the regulatory sequence, may be referred to herein as an expression cassette. In some embodiments, the foreign nucleic acid may be in the form of an expression vector. Examples of transcriptional regulatory elements include one or more promoters and / or enhancers, and optionally polyadenylated sequences and / or one or more introns inserted between exons of the protein-coding sequence. As used herein, the terms "regulatory element," "regulatory sequence," etc., refer to any nucleotide sequence that is essential or advantageous for the expression of the coding sequence. Regulatory sequences may include, but are not limited to, one or more promoters, enhancers, transcription terminators, polyadenylated sequences, signal peptide coding sequences, internal ribosome entry sites, and / or one or more introns inserted between exons of the protein-coding sequence.
[0217] vii. Viral vector
[0218] In some embodiments, the nucleic acid vectors provided herein include viral vectors. As used herein, a “viral vector” refers to a single-stranded or double-stranded nucleic acid vector having a 5’ viral terminal repeat sequence and / or a 3’ viral terminal repeat sequence at the 5’ and / or 3’ ends of a nucleic acid sequence of interest (e.g., an expression construct encoding a protein of interest). A viral vector may include a pair of TRs or a single TR. The terms “terminal repeat” or “TR” include any viral terminal repeat or synthetic sequence that forms a hairpin structure and mediates desired functions such as replication, viral packaging, integration, and / or proviral rescue. For example, the 5’ and 3’ viral terminal repeat sequences may contain a replication origin and allow DNA synthesis to be initiated at one viral terminal repeat and continue to the other viral terminal repeat. Examples of viral terminal repeats include, but are not limited to, inverted terminal repeats (ITRs) (e.g., those included in adeno-associated viruses (AAVs)), long terminal repeats (LTRs) (e.g., those included in retroviruses), etc. A viral vector may include one or more sequences heterologous to the viral genome between the ITRs.
[0219] Viral vectors can be prepared using methods known to those skilled in the art or otherwise described herein. For example, viral vectors can be constructed and / or purified using methods such as those shown in U.S. Patent No. 4,797,368 and Laughlin CA et al., 1983.
[0220] Viral vectors can be packaged within viral particles. A variety of viral vectors are known in the art suitable for delivering nucleic acids to subjects, such as humans. The most commonly used viral vectors include those derived from adenoviruses, adeno-associated viruses (AAVs), and retroviruses, including lentiviruses such as human immunodeficiency virus (HIV). Retroviral vectors, adenoviruses, and AAVs provide an efficient and useful method for the effective introduction and expression of exogenous genes in mammalian cells. These vectors have a broad range of host and cell types and express genes stably and efficiently. The safety of these vectors is well understood in the art. Other viral vectors that can be used to transfer genes into subjects include herpesviruses, papillomaviruses such as JC, SV40, and polyomaviruses; Epstein-Barr virus (EBV); papillomaviruses such as bovine papillomavirus type I (BPV); polioviruses; and other human and animal viruses.
[0221] A more detailed description of viral vectors can be found in other parts of this disclosure, particularly in the following sections, which cover a wide range of types of viral vectors that are commonly used as gene delivery tools for subjects.
[0222] a) AAV carrier
[0223] In some embodiments, the nucleic acid vectors provided herein include associated viral (AAV) vectors. AAV is a single-stranded human DNA parvovirus with a genome size of approximately 4.7 kb. The AAV genome contains two major genes: the rep gene, which encodes rep proteins (Rep 76, Rep 68, Rep 52, and Rep 40); and the cap gene, which encodes AAV structural proteins (VP-1, VP-2, and VP-3), flanked by 5' inverted terminal repeats (ITRs) and 3' ITRs. As used herein, the term "AAV vector" encompasses any viral vector containing a heterologous sequence flanked by one or more AAV inverted terminal repeat sequences. As is well understood in the art, the term "AAV ITR" is a sequence of approximately 145 nucleotides present at both ends of a natural single-stranded AAV genome. The outermost 125 nucleotides of the ITR can be present in either of two alternative orientations, resulting in heterogeneity between different AAV genomes and between the ends of a single AAV genome. The outermost 125 nucleotides also contain several shorter self-complementary regions that allow intra-chain base pairing to occur within this part of the ITR.
[0224] AAV ITRs can be derived from any AAV, including but not limited to AAV serotype 1 (AAV 1), AAV 2, AAV 3, AAV 4, AAV 5, AAV 6, AAV 7, AAV 8, AAV 9, AAV 10, AAV 11, AAV 12, avian AAV, bovine AAV, canine AAV, equine AAV, and sheep AAV, as well as any other AAV now known or later discovered (see, for example, Bernard NF et al., 2007 and Gao G et al., 2004). The nucleotide sequence of the AAV ITR region is known (see, for example, Kotin RM, 1994 and Berns KI, 1990). Early descriptions of the terminal repeat sequences of AAV1, AAV2, and AAV3 can be found in Xiao, X., 1996, which is incorporated herein by reference in its entirety.
[0225] AAV ITRs can be natural AAV ITRs, or alternatively, they can be altered from natural AAV ITRs, for example, through mutation, deletion, or insertion, as long as the altered ITR can still mediate the desired biological function, such as replication, viral packaging, integration, etc. The 5' and 3' ITRs of selected nucleotide sequences flanking the AAV vector need not be identical or derived from the same AAV serotype, as long as they function as intended, for example, allowing for the excision and rescue of the sequence of interest and integration into the recipient cell genome. The genomic sequence of AAV, as well as the AAV rep and cap genes, are known in the art and can be found in the literature and public databases such as the GenBank database.
[0226] In some embodiments, the AAV vector may be recombinant. A recombinant AAV vector may contain one or more heterologous sequences from different viral sources (e.g., from non-AAV viruses, from different serotypes of AAV, or from partially or fully synthesized sequences). In some embodiments, the heterologous sequence is side-mounted with at least one AAV ITR.
[0227] In some embodiments, the AAV vectors provided herein have a size suitable for packaging into AAV viral particles. For example, the size of the AAV vector can be within the size limits of the genome size of the AAV to be used, for example, up to 5.2 kb. In some embodiments, the size of the AAV vector does not exceed 5.2 kb, does not exceed about 5 kb, does not exceed about 4.5 kb, does not exceed about 4 kb, does not exceed about 3.5 kb, does not exceed about 3 kb, and the size does not exceed about 2.5 kb (see, for example, Dong JY et al., 1996).
[0228] Due to the size limitations of a single AAV vector, for heterologous sequences exceeding the packaging capacity of a single AAV vector, two or more AAV vectors can be constructed in a manner that allows for reconstruction into complete sequences or expression cassettes in cells co-transfected with these AAV vectors. Methods for constructing such AAV vectors are known in the art, such as methods for constructing overlapping dual vectors, trans-splicing vector pairs, and hybrid vector systems, and further details are available in Chamberlain K et al., 2016, and U.S. Patent No. 6,596,535.
[0229] b) Adenovirus vector
[0230] In some embodiments, the exogenous nucleic acid comprises an adenovirus vector. Adenoviruses have a double-stranded linear DNA genome that cannot integrate into the host genome. Illustrative examples of adenovirus vectors include first-generation adenovirus vectors (e.g., adenovirus vectors lacking the E1a and E1b genes, and adenovirus vectors lacking the E1 and E3 genes), second-generation adenovirus vectors (e.g., adenovirus vectors lacking the E1 and E2 genes, adenovirus vectors lacking the E1 and E4 genes), and enterovirus-free adenovirus vectors lacking all viral coding sequences (also known as helper-dependent adenovirus vectors).
[0231] Typically, to work with adenoviral vectors, certain replication-defective adenoviral vectors are generated in supplementary cell lines configured to provide, at appropriate levels, gene functions absent in the replication-defective adenoviral vector but required for viral replication, in order to produce high-titer viral transfer vector stock solutions. Supplementary cell lines can compensate for deficiencies in at least one replication-essential gene function encoded by early regions, late regions, viral packaging regions, viral-associated RNA regions, or combinations thereof, including all adenoviral functions (e.g., enabling the replication of adenoviral amplicon). The construction of supplementary cell lines involves standard molecular biology and cell culture techniques known to those skilled in the art, such as those described in Sambrook et al., 1989 and Ausubel FM et al., 1994.
[0232] Complementary cell lines used to generate adenovirus vectors include, but are not limited to, 293 cells (described, for example, by Graham FL et al., 1977), PER.C6 cells (described, for example, by International Patent Application WO 97 / 00326 and U.S. Patents 5,994,128 and 6,033,908), and 293-ORF6 cells (described, for example, by International Patent Application WO 95 / 34671 and Brough DE et al., 1997). In some cases, the supplementary cells will not supplement all the essential adenovirus gene functions. Helper viruses can be used to provide trans-gene functions not encoded by the cell or adenovirus genome to enable adenovirus vector replication. Adenovirus vectors can be constructed, propagated, and / or purified using, for example, the materials and methods described below: U.S. Patents 5,965,358, 6,033,908, 6,329,200, 6,383,795, 6,447,995, and 6,475,757; U.S. Patent Application Publication No. 2002 / 0034735A1; and international patent applications WO 98 / 53087, WO 98 / 56937, WO99 / 15686, WO 99 / 54441, WO 00 / 12765, WO 01 / 77304, and WO 02 / 29388, as well as other documents identified herein. Non-C group adenovirus vectors, including adenovirus serotype 35 vectors, can be generated using methods described, for example, in U.S. Patent Nos. 5,837,511 and 5,849,561 and International Patent Applications WO 97 / 12986 and WO 98 / 53087.
[0233] c) Lentiviral vectors
[0234] In some embodiments, the nucleic acid vectors provided herein include lentiviral vectors. Lentivirals are complex retroviruses that, in addition to the common retroviral genes gag, pol, and env, contain other genes with regulatory or structural functions. Illustrative examples of lentiviral vectors include, but are not limited to, vectors derived from HIV-1, SIV, FIV, CAEV, VMV, and EIAV.
[0235] Lentiviral vectors can be generated using any method known in the art. Examples of lentiviral vectors and / or methods of generating them can be found, for example, in U.S. Publications Nos. 20150224209, 20150203870, 20140335607, 20140248306, 20090148936, and 20080254008, such lentiviral vectors and methods of generating them being incorporated herein by reference.
[0236] As an example, when the lentiviral vector lacks integration capability, the lentiviral genome further includes an origin of replication (ori), the sequence of which depends on the nature of the cell in which the lentiviral genome must be expressed. The origin of replication can be of eukaryotic origin, optionally mammalian origin, and further optionally human origin. Because the lentiviral genome does not integrate into the host cell genome (due to a defective integrase), the lentiviral genome may be lost in cells undergoing frequent cell division; this is especially true in the case of immune cells such as B or T cells. In some cases, the presence of the origin of replication may be beneficial. The vector particles can be generated after transfection with suitable cells, such as 293T cells, via the plasmid or by other methods. In cells used to express the lentiviral particles, all or some of the plasmids can be used for stable expression of their encoded polynucleotides or transient or semi-stable expression of their encoded polynucleotides.
[0237] d) Retroviral vectors
[0238] In some embodiments, the nucleic acid vectors provided herein include retroviral vectors. Retroviruses have an RNA genome and can replicate in host cells via reverse transcriptase to produce DNA from the RNA genome. Illustrative examples of retroviral vectors include, but are not limited to, vectors derived from: avian leukosis virus, mouse mammary tumor virus, murine leukosis virus, bovine leukosis virus, Walleye dermal sarcoma virus, HIV-1 (human immunodeficiency virus), HIV-2, SIV (simian immunodeficiency virus), EIAV (equine infectious anemia virus), FIV (feline immunodeficiency virus), CAEV (capillary arthritis encephalitis virus), VMV (visna / maedivirus), human foamy virus, Moloney murine leukaemia virus, Raul's sarcoma virus, feline leukosis virus, human T-lymphocyte virus, and simian foamy virus.
[0239] e) Other viral vectors
[0240] Methods for generating other viral vectors as described herein are known in the art and may be similar to those exemplified above.
[0241] viii. Preparation of the medium
[0242] Inducer mediators and target mediators can be prepared using methods known in the art.
[0243] In some embodiments, the inducer and / or target agent is a viral agent. The viral agent may include a viral vector packaged within a virus.
[0244] Viral vectors can be constructed using methods known in the art. The general principles of constructing recombinant viral vectors are known in the art. See, for example, Carter BJ et al., 1992 and Muzyczka N et al., 1992. For example, heterologous sequences can be directly inserted between terminal repeat (TR) sequences of a viral genome (e.g., AAV) where some unwanted viral genes have been deleted. Other parts of the viral genome can also be deleted, provided that sufficient TR portions are preserved to allow for replication and packaging functions. Such constructs can be designed using techniques well-known in the art. See, for example, U.S. Patents 5,173,414 and 5,139,941; International Publications WO 92 / 01070 and WO 93 / 03769; Lebkowski JS et al. 1988; Vincent KA et al. 1990; Carter BJ et al. 1992; Muzyczka N et al. 1992; Kotin RM. 1994; Shelling and Smith 1994; and Zhou SZ et al. 1994.
[0245] Alternatively, the viral TR can be excised from the viral genome or from a viral vector containing the viral genome, and fused with the heterologous sequence at the 5' and 3' ends using standard ligation techniques such as those described in Sambrook J et al., 1989. AAV vectors containing AAV ITRs are commercially available and have been described, for example, in U.S. Patent No. 5,139,941.
[0246] In some embodiments, the viral vector comprises recombinant viral particles. The viral particles can be generated from a viral expression vector. Viral particles can be generated using known techniques, such as transfection of a viral expression vector along with plasmids encoding certain viral genes (e.g., the AAV cap / rep gene) and other necessary mechanisms, including helper genes provided by adenovirus or herpesvirus, into a suitable host cell (see, for example, Naso MF et al., 2017, the entirety of which is incorporated herein by reference). The viral expression vector can be expressed in host cells and packaged into viral particles.
[0247] In some embodiments, the viral vector further includes a capsid protein. In some embodiments, the capsid protein may be natural or recombinant. In some embodiments, the capsid protein may be modified, chimeric, or synthetic. A modified capsid may include modifications such as insertion, addition, deletion, or mutation. For example, a modified capsid may be incorporated into a detection or purification tag. A chimeric capsid comprises portions of two or more capsid sequences. A synthetic capsid comprises synthetic or artificially designed sequences.
[0248] In some embodiments, the viral vector includes an AAV vector. The capsid structure of AAV is also known in the art and described in more detail in Bernard NF et al., 2007. In some embodiments, the capsid protein is derived from two or more AAV serotypes. It is known in the art that various AAV serotypes are functionally and structurally related, even at the genetic level (see, for example, Blacklow NR, 1988 and Rose J, 1974). However, AAV viral particles from different serotypes may have different tissue tropisms (see Nonnenmacher M et al., 2012 for details) and gene therapy can be appropriately selected for target tissues. In some embodiments, the cap gene or the capsid protein may have specific tropisms. The term "tropism" refers to a transduction pattern of one or more target cells, tissues, and / or organs. For example, the capsid protein may have tropisms specific to the liver (e.g., hepatocytes), brain, eye, muscle, lung, kidney, intestine, pancreas, salivary glands, or synovium, or any other suitable cell, tissue, or organ.
[0249] In some embodiments, the cap gene or the capsid protein is derived from any suitable AAV capsid gene or protein, such as, but not limited to, those derived from the following AAV capsid genes or proteins: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV12, AAV843, AAVbb2, AAVcyS, AAVrh10, AAVrh20, AAVrh39, AAVrh43, AAVrh64, AAVhu37, AAV3B, AAVhu48. AAVhu43, AAVhu44, AAVhu46, AAVhu19, AAVhu20, AAVhu23, AAVhu22, AAVhu24, AAVhu21, AAVhu27, AAVhu28, AAVhu29, AA Vhu63, AAVhu64, AAVhu13, AAVhu56, AAVhu57, AAVhu49, AAVhu58, AAVhu34, AAVhu45, AAVhu47, AAVhu51, AAVhu52, AAVhu T41, AAVhu S17, AAVhu T88, AAVhu T71, AAVhu T70, AAVhu T40, AAVhuT32, AAVhu T17, AAVhu LG15, AAVhu9, AAVhu10, AAVhu11, AAVhu53, AAVhu55, AAVhu54, AAVhu7, AAVhu18, AAVhu15, AAVhu16, AAVhu25, AAVhu60, AAVch5, AAVhu3, AAVhu 1. AAVhu4, AAVhu2, AAVhu61, AAVrh62, AAVrh48, AAVrh54, AAVrh55, AAVcy2, AAVrh35, AAVrh37, AAVrh36, AAVcy6, AAVcy4, AAVcy3, AAVcy5, AAV rh13, AAVrh38, AAVhu66, AAVhu42, AAVhu67, AAVhu40, AAVhu41, AAVrh40, AAVrh2, AAVbb1, AAVhu17, AAVhu6, AAVrh25, AAVpi2, AAVpi3, AAVrh57, AAVrh50, AAVrh49, AAVhu39, AAVrh58, AAVrh61, AAVrh52, AAVrh53, AAVrh51, AAVhu14, AAVhu31, AAVhu32, AAVrh34, AAVrh33, AAVrh32, Avian AAV ATCC VR-865, Avian AAV strain DA-1, or Bovine AAV.The capsid of AAV843 is identical to that of the synthetic capsid AAVXL32 disclosed in WO 2019241324A1 (which is incorporated herein in its entirety), and AAV843 is also disclosed, for example, in Xu J. et al., 2019.
[0250] More examples of AAV capsid gene and protein sequences can be found in the Genebank database, see Genebank accession numbers: AF043303, AF028705, AF028704, J02275, J01901, J02275, X01457, AF288061, AH009962, AY028226, AY028223, NC 001358, NC 001540,AF513851,AF513852,AY530579,AY631965,AY631966,AF063497,AF085716,AF513852,AY530579,AAS99264.1,AY243022,A Y243015,AY530560,AY530600,AY530611,AY530628,AY530553,AY530606,AY530583,AY530555,AY530607,AY530580,AY530569,NC 006263, NC 005889, NC001862, AY530609, AY530581, AY530563, AY530591, AY530562, AY530584, AY530622, AY530601, AY530586, AY243021, AY530570, AY530589 , AY530595, AY530572, AY530588, AY530575, AY530565, AY530590, AY530602, AY530566, AY530587, AY530585, AY530564, AY530592, AY530623, AY5305 74. AY530593, AY530560, AY530594, AY530573, AF513852, AY530624, AY530561, AY242997, AY530625, AY530567, AY530556, AY530578, AY530568, AY53 0618,AY243020,AY530579,AY530619,AY530596,AY530612,AY243000,AY530597,AY530620,AY242998,AY530598,AY242999,AY530599,AY243016,NC 001729, NC 001401, AY243018, NC 001863, AY530608, AY243019, NC001829, AY530610, AY243017, AY243001, AY530613, AY243013, AY243002, AY5306 14. AY243003, AY695378, AY530558, AY530626, AY695376, AY695375, AY530605, AY 695374, AY530603, AY530627, AY695373, AY695372, AY530604, AY695371, AY5306 00, AY695370, AY530559, AY695377, AY243007, AY243023, AY186198, AY629583, NC 004828, AY530629, AY530576, AY243015, AY388617, AY530577, AY530582, AY530615, AY530621, AY530617, AY530557, AY530616 or AY530554.
[0251] In some embodiments, the AAV vector comprises a cap gene from one AAV serotype and an AAV ITR from a second serotype. In some embodiments, the AAV vector comprises AAV viral particles containing pseudotyped AAV. "Pseudotyped" AAV refers to an AAV containing a capsid protein from one serotype and a viral genome including a 5'-3' ITR from a second serotype. Pseudotyped AAV is expected to have the cell surface binding properties of the capsid protein-derived serotype and the genetic characteristics consistent with the ITR-derived serotype.
[0252] AAV particles or virions including the transgene of interest can be generated using any recombinant method. AAV generating cells, AAV packaging cells, and packaging techniques known to those skilled in the art are described in (see, for example, U.S. Patents 5,436,146; 5,753,500, 6,040,183, 6,093,570, and 6,548,286, and US2002 / 0168342).
[0253] Typically, the method involves culturing packaging cells containing a nucleic acid sequence encoding an AAV capsid protein or a fragment thereof; a functional rep gene; a recombinant AAV vector comprising an AAV inverted terminal repeat (ITR) and a transgene; and sufficient helper functions to allow the recombinant AAV vector to be packaged into the AAV capsid protein. The components to be cultured in the host cells to package the rAAV vector into the AAV capsid can be provided trans-to the host cells. Alternatively, any one or more of the desired components (e.g., the recombinant AAV vector, rep sequence, cap sequence, and / or helper functions) can be provided by stable host cells that have been engineered to contain one or more of the desired components using methods known to those skilled in the art. Preferably, such stable host cells can contain the desired components under the control of an inducible promoter. However, the desired components can be under the control of a constitutive promoter. The recombinant AAV vector, rep sequence, cap sequence, and helper functions required to produce the rAAV of the present invention can be delivered to the packaging host cells using any suitable gene element. Selected gene elements can be delivered by any suitable method, including those described herein. Methods for constructing any embodiment of the present invention are known to those skilled in nucleic acid manipulation and include genetic engineering, recombinant engineering, and synthetic techniques. See, for example, Sambrook J et al., 1989. Similarly, methods for generating rAAV virions are well known, and the choice of suitable methods is not a limitation of the invention. See, for example, Fisher KJ et al., 1993 and U.S. Patent No. 5,478,745.
[0254] Any cell used in the art to generate rAAV viral particles can be used to generate the subject vector, including, for example, mammalian cells, insect cells, microorganisms, and yeast.
[0255] In one instance, using mammalian-generating cells, a recombinant AAV (rAAV) vector including a transgene can be transfected into the mammalian-generating cells. In some embodiments, recombinant AAV particles can be generated using a triple transfection method (see, for example, U.S. Patent No. 6,001,650). Typically, recombinant AAV is generated by transfecting host cells with a recombinant AAV vector (including a transgene) to be packaged into AAV particles, an AAV helper function vector, and an accessory function vector. Typically, the AAV helper function vector encodes AAV helper function sequences (rep and cap) that act in trans-acting on productive AAV replication and capsid formation. Optionally, the AAV helper function vector supports efficient AAV vector generation without generating any detectable wild-type AAV virions (i.e., AAV virions containing the functional rep and cap genes). The helper function vector may encode nucleotide sequences of non-AAV-derived viral and / or cellular functions that AAV replicates dependently on. Accessory functions include those required for AAV replication, including but not limited to those involving activation of AAV gene transcription, stage-specific AAV mRNA splicing, AAV DNA replication, synthesis of the cap expression product, and those parts of AAV capsid assembly. Virus-based accessory functions can be derived from any known helper virus, such as adenovirus, herpesvirus (except herpes simplex virus type 1), and vaccinia virus. In some cases, packaging cells can be used, where the AAV rep and cap genes are stably maintained in host cells (e.g., 293 cells or HeLa cells). In some cases, the host cell is the generating cell in which the AAV vector genome is stably maintained and packaged. Generating cells can be cultured to produce rAAV particles that are purified and formulated using standard techniques known in the art.
[0256] In another instance, the AAV expression vector can be packaged as a baculovirus and introduced into insect-producing cells (e.g., Sf9 cells). The AAV REP and CAP genes are also introduced into insect cells via another baculovirus. Baculoviruses—as viruses—include genes encoding auxiliary functions essential for efficient rAAV virus production. Therefore, when insect cells are infected with two baculoviruses, producing cells can be cultured to generate rAAV, and the AAV vector can be purified and formulated using standard techniques known in the art.
[0257] In some embodiments, the inducer and / or target agent are non-viral agents. In some embodiments, the non-viral inducer agent comprises an immunogenic synthetic nanocarrier capable of delivering the at least one immunosuppressant or a nucleic acid carrier encoding the at least one immunosuppressant.
[0258] In some embodiments, the target medium includes an immunogenic synthetic nanocarrier capable of delivering the at least one target gene or a nucleic acid carrier capable of delivering the at least one target gene.
[0259] In other words, delivering the medium to the subject does not require viral particles containing nucleic acid vectors, but involves delivering nucleic acid vectors using non-viral vectors.
[0260] Synthetic nanocarriers can be prepared using a variety of methods known in the art. Such references include U.S. Patents 5,578,325 and 6,007,845 and Doubrow, 1992; Mathiowitz E et al., 1987a, Mathiowitz E et al., 1987b, Mathiowitz E et al., 1988 and Paolicelli P et al., 2010.
[0261] For example, synthetic nanocarriers can be formed by methods such as nanoprecipitation, flow focusing using fluid channels, spray drying, solvent evaporation of monoemulsions and biemulsions, solvent extraction, phase separation, grinding, microemulsion processes, precision machining, nanofabrication, sacrificial layers, simple and complex agglomeration, and other methods well known to those skilled in the art. Alternatively, aqueous and organic solvent synthesis for monodisperse semiconductor nanomaterials, conductive nanomaterials, magnetic nanomaterials, organic nanomaterials, and other nanomaterials has been described in published U.S. Patent Nos. 5,578,325 and 6,007,845.
[0262] Various methods (including, but not limited to, those already published) can be used to encapsulate various materials into synthetic nanocarriers as needed (e.g., Astete CE et al., 2006; Avgoustakis K, 2004; Reis CP et al., 2006; and Paolicelli P et al., 2010). Other methods suitable for encapsulating materials into synthetic nanocarriers can be used, including, but not limited to, the methods disclosed in U.S. Patent No. 6,632,671.
[0263] In some embodiments, synthetic nanocarriers are prepared by nanoprecipitation or spray drying. The conditions used to prepare the synthetic nanocarriers can be varied to produce particles with desired sizes or properties (e.g., hydrophobicity, hydrophilicity, external morphology, "viscousness," shape, etc.). The method for preparing the synthetic nanocarriers and the conditions used (e.g., solvent, temperature, concentration, airflow rate, etc.) may depend on the composition of the material and / or polymer matrix to be attached to the synthetic nanocarriers. If the synthetic nanocarriers prepared by any of the methods described above have a size range outside the desired range, then such synthetic nanocarriers can be sized, for example, using a sieve.
[0264] Elements (i.e., components) of the synthetic nanocarrier can be attached to the entire synthetic nanocarrier, for example, through one or more covalent bonds, or through one or more connectors (e.g., amide connectors, disulfide connectors, thioether connectors, hydrazone connectors, hydrazide connectors, imine or oxime connectors, urea or thiourea connectors, amidine connectors, amine connectors, sulfonamide connectors, etc.). The compositions and methods can be adapted from U.S. Patent Applications No. 20060002852 and No. 20090028910, International Patent Application No. WO 2008127532, and published literature including Sharpless VV et al., 2002 and Meldal M et al., 2008.
[0265] Alternatively or additionally, synthetic nanocarriers can be attached to components directly or indirectly via non-covalent interactions. In non-covalent embodiments, non-covalent coupling is mediated by non-covalent interactions, including but not limited to charge interactions, affinity interactions, metal coordination, physisorption, host-guest interactions, hydrophobic interactions, TT stacking interactions, hydrogen bonding interactions, van der Waals interactions, magnetic interactions, electrostatic interactions, dipole-dipole interactions, and / or combinations thereof. Such couplings can be arranged on the outer or inner surface of the synthetic nanocarrier. In embodiments, encapsulation and / or absorption is a form of coupling. In embodiments, synthetic nanocarriers can be combined with therapeutic macromolecules or other compositions by mixing them into the same medium or delivery system.
[0266] application
[0267] As used herein and in the broadest sense, the term "administer" (administering or administration) means the administration or dispensing of a pharmaceutically active material to a subject in a pharmacologically compatible manner. The term is intended to include "causing administration," which means directly or indirectly causing, urging, encouraging, assisting, inducing, or guiding another party to administer the pharmaceutically active material to a subject. It should be noted that in some embodiments, the term may also be used interchangeably with "deliver, delivery, or delivering," etc. As used herein, pharmaceutically active materials include mediators (i.e., inducer mediators and / or target mediators).
[0268] In a general sense, the administration of the inducer mediator and / or target mediator can take various routes, which can be systemic or localized to the treatment area. Optionally, the mediator can be administered to the subject via parenteral, oral, enteral, oral, nasal, local, rectal, vaginal, transmucosal, epidermal, transdermal, dermal, ocular, lung, cardiac, subcutaneous, intraparenchymal, intraventricular, or intrathecal administration. In some embodiments, the inducer mediator and / or target mediator is delivered to the subject orally, intravenously, intraperitoneally, intramuscularly, subcutaneously, intrathecally, intraventricularly (ICV), or rectally. Administration routes may also include inhalation or pulmonary aerosol administration. Techniques for preparing aerosol delivery systems are well known to those skilled in the art.
[0269] In some embodiments, the medium includes a viral particle (or virus particle), i.e., the inducer medium includes an inducer viral particle, and / or the target medium includes a target viral particle. Therefore, methods and uses for administering or delivering viral particles include any mode compatible with the subject. In specific embodiments where the viral particle includes AAV viral particles, the viral particle is administered to the subject intravenously, intra-arterially, intramuscularly, subcutaneously, orally, via cannulation, through a catheter, through the skin, intracranially, via inhalation, intracavitaryly, or through a mucosa.
[0270] In some embodiments, in combination with the administration of a mediator (e.g., an inducer mediator), at least one immunosuppressive agent (e.g., a compound, nucleic acid, peptide, or combination thereof with immunosuppressive function) is additionally administered to the subject. In this document, the administration of said at least one immunosuppressive agent may involve the use of certain mediators such as nanocarriers or nanoparticles encapsulating the immunosuppressive agent. Furthermore, said at least one immunosuppressive agent need not be administered simultaneously with the mediator or in the same composition as the mediator. In other words, said at least one immunosuppressive agent may be administered before or after the mediator administration as needed, and may be administered via the same or different routes / methods as the mediator.
[0271] Depending on the specific needs, the administration of the active pharmaceutical ingredient (i.e., the mediator) may include a single, single administration or repeated administration, i.e., more than one administration of the same active pharmaceutical ingredient. As used herein, the terms "repeated administration," "repeatedly administer," or "repeatedly administering" refer to the enhancement or prolongation of a previously established effect (i.e., expression of a target gene or treatment of a symptom, etc.) achieved through multiple administrations of the target mediator to a subject. These implementations typically involve the (n+1)th administration of the target mediator after the nth administration (where n is an integer not less than 0), and the (n+1)th administration is usually performed when the established effect of the target mediator following the nth administration is declining or about to decline.
[0272] For example, depending on whether immune tolerance to the immunogenic target agent can be achieved in the subject, the inducer agent may be administered once, and if so, only once, or more than once (e.g., two, three, four, etc.) if subsequent administration is required after the first administration to enhance the effect. In the latter case, repeated administration may be considered interchangeable with "repeated dose" or "repeated administration," meaning administering at least one additional dose or administration to the subject after an earlier dose or administration of the same material. For example, a repeated dose of viral particles is at least one additional dose of viral particles after a previous dose of the same viral particles, and in this context, the viral particles may be either inducer viral particles or target viral particles.
[0273] While the active pharmaceutical material used for repeated administration can be the same, the amount of material (i.e., the dose) in the repeated dose can be the same as or different from the earlier dose. For example, in some embodiments where the inducer medium includes inducer virus particles, the amount of inducer virus particles in the repeated dose (i.e., the subsequently administered dose) may be less than the amount of inducer virus particles in the earlier dose. Alternatively, the amount in the repeated dose can be at least equal to the amount of inducer virus particles in the earlier dose.
[0274] Apart from dosage, the frequency and / or route / method of repeated administration or application of the pharmaceutical active material can vary as needed. For example, repeated doses may be administered weeks, months, or years after a previous dose. In some embodiments, the repeated dose or administration is administered at a dose that occurred exactly before the repeated dose or administration, or at least one week after administration.
[0275] Immune tolerance
[0276] The method described herein can induce immune tolerance to an immunogenic target agent in a subject by administering an immunogenic inducer mediated as described herein, for example, an immunogenic inducer mediated comprising an inducer nucleic acid vector encoding at least one immunosuppressant.
[0277] Immune tolerance can be determined, for example, by the antibody titer of anti-mediator antibodies in the subject's serum. As used herein, the term "anti-mediator antibody" means one or more antibodies that can specifically bind to an inducer mediator and / or a target mediator.
[0278] In some embodiments, immune tolerance is characterized by the subject's serum having an antibody titer of anti-mediator antibodies below a predetermined threshold level after administration of an immunogenic inducer mediator. The anti-mediator antibody titer can be measured by any suitable method known in the art, for example, ELISA, and can be determined by the serum dilution factor to produce threshold-specific binding with the inducer mediator or target mediator, optionally present in a given amount. Different dilution factor thresholds can be selected to determine the presence of induced immune tolerance, depending on the required sensitivity.
[0279] In some embodiments, immune tolerance is characterized in that, after administration of the immunogenic inducer mediated agent, the antibody titer of the subject's serum against the mediated agent does not exceed 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200, and wherein the antibody titer is defined as the dilution factor by which the subject's serum produces threshold-specific binding to the inducer mediated agent or the target particle. In some embodiments, the specific binding of the anti-mediated agent antibody to the inducer mediated agent or the target particle is determined by ELISA.
[0280] In some embodiments, threshold-specific binding is determined based on a given amount of the medium, wherein threshold-specific binding is considered sufficient to indicate an antibody binding level specifically to the medium. In some embodiments, binding is determined based on the following formula: (binding) (存在媒剂) –Combination (不存在媒剂) ) / combination (不存在媒剂) The threshold for specific binding can be appropriately set by those skilled in the art. In some embodiments, the threshold for specific binding is set to 2, 2.5, 3, 3.5, 4, or 5.
[0281] In some embodiments, the inducing agent and / or target agent are viral particles, and immune tolerance can be determined by the antibody titer of neutralizing antibodies in the subject's serum. As used herein, the term "neutralizing antibody" refers to an antibody that can effectively inhibit viral particles from infecting their susceptible host cells. Neutralizing antibody titers can be analyzed by assessing the ability of serum antibodies to inhibit the transduction or infection of susceptible host cells (i.e., HUH-7 cells or HEK293 cells against AAV), where the viral particles of interest may express reporter genes such as β-galactosidase or luciferase after transduction or infection. Neutralizing antibody titers can be determined by dilution factors of serum to produce maximum neutralization of approximately 50% against the inducing agent and / or target agent, optionally present in a given amount. Different dilution factor thresholds can be selected to determine the presence of induced immune tolerance, depending on different sensitivity requirements.
[0282] In some embodiments, immune tolerance is characterized in that, after administration of an immunogenic inducer mediator, the antibody titer of neutralizing antibodies in the subject's serum does not exceed 2, 4, 6, 8, 18, or 32, and wherein the antibody titer is defined as the dilution factor by which the subject's serum produces a maximum neutralization of 50% with the inducer mediator or target mediator.
[0283] Pre-existing immunity
[0284] In some implementations, the subject does not have a pre-existing immune response to the inducer or the target agent, or both.
[0285] As used herein, the phrase “pre-existing immune response” refers to an acquired immune response that is present prior to administration of the inducer mediated to the subject. Such a pre-existing immune response may be acquired due to prior exposure to the relevant antigen. For example, if the inducer mediated includes AAV viral particles, prior exposure to or infection with the relevant AAV may have resulted in an acquired immune response to the inducer mediated, even before administration of the inducer mediated to the subject.
[0286] In some embodiments, the pre-existing immune response is characterized by the subject's serum having an antibody titer of anti-mediator antibodies above a predetermined threshold level prior to administration of the immunogenicity inducer mediator. Similarly, the antibody titer of the anti-mediator antibodies can be measured by any suitable method known in the art, such as ELISA, and different antibody titer thresholds can be selected to determine the presence of pre-existing immunity depending on the required sensitivity.
[0287] In some embodiments, the pre-existing immune response is characterized in that, prior to step a), the subject's serum has an antibody titer of at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 against the anti-mediator antibody, and wherein the antibody titer is defined as the dilution factor by which the subject's serum produces threshold-specific binding to the inducer mediator or the target mediator.
[0288] In some embodiments, threshold-specific binding is determined based on a given amount of the medium, wherein threshold-specific binding is considered sufficient to indicate an antibody binding level specifically to the medium. In some embodiments, binding is determined based on the following formula: (binding) (存在媒剂) –Combination (不存在媒剂) ) / combination (不存在媒剂) The threshold for specific binding can be appropriately set by those skilled in the art. In some embodiments, the threshold for specific binding is set to 2, 2.5, 3, 3.5, 4, or 5.
[0289] In some embodiments, the inducer and / or target mediator comprises viral particles, and pre-existing immunity can be determined by the antibody titer of neutralizing antibodies in the subject's serum. Neutralizing antibody titers can be analyzed by any suitable method, such as a reporting assay as described above. Neutralizing antibody titers can be determined by a dilution factor of the serum to produce maximum neutralization of approximately 50% against the inducer and / or target mediator optionally present in a given amount. Different thresholds can be selected to determine the presence of pre-existing immunity, depending on the required sensitivity.
[0290] In some embodiments, the pre-existing immune response is characterized in that, prior to administration of the inducer mediator to the subject, the subject's serum has a neutralizing antibody titer of at least 2, 4, 6, 8, 18, or 32, and wherein the antibody titer is defined as the dilution factor by which the subject's serum produces a maximum neutralization of 50% with the inducer mediator or target mediator.
[0291] In some embodiments, the anti-mediator antibody or neutralizing antibody targets the capsid of the inducer virus particle of the inducer mediator or the capsid of the target virus particle of the target mediator, or both.
[0292] Methods for expressing target genes
[0293] In one aspect, this disclosure further provides a method for expressing a target gene in a subject, wherein the subject has existing immune tolerance to the immunogenic target agent. In one embodiment, such existing immune tolerance can be induced by the method provided herein using the immunogenicity inducer agent provided herein.
[0294] Basically, the method for expressing a target gene in a subject is through an immunogenic target agent comprising a target vector encoding the target gene, wherein the subject has existing immune tolerance to the immunogenic target agent. The method includes the following steps: a) administering the immunogenic target agent to the subject.
[0295] In this document, prior to administration of the target agent, existing immune tolerance has been induced by exposing the subject to the immunogenic inducer agent provided herein. In some embodiments, the inducer agent comprises an inducer nucleic acid vector encoding at least one immunosuppressant, whereby the at least one immunosuppressant has been expressed in the subject to allow suppression of the immune response against the inducer agent and cross-reactive with the target viral agent.
[0296] In one aspect, this disclosure further provides a method for expressing a target gene in a subject using an immunogenic target agent comprising a target vector encoding the target gene. This method is also based on a method for inducing immune tolerance to the immunogenic target agent used for gene delivery in a subject as described above. Essentially, the method comprises the following two steps:
[0297] a) Administering the immunogenicity inducer mediator provided herein to the subject, thereby inhibiting the immune response to the inducer mediator and cross-reactive to the target mediator, thereby inducing immune tolerance to the target mediator in the subject; and
[0298] b) Administer the target agent to the subject having such induced immune tolerance, thereby expressing the target gene in the subject.
[0299] In some embodiments, the immunogenicity inducer mediator includes an inducer nucleic acid vector encoding at least one immunosuppressant, thereby allowing the at least one immunosuppressant to be expressed in the subject, the at least one immunosuppressant inhibiting an immune response against the inducer mediator and cross-reactive to the target mediator, thereby inducing immune tolerance against the target mediator in the subject.
[0300] The expression of transgenes carried by inducers / target vectors, such as any of the at least one immunosuppressant encoded by an inducer nucleic acid vector and / or any of the at least one target gene encoded by a target nucleic acid vector, can be qualitatively or quantitatively characterized in subjects. For this purpose, the following general means and methods can be employed, which may include the qualitative detection of the presence of transgenes in certain organs, body fluids, or target cells of the subject and / or the quantitative determination of their expression levels.
[0301] Qualitative and quantitative characterization of the corresponding polynucleotides in a transgene can be performed using any convenient method. For example, PCR (including quantitative PCR, real-time PCR, etc.), Southern blotting, next-generation sequencing, and microarrays can be used for qualitative or quantitative characterization of polynucleotides. If the transgene encodes a gene product such as an RNA product (e.g., mRNA, miRNA, or antisense RNA), the expression of the RNA product can be qualitatively or quantitatively characterized using methods such as RT-PCR (including real-time RT-PCR), Northern blotting, RNase protection, and microarrays. If the transgene's mRNA product is further translated into a polypeptide product, the polypeptide product can be qualitatively or quantitatively characterized using methods such as Western blotting, ELISA, and immunohistochemistry, using a specific antibody targeting each polypeptide in this class. Other transgene qualitative and / or quantitative detection techniques and methods can also be used.
[0302] As used herein, the term "expression" (or "expressing") refers to the transcription of a coding DNA sequence into mRNA and / or the translation of a coding DNA sequence into a peptide or protein. As used herein, the phrase "expression of a transgene" refers to the expression of a coding sequence (e.g., a sequence encoding a protein of interest) included in an inducer / target vector. In some embodiments, the expression level of the exogenous nucleic acid is determined based on either the mRNA or protein level.
[0303] In some implementations, the expression level of the target gene can be increased, or the duration of expression can be prolonged.
[0304] Treatment
[0305] In one aspect, this disclosure further provides a method for treating a subject's condition with an immunogenic target agent comprising a target vector encoding a target gene capable of treating the condition, wherein the subject has existing immune tolerance to the target agent. The method includes the steps of: a) administering an effective amount of the target agent to the subject, thereby expressing the target gene in the subject to treat the condition. In this document, existing immune tolerance has been induced prior to administration of the target agent by exposing the subject to the immunogenicity inducer agent provided herein.
[0306] In some embodiments, the inducer medium includes an inducer nucleic acid vector encoding at least one immunosuppressant, wherein the at least one immunosuppressant has been expressed in the subject to allow suppression of the immune response against the inducer medium and cross-reactive to the target medium.
[0307] In one aspect, this disclosure further provides a method for treating a subject's condition with an immunogenic target agent comprising a target vector encoding a target gene capable of treating the condition. The method comprises the following two steps:
[0308] a) Administering an effective amount of the immunogenic inducer mediator provided herein to the subject, thereby inhibiting the immune response against the inducer mediator and cross-reactive to the target mediator, thereby inducing immune tolerance to the target mediator in the subject; and
[0309] b) Administer an effective amount of the target agent to the subject having such induced immune tolerance, thereby expressing the target gene in the subject to treat the condition.
[0310] In some embodiments, the inducer medium includes an inducer nucleic acid vector encoding at least one immunosuppressant, thereby allowing the at least one immunosuppressant to be expressed in the subject, the at least one immunosuppressant inhibiting an immune response that is cross-reactive against the inducer medium and to the target medium, thereby inducing immune tolerance against the target medium in the subject.
[0311] In any of the methods provided in the foregoing aspects of this disclosure, various embodiments of the inducing agent, the at least one immunosuppressant, the target agent, cross-reactivity, immune response, and / or immune tolerance can be referenced to various embodiments of the methods for inducing immune tolerance to an immunogenic target agent for gene delivery in subjects described above. For the sake of brevity, detailed descriptions of the various embodiments are omitted herein.
[0312] As used herein, the term "symptom" refers to any disease or condition in a subject who is readily treatable with a target vector that may carry a target vector encoding and expressing a target gene. The term "treating" (or "treatment") as used herein includes alleviating the symptom, slowing the onset or progression of the symptom, reducing, alleviating, or ending symptoms associated with the symptom, producing complete or partial remission of the symptom, curing the symptom, or some combination thereof.
[0313] In some embodiments, such conditions are characterized by the absence of one or more functional genes or proteins. In some embodiments, such conditions are suitable for gene therapy. The target gene carrying the target agent delivered to the subject may be useful for replacing or repairing missing or dysfunctional molecular elements (e.g., genes) in the DNA of the subject's living cells, or alternatively, may provide or enhance the function of missing or dysfunctional genes in the cells by introducing and expressing functional genes in the cells.
[0314] In some embodiments, the condition is a "monogenous disease," which is caused by one or more abnormalities in the genome affecting one or two copies of a single gene. Genomic abnormalities damage genes and lead to a loss or deficiency of activity in endogenous proteins encoded by the damaged gene. Symptoms of a monogenic disease are caused by the loss or deficiency of activity in these endogenous proteins. In some embodiments, the monogenic disease is autosomal dominant, autosomal recessive, X-linked, Y-linked, or mitochondrial.
[0315] Examples of autosomal dominant single-gene disorders include, but are not limited to, Brugada syndrome, myotonic dystrophy type 1, myotonic dystrophy type 2, hereditary multiple infarct dementia, Huntington's disease, neurofibromatosis type 1, neurofibromatosis type 2, Marfan syndrome, familial hypercholesterolemia (FH), polycystic kidney disease, hereditary spherocytosis, hereditary nonpolyposis colorectal cancer, hereditary multiple exostosis, tuberous sclerosis, Von Willebrand disease and acute intermittent porphyria, Dravet syndrome, Peutz-Jeghers syndrome, achondroplasia, primary combined immunodeficiency, familial adenomatous polyposis (FAP), spinocerebellar ataxia, and multiple endocrine neoplasia.
[0316] Examples of autosomal recessive single-gene disorders include, but are not limited to, β-ketothiolate deficiency, biotinylate deficiency, Wilson's disease, spinal muscular atrophy, N-acetylglutamate synthase deficiency, lysosomal acid lipase deficiency, lysineuria protein intolerance, long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, Laron syndrome, isovaleric acidemia, hyperornithine-hyperammonia-hypercitrullinuria syndrome, carboxylase synthase deficiency, hereditary fructose intolerance, type II glycogen storage disease, type I glutamateemia, Gitelman syndrome, and Gaucher disease. Diseases, familial Mediterranean fever, congenital myotonia, citrullinemia I, citrullinemia II, primary carnitine deficiency, arginase deficiency, medium-chain acyl-CoA dehydrogenase deficiency, sickle cell anemia, cystic fibrosis, Tay-Sachs disease, phenylketonuria, lysosomal acid lipase deficiency, glycogen storage disease, galactosemia, Niemann-Pick disease, spinal muscular atrophy (SMA), Roberts syndrome, very long-chain acyl-CoA dehydrogenase deficiency, cystic fibrosis, Gaucher disease, Werner syndrome, Fanconi anemia, mucopolysaccharidosis (I, IIIA, IIIB, IVA, IVB, VI, VII, IX).
[0317] Examples of X-linked monogenic disorders include, but are not limited to, Fragile X syndrome, congenital adrenal dysplasia, Duchenne muscular dystrophy and hemophilia A, hemophilia B, Fabry disease, X-linked agammaglobulinemia, X-linked adrenoleukodystrophy, spinal and bulbar muscular atrophy, ornithine transcarbamase deficiency and mucopolysaccharidosis II, adrenoleukodystrophy (ALD), and chronic granulomatous disease.
[0318] Other examples of monogenic disorders include McCune-Albright syndrome, paroxysmal nocturnal hemoglobinuria, ADA immunodeficiency, amyotrophic lateral sclerosis (ALS), glucose-galactose, muscular dystrophy, azoospermia, Ehlers-Danlos syndrome, retinitis pigmentosa, hemochromatosis, melanoma, retinoblastoma, Alzheimer's disease, amyloidosis, myotonic dystrophy, giant axonal neuropathy, alpha-1 antitrypsin, Parkinson's disease, and severe combined immunodeficiency (ADA-SCID / X-SCID).
[0319] Examples of polygenic disorders include heart disease, cancer (e.g., leukemia, specifically acute lymphoblastic leukemia), diabetes, schizophrenia, and Alzheimer's disease.
[0320] Repeated application
[0321] In any of the methods provided above, the step of administering the target agent to the subject includes repeatedly administering the target agent to the subject. The time interval between two adjacent administrations can be from 2 weeks to 1 year, and optionally from 1 to 6 months. However, it should be noted that this disclosure also covers implementations involving repeated administration according to a regular schedule of administration every half week, week, bi-weekly, or any other regular schedule.
[0322] Pharmaceutical Compositions and Kits
[0323] In one aspect, this disclosure further provides a kit for inducing immune tolerance to an immunogenic target agent to be delivered in a subject. Such a kit can be used to implement the method for inducing immune tolerance to an immunogenic target agent in a subject as described above.
[0324] The kit includes a first pharmaceutical composition comprising a therapeutically effective amount of an inducer mediator. The inducer mediator comprises at least one inducer nucleic acid vector, each inducer nucleic acid vector encoding and configured to allow expression of at least one immunosuppressant in a subject. In this document, each of the at least one immunosuppressant is characterized in that, when expressed in a subject, the immunosuppressant can suppress an immune response in the subject against the inducer mediator, and the immune response is configured to be cross-reactive to the target mediator.
[0325] Optionally, the inducer and / or target agent may be a virus-based agent comprising virus particles, or may be based on a non-viral agent.
[0326] In some embodiments of the kit, the inducer medium comprises inducer virus particles, and / or the target medium comprises target virus particles.
[0327] Optionally in this document, each of the inducer virus particles and the target virus particles may include a capsid.
[0328] Further optionally, the immune response may include generating at least one antibody capable of binding to the capsid of the inducer virus particle.
[0329] Further optionally, the at least one antibody may be cross-reactive to the capsid of the target virus particle.
[0330] In the kit, both the inducer virus particles and the target virus particles may optionally have the same type of virus. In this document, the type of virus may be selected from the group consisting of adenovirus, adeno-associated virus (AAV), lentivirus, retrovirus, and oncolytic virus. In some embodiments, the type of virus is adeno-associated virus (AAV). Furthermore, both the inducer virus particles and the target virus particles may be based on AAV having serotype AAV8.
[0331] In some embodiments of the kit, the inducer virus particles and the target virus particles have the same serotype or different serotypes.
[0332] In some embodiments of the kit, each of the inducer virus particles and the target virus particles includes the same capsid protein.
[0333] In any of the embodiments of the kit described above, the at least one immunosuppressant may act by downregulating the immune stimulation pathway and / or by upregulating the immunosuppressive pathway.
[0334] According to some embodiments, one or more of the at least one immunosuppressant reduces the expression or activity of one or more targets in an immune stimulation pathway. Optionally, each of the one or more targets is selected from the group consisting of: CD27, CD70, CD28, CD80 (B7-1), CD86 (B7-2), CD40, CD40L (CD154), CD122, CD137, CD137L, OX40 (CD134), OX40L (CD252), GITR, ICOS (CD278), and ICOSLG (CD275).
[0335] Further optionally, the one or more targets are in at least one of the B7 / CD28 co-stimulatory signaling pathway or the CD40 / CD40L co-stimulatory signaling pathway.
[0336] Further optionally, each of the one or more targets is selected from the group consisting of: CD28, CD80 (B7-1), CD86 (B7-2), CD40, or CD40L (CD154).
[0337] According to some other embodiments, one or more of the at least one immunosuppressant increases the expression or activity of one or more targets in an immunosuppressive pathway. Optionally, each of the one or more targets is selected from the group consisting of: A2AR, B7-H3 (CD276), B7-H4 (VTCN1), BTLA (CD272), CTLA-4 (CD152), IDO1, IDO2, TDO, KIR, LAG3, NOX2, PD-1, PD-L1, PD-L2, TIM-3, VISTA, SIGLEC7 (CD328), TIGIT, PVR (CD155), and SIGLEC9 (CD329).
[0338] According to some other embodiments, the at least one immunosuppressant regulates the expression or activity of at least one of TLR2, TLR9, MyD88, IFN-1, IRF-7, NF-κB, mTOR, CD3, CD4, CD278, CD19, CD20, CD79, IL-4, IL-2R, IL-5, IL-6R, TNF-α, or LFA-1.
[0339] In some embodiments, the at least one immunosuppressant downregulates the B7-CD28 immune stimulation pathway. Optionally herein, the at least one immunosuppressant inhibits the expression and / or function of CD28, CD80 (B7-1), and CD86 (B7-2). In some embodiments, the at least one immunosuppressant disrupts or blocks B7-CD28 interaction (e.g., binding). In some embodiments, the at least one immunosuppressant competes with CD28 for binding to B7, or competes with B7 for binding to CD28.
[0340] In some embodiments, the at least one immunosuppressant comprises a CTLA-4 derivative. Optionally, the at least one immunosuppressant comprises an extracellular domain of CTLA-4, a B7-binding fragment of CTLA-4, or a mutant thereof. Various embodiments of suitable CTLA-4 derivatives can be found in other parts, for example, methods described in other aspects of this disclosure.
[0341] In some embodiments, the at least one immunosuppressant downregulates the CD40 / CD40L immune stimulation pathway. In some embodiments, the at least one immunosuppressant inhibits the expression and / or function of CD40 or CD40L. In some embodiments, the at least one immunosuppressant disrupts or blocks the interaction between CD40 and CD40L. In some embodiments, the at least one immunosuppressant competes with CD40L for binding to CD40, or competes with CD40 for binding to CD40L. In some embodiments, the at least one immunosuppressant comprises a CD40L-binding ligand or a CD40L-binding fragment of an anti-CD40L antibody.
[0342] In some embodiments, the at least one immunosuppressant comprises a CD40 derivative. Optionally, the at least one immunosuppressant comprises an extracellular domain of CD40, a CD40L-binding fragment of CD40, or a mutant thereof that retains CD40L binding function or affinity. Various different embodiments of suitable CD40 derivatives can be found in other parts, for example, methods described in other aspects of this disclosure.
[0343] In some embodiments, the at least one immunosuppressant downregulates both the B7-CD28 immune stimulation pathway and the CD40 / CD40L immune stimulation pathway. In some embodiments, the at least one immunosuppressant comprises a first immunosuppressant that downregulates the B7-CD28 immune stimulation pathway and a second immunosuppressant that downregulates the CD40 / CD40L immune stimulation pathway. Downregulation of the B7-CD28 immune stimulation pathway may involve inhibiting the expression and / or function of CD28, CD80 (B7-1), or CD86 (B7-2), or disrupting or blocking B7-CD28 interactions (e.g., binding). Downregulation of the CD40-CD40L immune stimulation pathway may involve inhibiting the expression and / or function of CD40 or CD40L, or disrupting or blocking CD40-CD40L interactions.
[0344] In some embodiments of the kit, the at least one immunosuppressant comprises at least one immunosuppressive protein.
[0345] In some embodiments, the at least one immunosuppressive protein includes one of the following, or a combination of two immunosuppressive proteins including the following:
[0346] (1) The extracellular domain of CTLA-4 or a fragment thereof capable of binding to at least one of CD80(B7-1) or CD86(B7-2); and
[0347] (2) The extracellular domain of CD40 or a fragment or antibody fragment that can bind to CD40L (CD154).
[0348] Further optionally, each of the at least one immunosuppressive protein further includes a half-life-extending peptide portion. In some embodiments, the half-life-extending peptide portion includes an Fc portion such as IgG Fc. Other embodiments of the half-life-extending peptide portion may include albumin family member proteins (e.g., HSA), follicle-stimulating hormone (FSH), fibronectin, fibroblast activating protein (FAP), coagulation factors (e.g., von Willebrand factor, factor V, etc.) or functional (i.e., capable of extending half-life) fragments, and may also include serum albumin-binding polypeptides. Further details can be found in other parts of other aspects of this disclosure, for example, as described above.
[0349] In any implementation of the kit described above, the at least one immunosuppressant comprises at least one immunosuppressive nucleic acid.
[0350] In some embodiments of the kit that includes viral particles in each of the inducer mediators and target mediators, the kit may optionally further include a packaging cell line configured to allow the production of an inducer mediator comprising each of the at least one inducer nucleic acid vector.
[0351] Optionally, the viral particles described herein are derived from adeno-associated virus (AAV), and optionally, the viral particles are derived from a packaging cell line, optionally the HEK293 cell line or a variant thereof. Many variants of the HEK 293 cell line have been reported, such as HEK293 (e.g., ATCC crl-1573); HEK293T (e.g., ATCC CRL-11268; ACS-4500, CRL-11268G-1; ATCC CRL-3216); HEK 293STF (ATCC CRL-3249); HEK-293.2sus (ATCC CRL-1573.3); AAVpro 293T (TaKaRa catalog number 632273); HEKExpress (ExcellGene); 293AAV cell line (Cell Biolabs, catalog number AAV-100), etc. These can be used for AAV generation.
[0352] In any embodiment of the kit described above, the kit may further include a first instruction manual for administering the first pharmaceutical composition to a subject. Hereinafter, the first instruction manual may include information specifying the dosage and / or route / mode of delivery of the first pharmaceutical composition to the subject.
[0353] In any embodiment of the kit described above, the kit may further include a first detection kit for determining whether immune tolerance to the target agent has been induced in the subject. In some embodiments, the immune response against the inducing agent and the cross-reactive immune response to the target agent includes the production of at least one anti-target agent antibody or at least one neutralizing antibody capable of binding to the inducing agent and cross-reactive with the target agent. Therefore, the first detection kit may further include at least one first reagent configured to allow determination of the titer of one or more anti-target agent antibodies and / or one or more neutralizing antibodies in the subject's serum. Optionally, the at least one antibody may include antibodies capable of neutralizing the inducing agent and / or the target agent. The first detection kit provides information regarding whether the claimed immune tolerance has been induced in the subject after administration of the first pharmaceutical composition. If an acceptable level of immune tolerance is shown to have been induced in the subject, the subject may subsequently undergo further administration of the immunogenic target agent, resulting in improved efficiency and efficacy of the target agent delivery in the subject.
[0354] Optionally, the kit may further include a second detection kit comprising at least one second reagent configured to allow detection of the expression of each of the at least one immunosuppressant in the subject.
[0355] In any embodiment of the kit described above, the kit may further include a second pharmaceutical composition comprising a therapeutically effective amount of the target agent, and may optionally further include a second instruction manual for administering the second pharmaceutical composition to the subject. Hereinafter, the second instruction manual may include information specifying the dosage and / or route / mode of delivery of the second pharmaceutical composition to the subject. Further optionally, the second instruction manual may further include a first sub-instruction manual for administering the second pharmaceutical composition to the subject after administration of the first pharmaceutical composition.
[0356] Optionally, the second instruction manual may further include a second sub-instruction manual for repeated administration of the second pharmaceutical composition. In this document, the second sub-instruction manual may specify information such as the repeated dosage, the delivery pattern for each subsequent administration, and the frequency of repeated administration, i.e., the time interval between each two adjacent administrations of the second pharmaceutical composition.
[0357] In any of the embodiments described above, the target agent included in the second pharmaceutical composition may include a target vector encoding a target gene and configured to allow expression of the target gene in a subject. In other words, the second pharmaceutical composition may allow delivery of the target gene to a subject and expression therein. Optionally herein, the kit may further include a third detection kit comprising at least one third reagent configured to allow detection of the expression of the target gene in the subject. Hereinafter, the at least one third reagent may be used for any applicable gene expression analysis, which may include Northern blotting, quantitative PCR, Western blotting, microarray analysis (e.g., Illumina or Affymetrix), next-generation analysis, or protein chip analysis, etc., and is not limited herein.
[0358] As an alternative to the above embodiments in which the inducer and / or target agent includes a viral agent, in some embodiments of the kit, the inducer and / or target agent may include a non-viral nanocarrier, such as a synthetic nanocarrier. Further details can be found in other parts of this disclosure, such as the methods described in other aspects.
[0359] In one aspect, this disclosure further provides a kit for expressing a target gene in a subject.
[0360] The kit includes a pharmaceutical composition comprising an immunogenic target agent, and the target agent comprising a target vector encoding the target gene and configured to allow expression of the target gene in the subject.
[0361] The kit further includes instructions for administering the pharmaceutical composition to a subject, the instructions including a method for inducing immune tolerance to the target agent prior to administering the pharmaceutical composition to the subject. The method includes: a) administering an immunogenicity inducer agent to the subject, wherein the inducer agent comprises an inducer nucleic acid vector encoding at least one immunosuppressant, thereby allowing the at least one immunosuppressant to be expressed in the subject, the at least one immunosuppressant inhibiting an immune response in the subject against the inducer agent, wherein the immune response is cross-reactive to the target agent. In this document, the delivery instructions may contain information specifying the dosage and / or route / mode of delivery of the pharmaceutical composition.
[0362] Optionally, the kit may further include a first detection kit for determining whether an immune response has been induced in subjects with immune tolerance.
[0363] In embodiments where the immune response includes generating at least one antibody capable of binding to an inducer mediator and cross-reactive to a target mediator, the first detection kit may include at least one first reagent configured to allow determination of the titer of one or more of the at least one antibody in the serum of a subject. In this document, the at least one or more antibodies may include antibodies capable of neutralizing the inducer mediator and / or the target mediator.
[0364] In some embodiments, the kit further includes a second detection kit comprising at least one second reagent configured to allow detection of the expression of each of the at least one immunosuppressant in the subject.
[0365] In some embodiments, the kit may further include a third detection kit comprising at least one third reagent configured to allow detection of the expression of the target gene in the subject.
[0366] In this regard, in any embodiment of the kit described above, the instructions may further include a sub-instruction manual for repeated administration of the pharmaceutical composition. In this document, the sub-instruction manual may specify information such as the repeated dose, the delivery pattern for each subsequent administration, and the frequency of repeated administration, i.e., the time interval between each two adjacent administrations of the pharmaceutical composition.
[0367] In one aspect, this disclosure further provides a kit for expressing a target gene in a subject using an immunogenic target agent that encodes the target gene.
[0368] The kit comprises a first pharmaceutical composition and a second pharmaceutical composition, the first pharmaceutical composition being used to induce immune tolerance to the target agent in the subject, and the second pharmaceutical composition containing the target agent. The first pharmaceutical composition contains an inducer agent, the inducer agent comprising at least one inducer nucleic acid vector, each inducer nucleic acid vector encoding at least one immunosuppressant and configured to allow expression of the at least one immunosuppressant in the subject, and each of the at least one immunosuppressant being configured to inhibit an immune response in the subject against the inducer agent when expressed in the subject, and the immune response being cross-reactive to the target agent. The target agent comprises a target vector encoding a target gene.
[0369] Optionally, the kit further includes a first detection kit for determining whether immune tolerance was induced in the subject after administration of the first pharmaceutical composition.
[0370] In embodiments where the immune response includes generating at least one antibody capable of binding to an inducer and having cross-reactivity with a target, the first detection kit may include at least one first reagent configured to allow determination of the titer of one or more of the at least one antibody in the serum of a subject.
[0371] The kit may optionally further include a second detection kit comprising at least one second reagent configured to allow detection of the expression of each of the at least one immunosuppressant in the subject.
[0372] The kit may optionally further include a third detection kit comprising at least one third reagent configured to allow detection of the expression of the target gene in the subject.
[0373] In any of the embodiments described above, the kit may further include a first instruction manual for administering the first pharmaceutical composition; and a second instruction manual for administering the second pharmaceutical composition. In this document, the first and second instructions manuals may include information specifying the delivery dosage and / or route / mode of delivery for the first and second pharmaceutical compositions, respectively.
[0374] Optionally, the second instruction manual further includes a first sub-instruction manual for administering the second pharmaceutical composition to the subject after administration of the first pharmaceutical composition.
[0375] Optionally, the second sub-instruction manual further includes a second sub-instruction manual for repeated administration of the second pharmaceutical composition. In this document, the second sub-instruction manual may specify information such as the repeated dose, the delivery pattern for each subsequent administration, and the frequency of repeated administration, i.e., the time interval between each two adjacent administrations of the second pharmaceutical composition.
[0376] In any embodiment of the kit addressing any aspect of the various aspects described above, the kit may optionally further comprise a third pharmaceutical composition containing at least one immunosuppressive agent. Each of the at least one immunosuppressive agent is configured to inhibit the activity of a target in an immune stimulation pathway or enhance the activity of a target in an immunosuppressive pathway. Optionally herein, each of the at least one immunosuppressive agent comprises a compound, a nucleic acid, a peptide, or a combination thereof. In some embodiments of the kit, each of the at least one immunosuppressant and each of the at least one immunosuppressive agent is configured to have different targets to achieve a synergistic effect, thereby obtaining improved immunosuppression.
[0377] In various embodiments of the kits relating to the aspects described above, the pharmaceutical composition, the at least one first reagent, the at least one second reagent, and the at least one third reagent will be described in more detail in the following sections.
[0378] As used herein and in the broadest sense, the term "pharmaceutical composition" means a formulation comprising a therapeutically effective amount of the active pharmaceutical ingredient and optionally, pharmaceutically acceptable excipients and / or carriers. As used herein, the term "pharmaceuticalally acceptable" means suitable for normal pharmaceutical use, i.e., it does not cause serious side effects such as adverse events in subjects. As used herein, the terms "therapeutically effective amount" or "effective amount" mean a dose sufficient to make a patient's treatment effective compared to no treatment. As used herein, "effective amount" means an amount that produces the desired effect, such as an amount capable of treating or improving a disease or symptom, or otherwise capable of producing the expected therapeutic effect (e.g., inducing immune tolerance).
[0379] Pharmaceutically active ingredients typically require one or more pharmaceutically acceptable carriers or excipients to form a suitable form (i.e., a pharmaceutical composition) and dosage form for effective administration to a subject. As used herein, the term "pharmaceutically acceptable carrier" refers to a carrier or diluent that does not cause significant irritation to an organism and does not eliminate the biological activity and properties of the administered pharmaceutically active ingredient. In this context, the term "pharmaceutically acceptable excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate the administration of the pharmaceutically active ingredient.
[0380] In this document, applicable pharmaceutical compositions include sterile aqueous solutions or dispersions and sterile powders for the ad hoc preparation of sterile injectable solutions or dispersions. In all cases, the composition must be sterile and stable under the conditions of manufacture and storage, and must be preserved against contamination by microorganisms such as bacteria and fungi.
[0381] Pharmaceutically acceptable carriers can be solvents or dispersion media containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. For example, suitable carriers for intravenous administration may include physiological saline, antibacterial aqueous solution, or phosphate-buffered saline (PBS). Appropriate flowability can be maintained, for example, by using coatings such as lecithin, by maintaining the desired particle size in the case of dispersions, and by using surfactants. Antimicrobial activity can be achieved by various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc.). In many cases, it is preferred to include isotonic agents in the composition, such as sugars, polyols (e.g., mannitol, sorbitol), or sodium chloride. Prolonged absorption of the internal composition can be achieved by including agents that delay absorption, such as aluminum monostearate and gelatin, in the composition.
[0382] As needed, a sterile solution can be prepared by incorporating the active compound in the desired amount into a suitable solvent containing one or a combination of the components listed above, followed by sterile filtration. Typically, a dispersion is prepared by incorporating the active compound into a sterile medium containing a base dispersion medium and any other desired components from those listed above. In the case of sterile powders used to prepare sterile injectable solutions, preparation methods include vacuum drying and freeze-drying, which produce a powder containing the active ingredient plus any other desired components from its previously sterile filtered solution.
[0383] In one embodiment, the active compound is prepared together with a carrier that protects these compounds from rapid elimination from the body, such as a controlled-release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Methods for preparing such formulations are readily apparent to those skilled in the art. The materials are also commercially available. Liposome suspensions (including liposomes targeting infected cells with monoclonal antibodies against viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
[0384] Pharmaceutical compositions may comprise, but are not limited to, solutions, emulsions, and formulations containing liposomes. These compositions may be generated from a variety of components, the methods of which include, but are not limited to, preformed liquids, self-emulsifying solids, and self-emulsifying semi-solids.
[0385] In some embodiments, the pharmaceutical compositions provided herein comprise viral particles or virions (e.g., rAAV or adenovirus vectors) as the active pharmaceutical ingredient. Viral particles typically comprise a nucleic acid vector and a viral capsid. In this document, the nucleic acid vector may encode at least one immunosuppressant (for inducer vectors) or a target gene (for target vectors), the viral capsid comprises one or more viral capsid proteins, and the nucleic acid vector is packaged or encapsulated into a viral capsid to form viral particles.
[0386] Viral particles (e.g., recombinant AAV) can be incorporated into pharmaceutical compositions for administration to mammalian patients, particularly humans. The virions can be formulated in a non-toxic, inert, pharmaceutically acceptable aqueous carrier, optionally with a pH ranging from 3 to 8, such as from 6 to 8. Such sterile compositions will comprise a carrier or virion containing nucleic acids encoding a therapeutic molecule dissolved in an aqueous buffer solution with an acceptable pH after reconstitution.
[0387] In some embodiments, the pharmaceutical compositions provided herein comprise a therapeutically effective amount of virions mixed with pharmaceutically acceptable carriers and / or excipients, such as saline, phosphate-buffered saline, phosphates and amino acids, polymers, polyols, sugars, buffers, preservatives, and other proteins. Exemplary amino acids, polymers, and sugars include octylphenoxypolyethoxyethanol compounds, polyethylene glycol monostearate compounds, polyoxyethylene sorbitan fatty acid esters, sucrose, fructose, dextran, maltose, glucose, mannitol, dextran, sorbitol, inositol, galactitol, xylitol, lactose, trehalose, bovine or human serum albumin, citrate esters, acetate esters, Ringer's and Hank's solutions, cysteine, arginine, carnitine, alanine, glycine, lysine, valine, leucine, polyvinylpyrrolidone, polyethylene glycol, and glycols. In some embodiments, this formulation is stable at 4°C for at least six months.
[0388] In some cases, the unit dose of the pharmaceutical composition of this disclosure can be measured as pfu (plaque-forming units). In some cases, the unit dose of the pharmaceutical composition of this disclosure containing an inducer mediator may be about 1 × 10⁻⁶ pfu. 8 Approximately 5×10 12 PFU. In some cases, the PFU per unit dose of the pharmaceutical composition of this disclosure containing the target medium may be higher than the dose of the inducer medium. In some cases, the PFU per unit dose of the pharmaceutical composition of this disclosure containing the target medium may be 1 × 10⁻⁶. 8 From above to approximately 1×10 14 pfu.
[0389] In some embodiments, the medium includes a viral vector. In some cases, the viral vector of this disclosure can be measured as a vector genome.
[0390] In some cases, the unit dose of the pharmaceutical composition of this disclosure containing the inducer mediator is about 1 × 10⁻⁶. 8 Approximately 5×10 12 One vector genome or more. In some embodiments, the unit dose of the pharmaceutical composition of this disclosure comprising the target agent is 1 × 102 8 From above to approximately 1×10 14 One vector genome.
[0391] In some respects, pharmaceutical compositions containing inducer mediators contain about 1 × 10 8 To approximately 1×10 12 One recombinant virus. In some respects, the pharmaceutical composition containing the target agent contains 1×10 8 From above to approximately 1×10 14 A recombinant virus.
[0392] In some embodiments, a non-viral delivery system is used for one or both of the inducer and target agents in the methods and kits provided in this disclosure.
[0393] The compositions provided herein may contain inorganic or organic buffers (e.g., sodium or potassium salts of phosphates, carbonates, acetates, or citrates) and pH adjusters (e.g., hydrochloric acid, sodium or potassium hydroxide, citrates or acetates, amino acids and their salts), antioxidants (e.g., ascorbic acid, α-tocopherol), surfactants (e.g., polysorbate 20, polysorbate 80, polyoxyethylene 9-10 nonylphenol, sodium deoxycholate), solution and / or freeze / lyophilize stabilizers (e.g., sucrose, lactose, mannitol, trehalose), osmotic conditioners (e.g., salts or sugars), antimicrobial agents (e.g., benzoic acid, phenol, gentamicin), defoamers (e.g., polydimethylsiloxane), preservatives (e.g., thimerosal, 2-phenoxyethanol, EDTA), polymer stabilizers and viscosity modifiers (e.g., polyvinylpyrrolidone, poloxamer 488, carboxymethyl cellulose), and cosolvents (e.g., glycerol, polyethylene glycol, ethanol).
[0394] The compositions according to the invention may contain pharmaceutically acceptable excipients. The compositions can be prepared using conventional pharmaceutical manufacturing and compounding techniques to obtain useful dosage forms. Techniques suitable for practicing the invention can be found in *Handbook of Industrial Mixing: Science and Practice*, edited by Edward L. Paul, Victor A. Atiemo-Obeng, and Suzanne M. Kresta, 2004, John Wiley & Sons, Inc.; and *Pharmaceutics: The Science of Dosage Form Design*, 2nd edition, edited by MEAuten, 2001, Churchill Livingstone. In one embodiment, the composition is present with a preservative in a sterile saline solution for injection.
[0395] It should be understood that the compositions of the present invention can be prepared in any suitable manner, and the present invention is by no means limited to compositions produced using the methods described herein. Choosing a suitable manufacturing method may require consideration of the characteristics of the associated specific portions.
[0396] In some embodiments, the composition is manufactured or terminally sterilized under aseptic conditions. This ensures that the resulting composition is sterile and non-infectious, thereby improving safety compared to non-sterile compositions. This provides a valuable safety measure, especially when the subject receiving the composition has immunodeficiency, suffers from infection, and / or is susceptible to infection. In some embodiments, depending on the formulation strategy, the composition may be lyophilized and stored for extended periods in suspension or lyophilized powder form without losing its activity.
[0397] The methods of using these synthetic nanocarriers that carry the target cargo to the subject, i.e., administration, can take various routes, which can be systemic or localized to the treatment area. Optionally, administration can be performed on the subject via parenteral, oral, enteral, oral, nasal, local, rectal, vaginal, transmucosal, epidermal, transdermal, dermal, ocular, lung, heart, subcutaneous, intraparenchymal, intraventricular, or intrathecal administration. In some embodiments, the exogenous nucleic acid is delivered to the subject via oral, intravenous, intraperitoneal, intramuscular, subcutaneous, intrathecal, intraventricular (ICV), or rectal routes. Administration routes can also include inhalation or pulmonary aerosol administration. Techniques for preparing aerosol delivery systems are well known to those skilled in the art.
[0398] Methods for characterizing certain substances
[0399] In any of the embodiments of the methods, kits, or pharmaceutical kits described above, certain substances may be qualitatively or quantitatively characterized after administration to a subject to determine one or more of the following:
[0400] a) The level of pre-existing host immune response to the target agent can be determined by quantitatively characterizing the antibody titer of neutralizing antibodies against the target agent (e.g., anti-capsid antibody in the case of AAV vector) in the serum sample of the subject.
[0401] b) The effectiveness of the inducer carrier in delivering the agent to the subject, which can be determined by characterizing the expression of at least one immunosuppressant (e.g., CTLA4-Ig and / or CD40-Ig) encoded by the inducer nucleic acid carrier;
[0402] c) The expression of at least one of the immunosuppressive agents has an immunosuppressive effect on the host immune response that is cross-reactive against the inducer and / or the target agent (i.e., the level of induced immune tolerance), which can be determined by quantitatively characterizing the antibody titers, particularly neutralizing antibodies, against the inducer / target agent (e.g., anti-capsid antibody in the case of AAV vectors) in the subject's serum samples; and / or
[0403] d) The effectiveness of the target agent in delivering the agent to the subject, which can be determined by characterizing the expression of at least one target gene encoded by the target nucleic acid vector.
[0404] The following example is provided as a specific implementation of the methods and kits provided in this disclosure. It should be noted that the example is for illustrative purposes only and does not limit the scope of this disclosure.
[0405] Example 1
[0406] In this embodiment, in vivo studies of GFP gene expression were performed by repeated AAV8 delivery when mice were treated with a single administration of an AAV8 vector carrying either CTLA4-Ig alone or both CTLA4-Ig and CD40-Ig. Humoral immune responses and immune tolerance to AAV8 were also estimated during this process.
[0407] Materials and methods
[0408] AAV vector preparation
[0409] The transgenic plasmid was constructed by linking the extracellular domain of mouse CTLA4 or CD40 to the Fc portion of mouse IgG (defined as CTLA4-Ig or CD40-Ig, with sequences shown as SEQ ID NO:8 and 9, respectively), as previously reported (Ye X et al., 2005). The AAV8 vector genome contained an AAV2 terminal repeat sequence, a CAG promoter (CMV enhancer / chicken actin promoter / human globin intron), an SV40 splicing signal, the transgenic coding sequence CTLA4-Ig or CD40-Ig, and a polyadenylation signal. The generation, purification, and titration of the AAV8 vector were performed as previously disclosed (Wang B et al., 2000).
[0410] Animals and processing
[0411] C57BL / 6J 6-8 week old WT male mice were purchased from JiCui Biology Company (Nanjing, China). All mice were housed under standard conditions, and all procedures were performed in accordance with the guidelines of the University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee.
[0412] In the first administration experiment, mice (n=5 per group) were injected via the tail vein with two doses of 4×10⁻⁶. 12 vg / kg (high dose, HD) and 4×10 11 vg / kg (moderate dose, MD). The viral combinations were divided into four groups: AAV8-CTLA4-Ig, AAV8-CD40-Ig, AAV8-CTLA4-Ig+AAV8-CD40-Ig, and AAV8-GFP, with AAV8-GFP serving as the control group. Mice in all groups received 6 × 10 vg / kg via intravenous injection in the second and third administration experiments at week 8 (defined as "8w") and week 15 (defined as "15w"), respectively. 11 AAV8-GFP was administered at a dose of vg / kg. Mice were bled weekly to collect serum or plasma and were eventually sacrificed after 25 weeks.
[0413] To verify whether AAV8-CTLA4-Ig or AAV8-CD40-Ig immunomodulatory therapy could effectively inhibit the production of antibodies against other serotypes of AAV vectors, mice were intravenously injected with 4 × 10⁴ Ig at week 20 (defined as "20w"). 12AAV843 (AAV843-GLUC) was expressed at a dose of vg / kg as a Gaussian luciferase. Mice were bled weekly to obtain plasma or serum. GLUC expression in plasma was monitored according to the published protocol of Bakhos et al. (Bakhos A et al., 2009).
[0414] To elucidate the dynamic changes in exogenous transgene expression following multiple injections of the AAV vector, mice were pre-immunized with AAV-CTLA4-Ig or AAV-CTLA4+AAV-CD40-Ig, with AAV-GFP serving as a control. The high and medium doses were 4 × 10⁻⁶. 12 vg / kg(HD) and 4×10 11 vg / kg (MD). After 4 weeks, mice were administered 6×10 vg / kg intravenously twice every 3 weeks. 11 vg / kg AAV-GLUC. Mouse plasma was collected to observe GLUC expression.
[0415] Protein blot
[0416] HEK293 cells were transduced using pre-constructed CTLA4-Ig or CD40-Ig plasmids, and HUH-7 cells were transfected with AAV8 containing either the CTLA4-Ig or CD40-Ig expression cassette. Proteins from cells were extracted using RIPA lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% NP-40, 0.5% sodium deoxycholate, 1% sodium dodecyl sulfate) and a protease inhibitor mixture (Bimake), along with proteins from cell culture media supplemented with protease inhibitors. Protein concentrations were determined using a BCA kit (Thermo). Protein samples were separated using a 10% gel electrophoresis and then transferred to a polyvinylidene fluoride (PVDF) membrane. The membrane was incubated with HRP-conjugated secondary antibody (1:5000 dilution, Abcam) at room temperature in a tween-buffered saline (TBST) containing 5% skim milk for two hours. Finally, the protein bands were detected using ECL protein blot substrate (Tanon).
[0417] ELISA
[0418] The levels of CTLA4-Ig and CD40-Ig in cell culture medium, cell lysates, and mouse serum were quantified using either a mouse CTLA4 ELISA kit (R&D Systems, Minneapolis, MN) or a mouse CD40 ELISA kit (SAB, College Park, MD). Total IgG levels in mouse serum were measured using a mouse IgG ELISA kit (Mlbio, Shanghai, China). All procedures were performed according to the manufacturer's instructions. Finally, the OD values of the samples were read at 450 nm. Cytokines including TNF-α, IL-4, and IL-10 in mouse plasma were measured using a Luminex X-200 (R&D Systems, Minneapolis, MN), and data analysis was performed using a Milliplex according to the manufacturer's instructions.
[0419] AAV neutralization assay
[0420] To investigate neutralizing antibodies against the AAV vector, mice were bled weekly to analyze serum samples. Briefly, serum samples were incubated at 56°C for 30 minutes to inactivate complement. Serum samples were diluted 1:2 in round-bottom 96-well plates, mixed with the AAV vector expressing luciferase, and incubated at 37°C for one hour in a 5% CO2 incubator. Next, a volume of the vector-serum mixture was transferred to HUH-7 cell plates. After one hour, 20% FBS complete medium was carefully added, and the plates were incubated overnight at 37°C in a 5% CO2 incubator. Gaussian luciferase activity was measured after 72 hours. In this study, neutralizing antibody titers below 1:8 (an 8-fold serum dilution causing more than 50% inhibition of vector transduction) indicated negative NAb levels.
[0421] Combined with ELISA
[0422] To investigate IgG targeting the AAV8 capsid, binding IgG in mouse serum was determined according to a published procedure (Murrey DA et al., 2014). Briefly, IgG containing 1 × 10⁻⁶ g of [the antibody] was used. 10Carbonate-buffered saline (PBS) containing 1 particle / mL of empty AAV8 capsid was pre-coated onto 96-well plates overnight at 4°C. Samples containing AAV were used as positive antigens, and PBS was used only as negative antigens. After blocking with PBS (PBST) containing 5% milk powder and Tween-20, serum samples were initially diluted 1:50, added to the plates, and incubated at room temperature for one hour. Next, the plates were washed with PBST and then incubated with HRP-conjugated anti-mouse IgG (Sigma-Aldrich, St. Louis, MO) at room temperature for one hour. The plates were then washed for 10 minutes at room temperature with PBST containing substrate TMB (Sigma-Aldrich, St. Louis, MO). Finally, the samples were stopped with 1N sulfuric acid, and OD values were read at 450 nm. The anti-AAV8-IgG titer is calculated as follows: (OD of positive antigen – OD of negative antigen) / OD of negative antigen, where a result less than 2 is considered a negative anti-AAV-IgG level (in other words, threshold-specific binding is set to 2).
[0423] Immunofluorescence
[0424] To examine the transfection efficiency of the AAV8 vector in vivo or the transgene expression after repeated administration of AAV8, the fluorescence intensity of green fluorescent protein (GFP) in tissues was observed. Mice in all groups died at the end of the study. Mouse livers and muscles were collected, fixed in 4% paraformaldehyde, dehydrated in 30% sucrose, and 8-μm frozen or paraffin sections were prepared. These sections were observed at 20x magnification under a confocal laser scanning microscope (Nikon Inc., Melville, NY, USA).
[0425] Flow cytometry
[0426] To observe the status of immune T cells and B cells, single-cell suspensions obtained from mouse peripheral blood and spleen were stained with surface markers: anti-CD3 (APC-Cy7), anti-CD4 (FITC), anti-CD19 (PE), anti-B220 (APC), anti-GL7 (BV421), anti-CD25 (APC), and intracellular staining (PE) for FoxP3. All antibodies were purchased from BD Biosciences, and procedures were performed according to the manufacturer's instructions. Samples were observed using a CytoFLEX flow cytometer (Beckman Coulter Inc., Brea, CA). Data were analyzed using CytExpert 2.0 software (Beckman Coulter Inc., Brea, CA) or FlowJo software (Tree Star, Ashland, OR).
[0427] Statistical analysis
[0428] Data are shown as mean ± SEM values. Statistical analysis was performed using GraphPad Prism v7 (GraphPad Software Inc., La Jolla, CA). One-way ANOVA and unpaired Student t-tests were performed for multiple group comparisons. A p-value less than 0.05 (*) or 0.01 (**) was considered statistically significant.
[0429] result
[0430] AAV8 delivers CTLA4-Ig or CD40-Ig for stable expression in vivo.
[0431] In this embodiment, pAAV-CTLA4-Ig and pAAV-CD40-Ig are constructed. Figure 1A The recombinant protein was transfected into HEK293 cells. Seventy-two hours after transfection, cell and culture medium levels were assessed by Western blotting and ELISA. Results showed that CTLA4-Ig and CD40-Ig were significantly upregulated in transfected cells compared to untransfected cells, and both recombinant proteins were secreted in the culture medium. Figure 1B When HUH-7 cells are infected with AAV8-CTLA4-Ig or AAV8-CD40-Ig, these two proteins are also strongly expressed in the cells and efficiently secreted into the culture medium. Figure 1C ).
[0432] Furthermore, mice were intravenously injected with two doses (HD and MD) of AAV8-CTLA4-Ig, AAV8-CD40-Ig, or AAV8-CTLA4-Ig + AAV8-CD40-Ig. ELISA assays showed increased CTLA4-Ig expression in the HD group, peaking at week 8 post-administration (PFAW) at a concentration of 600-800 μg / mL. Subsequently, serum concentrations gradually decreased and remained at 350-600 μg / mL. Figure 1D CD40-Ig expression gradually increased in the HD group, peaking at PFAW 12 at a concentration of 10-15 μg / mL, after which the concentration decreased and remained at 2.5-10 μg / mL. Figure 1E Interestingly, the serum CTLA4-Ig concentration was approximately 60 times that of CD40-Ig. Due to the corresponding dose being halved, the CTLA4-Ig and CD40-Ig concentrations in the AAV8-CTLA4-Ig+AAV8-CD40-Ig group were lower than those in the AAV8-CTLA4-Ig or AAV8-CD40-Ig groups. Furthermore, the in vivo transfection efficiency of the AAV8 vector via different injection routes was... Figure 1F As shown in the figure. These results confirm that CTLA4-Ig and CD40-Ig are stably and efficiently expressed via AAV8 delivery in vitro and in vivo.
[0433] Persistent expression of CTLA4-Ig and CD40-Ig after repeated systemic administration suppressed humoral immunity against AAV8.
[0434] NAb levels were investigated at high and moderate doses following administration of AAV8-CTLA4-Ig, AAV8-CD40-Ig, and AAV8-CTLA4-Ig + AAV8-CD40-Ig. Furthermore, a strategy for estimating antibody inhibition following multiple systemic administrations of the AAV8-GFP vector was established. Figure 2A Serum NAb titers were measured weekly following primary AAV8 vector injection. Results showed that mice in both doses of AAV8-CTLA4-Ig and the AAV8-CTLA4-Ig+AAV8-CD40-Ig groups had lower NAb levels compared to the control group treated with AAV8-GFP. Figure 2B **p<0.01). Although NAb titers ranged between 1:10 and 1:25 at PFAW 1 in both the AAV8-CTLA4-Ig and AAV8-CTLA4-Ig+AAV8-CD40-Ig groups, they subsequently decreased to less than 1:5 (NAb negative). Figure 2BAt PFAW 8, AAV8-GFP was injected into mice expressing immunosuppressants including CTLA4-Ig, CD40-Ig, CTLA4-Ig+CD40-Ig, and the GFP group (control). Results showed that, compared to initial administration, NAb titers in the AAV8-CTLA4-Ig and AAV8-CTLA4-Ig+AAV8-CD40-Ig groups were significantly increased at PFAW 9, and then decreased. Figure 2B However, it is noteworthy that after a second exposure to the AAV8-GFP vector at PFAW 16, the NAb titers in the AAV8-CTLA4-Ig and AAV8-CTLA4-Ig+AAV8-CD40-Ig groups increased slightly, subsequently returning to negative levels. Figure 2B Furthermore, during these multiple administrations of the AAV8 vector, there was no difference in NAb titers between the AAV8-CTLA4-Ig group and the AAV8-CTLA4-Ig+AAV8-CD40-Ig group, but dose-dependent inhibition of NAb production was observed in the HD and MD groups. NAb levels in the AAV8-CD40-Ig group were also lower than in the control group, but there was no significant difference between the two groups (p = 0.089). In the absence of immunosuppressants, mice in the control group treated with only AAV8-GFP were NAb-positive (>1:32). The results show that long-term expression of CTLA4-Ig or CTLA4-Ig and CD40-Ig effectively inhibited the dramatic increase in NAb levels and maintained negative levels after single and multiple AAV8 injections.
[0435] Furthermore, the overall level of anti-AAV8 IgG was analyzed from week 5 after the initial AAV8 vector administration. Compared with the control group, mice in the AAV8-CTLA4-Ig and AAV8-CTLA4-Ig+AAV8-CD40-Ig groups had lower levels of anti-AAV8 IgG (**p<0.01), while in the AAV8-CD40-Ig group, the level of anti-AAV8 IgG was slightly lower but not significantly different. Figure 2C (p = 0.057). These data were consistent with NAb assays. Although all groups of mice showed an increase in anti-AAV8 IgG during the first week of exposure to each injection of the AAV8 vector, thereafter, anti-AAV8 IgG decreased and remained at levels less than 1:100 in the AAV8-CTLA4-Ig and AAV8-CTLA4-Ig+AAV8-CD40-Ig groups. Anti-AAV8 IgG was at high levels (>1:1600) in the control group. Figure 2C ).
[0436] There is still no detailed explanation of the relationship between AAV NAb and anti-AAV capsid IgG (Kruzik A et al., 2019), therefore, a correlation analysis was performed on AAV8 NAb titer and anti-AAV8-IgG level. Figure 2D ), and found that they were highly correlated with each other (n=5, R). 2 =0.8451, p<0.0001), which means that both NAb and anti-AAV capsid IgG have the characteristics of humoral immunity of AAV carriers.
[0437] In summary, these results indicate that delivery of AAV8-CTLA4-Ig or AAV8-CTLA4-Ig+AAV8-CD40-Ig allows sustained expression of CTLA4-Ig or CTLA4-Ig and CD40-Ig in vivo, which strongly inhibits antibodies against AAV8 and gradually induces immune tolerance to AAV8 in mice.
[0438] Sustained expression of CTLA4-Ig or CD40-Ig does not impair overall humoral immunity.
[0439] To investigate the effects of long-term CTLA4-Ig or CD40-Ig expression on humoral immunity following single or multiple AAV vector administrations, total mouse IgG and inflammatory cytokines, including TNF-α, IL-4, and IL-10 from peripheral blood, were analyzed at the initial and second AAV8-GFP vector injections. Total mouse IgG was measured weekly for 11 weeks. Figure 3A There was no significant difference between the immunosuppressant treatment group and the control group (p>0.05). Plasma was collected on days 4 and 7 after the second AAV8-GFP administration to test inflammatory cytokines. Figure 3B , 3C (and 3D). The results showed no significant differences in TNF-α, IL-4, and IL-10 levels between the immunosuppressant group and the control group (p>0.05). In conclusion, sustained exogenous expression of CTLA4-Ig and CD40-Ig delivered via AAV8 does not impair normal humoral immunity.
[0440] Immunosuppression by CTLA4-Ig and CD40-Ig improved transgene expression with repeated administration of the AAV8 vector.
[0441] At PFAW 25, mice were sacrificed to obtain liver and muscle tissue for observation of GFP expression. In the liver, GFP was expressed in the AAV8-CTLA4-Ig+AAV8-CD40-Ig and AAV8-CTLA4-Ig groups, but not in the AAV8-CD40-Ig group. Figure 4A and 4BIn both liver and muscle tissues, the AAV8-CTLA4-Ig+AAV8-CD40-Ig group showed higher GFP expression compared to the AAV8-CTLA4-Ig group. These results indicate that immunosuppressive treatment with CTLA4-Ig and CD40-Ig after repeated administration of the AAV8 vector can better improve transgene expression.
[0442] Furthermore, AAV8-GLUC was used to dynamically monitor exogenous transgene expression via AAV injection. Figure 4C Mice were pre-immunized with AAV8-CTLA4-Ig or a combination of AAV8-CTLA4-Ig and AAV8-CD40-Ig, and AAV8-GFP was used as a control group for HD and MD. Four weeks later, mice were administered 6 × 10⁶ Ig intravenously twice every three weeks. 11 vg / kg AAV8-GLUC. In the AAV8-CTLA4 and AAV8-CTLA4+AAV-CD40 groups, GLUC expression was lowest at the first injection of AAV8-GLUC, but significantly increased at the second injection, exceeding the control level. Figure 4D (5 weeks, ***p<0.001). This result is consistent with... Figure 2B Consistent with the findings shown, AAV immunity surges transiently with the first AAV8-GFP administration, while AAV immune tolerance develops upon the second AAV8-GFP injection. Despite using 6 × 10 11 In naive mice, a single dose of AAV8-GLUC (vg / kg) resulted in approximately five times the expression level upon re-administration. Figure 4E However, compared with the group without immunosuppression treatment, the sustained expression of CTLA4-Ig and CTLA4-Ig+CD40-Ig significantly improved exogenous gene expression after repeated systemic administration of the AAV vector.
[0443] This study clearly demonstrates that successful delivery of AAV8 expressing CTLA4-Ig and CD40-Ig induces immune tolerance that specifically inhibits the immune response against AAV8, allowing for repeated administration of AAV8 expressing another transgene of interest, such as GFP or GLUC. It is well known in the art that GFP and GLUC are two recognized model genes used solely for proof-of-concept purposes. In other words, if GFP and GLUC are found to be expressed in this invention, other genes of interest, such as those with therapeutic potential or applications, can also be expressed in the same or similar manner. It is expected that those skilled in the art will readily replace GFP and GLUC in the examples with other therapeutic genes and achieve the desired results.
[0444] Persistent expression of CTLA4-Ig and CD40-Ig does not affect humoral immunity against AAV843.
[0445] Although CTLA4-Ig and CD40-Ig inhibited anti-AAV8 NAb, it was unclear whether they could inhibit the production of other serotypes of NAb. To test this idea, the inhibition of AAV843 NAb was investigated.
[0446] At week 0, mice in both groups were intravenously injected with two different doses (HD and MD) of AAV8-CTLA4-Ig or AAV8-CTLA4-Ig + AAV8-CD40-Ig, followed by administration of the AAV8-GFP vector twice, at week 8 (PFAW8) and week 15 (PFAW15) (see [link to relevant documentation]). Figure 5A To verify the long-term expression of CTLA4-Ig or CTLA4-Ig and CD40-Ig to induce antigen-specific tolerance to other AAV vectors, mice were intravenously injected with AAV843-GLUC, a novel AAV serotype that delivers Gaussian luciferase, at week 20. Figure 5A ).
[0447] Prior to treatment with AAV843-GLUC, there were no detectable NAb titers of AAV843 in any group, and after PFAW 16, AAV8 NAb titers remained negative in all CTLA4-Ig expression groups. Figure 5B At PFAW 20, AAV843 was injected into mice pretreated with AAV8-CTLA4-Ig+AAV8-CD40-Ig or AAV8-CTLA4-Ig, and the NAb titer of AAV843 increased significantly to over 1:32 after one week, while transgenic GLUC expression was severely suppressed. Figure 5C Subsequently, NAb levels gradually decreased. Figure 5B *p<0.05, **p<0.01), and GLUC expression was upregulated ( Figure 5C The AAV8-CTLA4-Ig+AAV8-CD40-Ig HD group showed the highest GLUC expression. Figure 5C *p<0.05). The results showed that delivery of AAV8-CTLA4-Ig or AAV8-CTLA4-Ig+AAV8-CD40-Ig allowed for prolonged expression of exogenous CTLA4-Ig and CD40-Ig in vivo, which not only provided antigen-specific tolerance to AAV8 but also effectively reduced antibodies against AAV843. Interestingly, immune tolerance to AAV8 also applied to AAV843, as demonstrated by the gradual decrease in Nab levels of AAV843 and the stable GLUC expression of AAV843.
[0448] Long-term expression of CTLA4-Ig and CD40-Ig inhibits T cell activation and B cell proliferation.
[0449] To further elucidate the effects of long-term expression of CTLA4-Ig and CD40-Ig on the immune response, flow cytometry was used to analyze T cell and B cell subsets. At PFAW 2, CD40-Ig expression was found in peripheral blood mononuclear cells (PBMCs). + T cells and B220 + CD19 + There was no significant difference in B cell frequency between the immunosuppressant group and the control group. Figure 6A Compared to the AAV8-GFP group, CD25 in the AAV8-CTLA4-Ig and AAV8-CTLA4-Ig+AAV8-CD40-Ig groups was significantly lower. + FoxP3 + Regulatory T cells (Tregs) decreased at PFAW 2 and 7. Figure 6B The Treg frequency was low in the HD group (**p<0.01). CD4 from PBMCs was explored at PFAW 17 with repeated AAV8-GFP administration. + GL7 + The proportion of T cells. Compared with the control group, the number of CD4 cells expressing GL7 in the AAV8-CTLA4-Ig group, AAV8-CD40-Ig HD group, and AAV8-CTLA4-Ig+AAV8-CD40-Ig group was significantly higher. + The T cell frequency decreased slightly, but these changes were not statistically significant. GL7 is an activation marker expressed on germinal center T cells. Figure 6C and 6D ).
[0450] CD4 in the spleen was studied at PFAW 25. + T cells, B cells, and Tregs. Compared to the AAV8-GFP HD group, the AAV8-CTLA4-Ig+AAV8-CD40-Ig HD group showed significantly higher levels of CD4+. + The frequency of T cells decreased ( Figure 6E-6F *p<0.05). Compared with the control group, splenic Tregs were reduced in the AAV8-CTLA4-Ig HD (**p<0.01), AAV8-CTLA4-Ig MD (*p<0.05), AAV8-CD40-Ig HD (**p<0.01), and AAV8-CTLA4-Ig+AAV8-CD40-Ig HD (**p<0.01) groups, indicating that immunosuppressive therapy affects Treg subsets in a dose-dependent manner. B220 in the spleen+ CD19 + There was no significant difference in B cells between the immunosuppressant group and the control group. Figure 6E-6F However, compared with the previous positivity at PFAW 2, the positivity of the AAV8-CTLA4-IgHD group (p=0.041) and the AAV8-CTLA4-Ig+AAV8-CD40-IgHD group (p=0.033) was reduced. Figure 6G The results showed that CTLA4-Ig and CD40-Ig suppressed the immune response against AAV by inhibiting T cell activation and B cell proliferation.
[0451] discuss
[0452] rAAV, as a promising gene vector, has been widely used in gene therapy. However, its application is limited by the widespread presence of NAbs and macrophages targeting rAAV, with up to 70% of the population exhibiting NAbs (Mingozzi F et al., 2013). Patients with high NAb titers cannot be treated with rAAV gene therapy, and currently, rAAV gene therapy remains a single-treatment technique because NAbs generated from the first treatment inactivate rAAV, rendering it ineffective upon reapplication. A NAb titer of 1:5 has been reported to almost completely prevent the delivery of human FIX via rAAV in non-human primates (Jiang H et al., 2006). Furthermore, cytotoxic T cells also reduce transgene products by depleting AAV-infected cells (Murphy SL et al., 2008). Therefore, a safe and effective clinical strategy is urgently needed to suppress the AAV immune response to achieve stable transgene expression and vector reapplication.
[0453] In this embodiment, CTLA4-Ig or CD40-Ig was expressed via in vivo AAV8 delivery. NAb inhibition and immune tolerance were analyzed when AAV8-GFP or AAV843-GLUC were administered as immunogens. Following a single intravenous injection of AAV8-CTLA4-Ig or AAV8-CD40-Ig, CTLA4-Ig or CD40-Ig could be persistently expressed and efficiently secreted into serum. Previous studies have shown that exogenous CTLA4-Ig or anti-CD40L antibodies prevent humoral immunity to rAAV, and rAAV re-administration was successfully achieved via pulmonary or intramuscular injection (Halbert CL et al., 1998 and Lorain, 2008). Intravenous delivery of rAAV gene-modifying agents is the safest and most convenient method, but NAbs may be readily neutralized by AAV (Wang D et al., 2019). It was found that although NAbs were strongly upregulated after the first administration of the AAV8 immunogen, they subsequently decreased rapidly. Interestingly, NAb was not significantly upregulated after two administrations of the AAV8 immunogen in the high-dose CTLA4-Ig or CTLA4-Ig+CD40-Ig groups. Furthermore, long-term expression of CTLA4-Ig or CTLA4-Ig and CD40-Ig also reduced anti-AAV IgG after multiple intravenous administrations of the same AAV vector. Further, it was confirmed that cytokine levels were unaffected by long-term expression of CTLA4-Ig and CD40-Ig. These results indicate that CTLA4-Ig and CTLA4-Ig+CD40-Ig inhibit NAb in a dose-dependent manner and gradually induce immune tolerance to AAV8. Moreover, long-term expression of CTLA4-Ig and CD40-Ig in vivo does not deplete humoral immunity, suggesting that it is a safe and effective candidate method for establishing immune tolerance against AAV.
[0454] It was observed that long-term expression of CTLA4-Ig and CD40-Ig improved the expression of exogenous genes, GFP, or GLUC. Furthermore, compared to a single application of CTLA4-Ig, co-application of CTLA4-Ig and CD40-Ig resulted in strong expression of the exogenous gene. It has been reported that multiple injections of CTLA4-Ig+MR1 can preserve but not improve exogenous gene expression when rAAV is re-administered (Halbert CL et al., 1998 and Lorain, 2008). However, in this example, no improvement in GFP expression was observed with a single application of CD40-Ig. Previously, Moskalenko et al. demonstrated that anti-CD40L antibody did not improve transgene expression after systemic re-application of the AAV2 vector (Moskalenko M et al., 2000), and that CTLA4-Ig is considered to play a dominant role in immune regulation when co-expressed with CTLA4-Ig and MR1 (Manning WC et al., 1998). Notably, when GLUC, another transgenic product delivered by AAV843, was detected after two AAV8-GFP administrations, GLUC expression was significantly suppressed, and NAb against AAV843 immediately and dramatically increased. Subsequently, AAV843 NAb titers decreased, and GLUC expression was upregulated, indicating that persistent expression of CTLA4-Ig and CD40-Ig again suppressed anti-AAV843 NAb. These results suggest that the immune tolerance induced by CTLA4-Ig and CD40-Ig is antigenically selective and specific to AAV8, but this tolerance also exhibits cross-reactivity with different serotypes (i.e., AAV843).
[0455] CTLA4-Ig and CD40-Ig downregulate T cells and B cells by blocking the CD28 / B7 and CD40 / CD40L co-stimulatory pathways (Boise LH et al., 1995 and June CH et al., 1990). In this example, CD40-Ig was downregulated in the high-dose AAV8-CTLA4-Ig + AAV8-CD40-Ig group. + T cells, CD4 + GL7 + T cells and B220 + CD19 +The reduction in B cells indicates that T cell activation and B cell proliferation were suppressed. These results also suggest that CTLA4-Ig + CD40-Ig has a better inhibitory effect on antibody production and transgene expression improvement after repeated AAV administrations. However, the mechanism by which CTLA4-Ig and CD40-Ig induce AAV tolerance remains unclear. Several studies have shown tolerance induction associated with Treg amplification (Sakaguchi S et al., 2001 and Bacchetta R et al., 2005). Surprisingly, however, in this example, the proportion of Tregs in the CTLA4-Ig-involved group was decreased. Vogel et al. confirmed that Treg amplification was observed in the presence of MR1 alone or in combination with low-dose CTLA4-Ig (Vogel I et al., 2016). However, when the CTLA4-Ig dose was equal to or greater than approximately 50 μg / ml, Treg amplification was suppressed, indicating that high-dose CTLA4-Ig provides immunosuppression in a Treg-independent manner (Vogel I et al., 2016). In this embodiment, the peak concentration of CTLA4-Ig in the CTLA4-Ig group reached approximately 200-600 μg / ml, which is equivalent to a high dose of the soluble protein CTLA4-Ig, thereby downregulating the Treg ratio.
[0456] In summary, persistent expression of CTLA4-Ig and CD40-Ig carried by certain serotypes of AAV can effectively suppress AAV-induced immunity, establish immune tolerance to this AAV vector, and improve transgene expression after repeated intravenous administration of the same serotype of AAV. Furthermore, persistent expression of these two immunosuppressants does not affect overall humoral immunity. These results could provide a safe and convenient approach for patients with NAbs or those requiring multiple clinical administrations of AAV gene-modifying drugs.
[0457] References:
[0458] Altschul SF et al., Basic local alignment searchtool. Journal of Molecular Biology, (1990) 215:403–410.
[0459] Altschul SF et al., Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res., (1997) 25:3389–3402.
[0460] Higgins DG et al., Using CLUSTAL for multiple sequence alignments. Methods Enzymol. (1996) 266:383-402.
[0461] Larkin MA et al., Clustal W and Clustal X version 2.0. Bioinformatics (Oxford, England) (2007) 23(21):2947-8.
[0462] Goode I et al., Regulatory B cells: the new “it” cell. Transplant Proc (2014) 46:3–8.
[0463] Good NE et al., Hydrogen ion buffers for biological research. Biochemistry (1966) 5, 2, 467–477.
[0464] Wu GY et al., Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. Journal of Biol Chem (1987) 262(10):4429-32.
[0465] Krieg AM et al. CpG motifs inbacterial DNA trigger direct B-cell activation. Nature (1995) 374:546-549.
[0466] Yamamoto S et al., Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity (Journal of Immunology, 1992, 148:4072-76).
[0467] Ballas ZK et al., Induction of NK activity in murine and human cells by CpG motifs inoligodeoxynucleotides and bacterial DNA. Journal of Immunology (1996) 157:1840-45.
[0468] Kabat EA et al., Sequences of Proteins of Immunological Interest, 5th ed., National Institutes of Health, Bethesda, MD (1991).
[0469] Klinman DM et al., Contribution of CpG motifs to the immunogenicity of DNA vaccines. Journal of Immunology (1997) 158:3635-39.
[0470] Sato Y et al., Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science (1996) 273:352-354.
[0471] Pisetsky DS, The immunologic properties of DNA. Journal of Immunology (1996) 156:421-423.
[0472] Shimada S et al., In vivo amplification of natural killer cell activity with a deoxyribonucleic acid fraction of BCG. Japanese Journal of Cancer Research (Jpn.J.Cancer Res.) (1986) 77:808-816.
[0473] Cowdery JS et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. Journal of Immunology (1996) 156:4570-75.
[0474] Roman H et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. (1997) 3:849-854.
[0475] Lipford GB et al., CpG-containing synthetic oligonucleotides promote B cell and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. (1997) 27:2340-44.
[0476] Wang D et al., Adeno-associated virus vector as a platform for gene therapy delivery. Nature Reviews Drug Discovery (2019) 18(5):358-378.
[0477] Arima T et al. Inhibition of experimental allergic encephalomyelitis by CTLA4Ig. Journal of Immunology (1996) 156:4916–24.
[0478] Li W et al. CTLA4Ig gene transfer alleviates abortion in mice by expanding CD4+CD25+ regulatory T cells and inducing indoleamine 2,3-dioxygenase. Journal of Reproductive Immunology, (2009) 80(1-2):1-11.
[0479] Dall'Era M et al. CTLA4Ig: a novel inhibitor of costimulation. Lupus, (2004) 13(5):372-376.
[0480] Slavik JM et al. CD28 / CTLA-4 and CD80 / CD86 families: signaling and function. Immunol Research (1999) 19:1–24.
[0481] Genovese MC et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. New England Journal of Medicine (2005), 353:1114-1123.
[0482] Charpentier B. Belatacept: a novel immunosuppressive agent for kidney transplant recipients. Expert Rev. Clin. Immunol. (2012) 8:719-728.
[0483] Noelle RJ et al. found that a 39-kDa protein on activated helper T cells binds to CD40 and transduces the signal for cognate activation of B cells. Proceedings of the National Academy of Sciences (PNAS) (1992) 89(14):6550-4.
[0484] Boumpas DT et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. (2003) 48(3):719-727.
[0485] Kirk AD et al. CTLA4Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proceedings of the National Academy of Sciences (1997) 94:8789-8794.
[0486] Halbert CL et al. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. Journal of Virology, (1998) 72(12):9795-805.
[0487] Lorain et al. Transient immunomodulation allows repeated injections of AAV1 and correction of muscular dystrophy in multiple muscles. Molecular Therapy, 2008, 16(3):541-547.
[0488] Mcintosh JH et al. successfully attenuated humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine. (Gene Ther, (2012) 19(1):78-85.)
[0489] Jiang Z et al., Sustained muscle expression of dystrophin from a high-capacity adenoviral vector with systemic gene transfer of T cell costimulatory blockade. Molecular Therapy, (2004) 10(4): 688-696.
[0490] Chirmule N et al. readministration of adenovirus vector in nonhuman primate lungs by blocking CD40-CD40 ligand interactions. Journal of Virology, (2000) 74(7):3345-52.
[0491] Yang Y et al. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. Journal of Virology (1996a) 70:6370–6377.
[0492] Yang Y et al. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science (1996b) 273:1862–1864.
[0493] Ye X et al. prevented and reversed lupus in NZB / NZW mice by costimulatory blockade with adeno-associated virus–mediated gene transfer. Arthritis and Rheumatism, (2005) 52(12):3975-3986.
[0494] Wang B et al. found that an adeno-associated virus vector carrying human minidystrophingenes effectively ameliorates muscular dystrophy in the mdx mouse model. Proceedings of the National Academy of Sciences, (2000) 97(25):13714-13719.
[0495] Bakhos A et al. Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nature Protocols (2009) 4(4):582-91.
[0496] Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates. *Human Gene Ther. Clin. Dev.* (2014) 25, 72–84.
[0497] Prevalence of anti-adeno-associated virus immune responses in international cohorts of healthy donors (Kruzik A et al., *Molecular Ther Methods Clin Dev.*, 2019, 14:126-133).
[0498] Immune responses to AAV vectors: Overcoming barriers to successful gene therapy. Blood, (2013) 122(1): 23-26.
[0499] Jiang H et al. Effects of transient immunosuppression on adenoassociated virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood, (2006) 108:3321-3328.
[0500] Murphy SL et al., Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver. Molecular Therapy, (2008) 16(1):138-145.
[0501] Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. Journal of Virology, (2000) 74: 1761-1766.
[0502] Manning WC et al. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Human Gene Therapy (1998) 9, 477–485.
[0503] Boise LH et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity (1995) 3, 87–98.
[0504] June CH et al., Role of the CD28 receptor in T-cell activation. Immunol. Today. (1990) 11, 211–216.
[0505] Sakaguchi S et al., Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. (2001) 182, 18–32.
[0506] Bacchetta R et al. CD4+ regulatory T cells: mechanisms of induction and effector function. Autoimmunity Review (2005) 4, 491–496.
[0507] Vogel I et al., Regulatory T cell-dependent and independent mechanisms of immune suppression by CD28 / B7 and CD40 / CD40L costimulation blockade. Journal of Immunology, (2016) 197:533-540.
[0508] Najafian N et al., CTLA4-Ig: a novel immunosuppressive agent. Expert Opin Investig Drugs. (2000) 9: 2147-57.
[0509] Puttaraju M et al., Spliceosome-mediated RNA trans-splicing as a tool for gene therapy. Nature Biotech. (1999) 17:246.
[0510] Sharp PA et al., Molecular Biology. RNA interference. Science (2000) 287:2431.
[0511] Gorman L et al., Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs. Proceedings of the National Academy of Sciences (1998) 95:4929.
[0512] Adli M et al., The CRISPR tool kit for genome editing and beyond. Nature Communications (2018) 9(1):1911.
[0513] Sambrook and Russell. Molecular Cloning, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (2001).
[0514] Ausubel FM et al., Current Protocols in Molecular Biology, John Wiley & Sons (1992).
[0515] Ausubel FM et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons, New York, NY (1994).
[0516] Sambrook J et al., Molecular Cloning, a Laboratory Manual, 2nd ed., Cold Spring Harbor Press, Cold Spring Harbor, New York (1989).
[0517] Laughlin CA et al., Cloning of infectious adeno-associated virus genomes in bacterial plasmids. Gene. (1983) 23(1):65-73 (1983).
[0518] BERNARD NF et al., Fields Virology, 4th ed., 2(69), Lippincott-Raven Publishers (2007).
[0519] Gao G et al., Clades of adeno-associated viruses are widely disseminated in human tissues. Journal of Virology (2004) 78:6381-6388.
[0520] Kotin RM et al., Prospects for the use of adeno-associated virus as a vector for human gene therapy. Human Gene Therapy (1994) 5:793-801.
[0521] Berns, K.K. Parvoviridae and their Replication. Fundamental Virology, 2nd ed., BN Fields and DMKnipe, eds. (1990).
[0522] Xiao X, “Characterization of Adeno-associated virus (AAV) DNA replication and integration”, Doctoral dissertation, University of Pittsburgh, PA. (1996).
[0523] Naso MF et al., Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs. (2017) 31(4):317-334.
[0524] Dong JY et al., Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Human Gene Therapy (1996) 7(17):2101-12.
[0525] Chamberlain K et al., Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids. Human Gene Ther Methods. (2016) 27(1):1-12.
[0526] Carter BJ, Adeno-associated virus vectors. Current Opinion in Biotechnology, (1992) 3: 533-539.
[0527] Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol., (1992) 158: 97-129.
[0528] Lebkowski JS et al. Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types. Molecular Cell Biology (1988) 8:3988-3996.
[0529] Vincent KA et al., Vaccines (1990), Vol. 90, Cold Spring Harbor Laboratory Press.
[0530] Shelling AN and Smith MG. Targeted integration of transfected and infected adeno-associated virus vectors containing the neomycin resistance gene. Gene Therapy (1994) 1:165-169.
[0531] Zhou SZ et al. Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood. Journal of Experimental Medicine (1994) 179:1867-1875.
[0532] Blacklow NR et al. (1988) Adeno-associated viruses of humans. In: J. Pattison (ed.), Parvoviruses and Human Disease. CRC Press, Boca Raton, FL, pp. 165–174.
[0533] Rose J. Parvovirus reproduction. In Comprehensive Virology, Vol. 3, pp. 1-62. Edited by H. Fraenkel-Conrat & R.R. Wagner. New York: Plenum Press (1974).
[0534] Nonnenmacher M et al., Intracellular transport of recombinant adeno-associated virus vectors. Gene Therapy (2012) 19(6):649-658.
[0535] Xu J. et al., Prevalence of neutralizing antibodies against AAV8, AAV9, and AAV843 in a Chinese population. International Journal of Clinical and Experimental Medicine (Int J Clin Exp Med) (2019) 12(8):10253-10261.
[0536] Fisher KJ et al., Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. Journal of Virology (1993) 70:520-532.
[0537] Graham FL et al., Characteristics of a human cell line transformed by DNA from human adenovirus type 5. Journal of General Virology (1977) 36:59-72.
[0538] Brough DE et al., Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo. Journal of Virology, (1997) 71: 9206-9213.
[0539] Paolicelli P et al., Surface-modified PLGA-based nanoparticles that can efficiently associate and deliver virus-like particles. Nanomedicine. (2010) 5(6):843-853.
[0540] Look M et al., Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice. Journal of Clinical Investigation. 123(4):1741-1749.
[0541] Doubrow, Microcapsules and Nanoparticles in Medicine and Pharmacy, CRC Press, Boca Raton (1992).
[0542] Mathiowitz E et al., Polyanhydride microspheres as drug carriers I. Hot-melt microencapsulation. Journal of Controlled Release (1987a) 5:13-22.
[0543] Mathiowitz E et al., Novel microcapsules for delivery systems. Reactive Polymers (1987b) 6:275-283.
[0544] Mathiowitz E et al., Polyanhydride microspheres as drug carriers. II. Microencapsulation by solvent removal. Journal of Applied Polymer Science (1998) 35:755-744.
[0545] Astete CE, Synthesis and characterization of PLGA nanoparticles. Journal of Biomaterials Science and Polymer, (2006) 17(3): 247-289.
[0546] Avgoustakis K, Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Current Drug Delivery (2004) 1:321-333.
[0547] Reis CP et al., Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine (2006) 2:8-21.
[0548] Sharpless VV et al., A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective “ligation” of azides and terminal alkynes. Angewandte Chemie International Edition (2002) 41(14):2596-2599.
[0549] Meldal M et al., Cu-catalyzed azide-alkyne cycloaddition. Chem.Rev., (2008) 108(8): 2952-301.
[0550] Ito T et al. A convenient enzyme-linked immunosorbent assay for rapid screening of anti-adeno-associated virus neutralizing antibodies. Ann ClinBiochem. (2009) 46(Pt6):508-510.
[0551] Beattie WG et al., Structure and evolution of human alpha-fetoprotein deduced from partial sequence of cloned cDNA. Gene (1982) 20:415-422.
[0552] Lichenstein et al. Afamin is a new member of the albumin, alpha-fetoprotein, and vitamin D-binding protein gene family. Journal of Biochemistry (1984) 269:18149-18154.
[0553] Cooke NE et al. Serum vitamin D-binding protein is a third member of the albumin and alphafetoprotein gene family. Journal of Clinical Research (1985) 76:2420-2424.
[0554] Mueller DL et al., Clonal expansion versus functional clonal inactivation: acostimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev. Immunol. (1989) 7:445-480.
[0555] Bessis N et al., Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Therapy (2004) 11: S10-S17.
[0556] Jones NH et al., Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1 / Leu-1. Nature (1986) 323:346–349.
[0557] Elgueta R et al., Molecular mechanism and function of CD40 / CD40L engagement in the immune system. Immunology Review (2009) 229(1).
[0558] Clark EA et al., Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proceedings of the National Academy of Sciences (1986) 83(12):4494-8.
[0559] Noelle RJ et al., 39-kDa protein on activated helper T cells binds to CD40 and transduces homologous activation signals in B cells. Proceedings of the National Academy of Sciences (1992) 89(14):6550-4.
[0560] Datta-Mannan A et al., Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. Journal of Biochemistry (2007) 282(3):1709-17.
[0561] Datta-Mannan A et al., FcRn affinity-phacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug Metabolism and Disposition (2012) 40(8) 1545-1555.
[0562] Hinton PR et al., An Engineered Human IgG1 Antibody with Longer Serum Half-Life. Journal of Immunology (2006) 176:346-356.
[0563] Dall'Acqua WF et al., Properties of human IgG1s engineered for enhanced binding to theneonatal Fc receptor (FcRn). Journal of Biochemistry (2006) 281(33):23514-24.
[0564] Zalevsky J et al., Enhanced antibody half-life improves in vivo activity. Nature Biotechnol. (2010) 28(2):157-159.
[0565] Deng R et al., Pharmacokinetics of humanized monoclonal anti-tumornecrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metabolism and Disposal (2010) 38(4):600-5.
[0566] Maeda A et al., Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody. Monoclonal Antibody (MAbs) (2017) 9(5):844-853.
[0567] Ha JH et al., Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins. Frontiers in Immunology (2016) 7:394.
[0568] Wei H et al., Structural basis of a novel heterodimeric Fc for bispecific antibody production. Oncotarget. (2017) 8(31): 51037-51049.
[0569] Atwell S et al. used a phage display library to remodel the domain interface of a homodimer to create stable heterodimers. Journal of Molecular Biology (1997) 270(1):26-35.
[0570] Von Kreudenstein TS et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. Monoclonal Antibodies (2013) 5(5):646-54.
[0571] Gunasekaran K et al., Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. Journal of Biochemistry (2010) 285(25):19637-46.
[0572] Choi HJ et al., A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity. Molecular Cancer Ther. (2013) 12(12):2748-59.
[0573] Klein C et al., Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. Monoclonal Antibodies (2012) 4(6):653-63.
[0574] Xu Z et al., Affinity and Cross-Reactivity Engineering of CTLA4-Ig To Modulate T Cell Costimulation. Journal of Immunology (2012) 189(9) 4470-4477.
[0575] Xu H et al., Nanocarriers in gene therapy: a review. Journal of Biomedical Nanotechnology (2014) 10(12):3483-507.
[0576] Riley MK et al., Recent Advances in Nanomaterials for Gene Delivery—A Review. Nanomaterials (Basel). (2017) 7(5):94. sequence list <110> East China University of Science and Technology <120> Methods and kits for inducing immune tolerance to gene delivery target agents <130> 075580-8004WO01, 075580-8004WO02 <150> PCT / CN2020 / 134283 <151> 2020-12-07 <160> 17 <170> PatentIn version 3.5 <210> 1 <211> 223 <212> PRT <213> Artificial sequence <220> <223> Human CTLA-4 full-length protein sequence with signal peptide <400> 1 Met Ala Cys Leu Gly Phe Gln Arg His Lys Ala Gln Leu Asn Leu Ala 1 5 10 15 Thr Arg Thr Trp Pro Cys Thr Leu Leu Phe Phe Leu Leu Phe Ile Pro 20 25 30 Val Phe Cys Lys Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala 35 40 45 Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly 50 55 60 Lys Ala Thr Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln 65 70 75 80 Val Thr Glu Val Cys Ala Ala Thr Tyr Met Gly Asn Glu Leu Thr 85 90 95 Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val 100 105 110 Asn Leu Thr Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile 115 120 125 Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly 130 135 140 Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser 145 150 155 160 Asp Phe Leu Leu Trp Ile Leu Ala Ala Val Ser Ser Gly Leu Phe Phe 165 170 175 Tyr Ser Phe Leu Leu Thr Ala Val Ser Leu Ser Lys Met Leu Lys Lys 180 185 190 Arg Ser Pro Leu Thr Thr Gly Val Tyr Val Lys Met Pro Pro Thr Glu 195 200 205 Pro Glu Cys Glu Lys Gln Phe Gln Pro Tyr Phe Ile Pro Ile Asn 210 215 220 <210> 2 <211> 134 <212> PRT <213> Artificial sequence <220> <223> Human CD28ECD <400> 2 Asn Lys Ile Leu Val Lys Gln Ser Pro Met Leu Val Ala Tyr Asp Asn 1 5 10 15 Ala Val Asn Leu Ser Cys Lys Tyr Ser Tyr Asn Leu Phe Ser Arg Glu 20 25 30 Phe Arg Ala Ser Leu His Lys Gly Leu Asp Ser Ala Val Glu Val Cys 35 40 45 Val Val Tyr Gly Asn Tyr Ser Gln Gln Leu Gln Val Tyr Ser Lys Thr 50 55 60 Gly Phe Asn Cys Asp Gly Lys Leu Gly Asn Glu Ser Val Thr Phe Tyr 65 70 75 80 Leu Gln Asn Leu Tyr Val Asn Gln Thr Asp Ile Tyr Phe Cys Lys Ile 85 90 95 Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly 100 105 110 Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe 115 120 125 Pro Gly Pro Ser Lys Pro 130 <210> 3 <211> 124 <212> PRT <213> Artificial sequence <220> <223> Human CTLA-4 extracellular domain without signal peptide <400> 3 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr Glu Val 20 25 30 Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr Phe Leu Asp Asp Ser 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val Glu Leu 85 90 95 Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp 115 120 <210> 4 <211> 173 <212> PRT <213> Artificial sequence <220> <223> Human CD40 extracellular domain without signal peptide <400> 4 Glu Pro Pro Thr Ala Cys Arg Glu Lys Gln Tyr Leu Ile Asn Ser Gln 1 5 10 15 Cys Cys Ser Leu Cys Gln Pro Gly Gln Lys Leu Val Ser Asp Cys Thr 20 25 30 Glu Phe Thr Glu Thr Glu Cys Leu Pro Cys Gly Glu Ser Glu Phe Leu 35 40 45 Asp Thr Trp Asn Arg Glu Thr His Cys His Gln His Lys Tyr Cys Asp 50 55 60 Pro Asn Leu Gly Leu Arg Val Gln Gln Lys Gly Thr Ser Glu Thr Asp 65 70 75 80 Thr Ile Cys Thr Cys Glu Glu Gly Trp His Cys Thr Ser Glu Ala Cys 85 90 95 Glu Ser Cys Val Leu His Arg Ser Cys Ser Pro Gly Phe Gly Val Lys 100 105 110 Gln Ile Ala Thr Gly Val Ser Asp Thr Ile Cys Glu Pro Cys Pro Val 115 120 125 Gly Phe Phe Ser Asn Val Ser Ser Ala Phe Glu Lys Cys His Pro Trp 130 135 140 Thr Ser Cys Glu Thr Lys Asp Leu Val Val Gln Gln Ala Gly Thr Asn 145 150 155 160 Lys Thr Asp Val Val Cys Gly Pro Gln Asp Arg Leu Arg 165 170 <210> 5 <211> 232 <212> PRT <213> Artificial sequence <220> <223> Human Fc polypeptide sequence <400> 5 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly Lys 225 230 <210> 6 <211> 35 <212> PRT <213> Artificial sequence <220> <223> Human CTLA-4 signal peptide sequence <400> 6 Met Ala Cys Leu Gly Phe Gln Arg His Lys Ala Gln Leu Asn Leu Ala 1 5 10 15 Thr Arg Thr Trp Pro Cys Thr Leu Leu Phe Phe Leu Leu Phe Ile Pro 20 25 30 Val Phe Cys 35 <210> 7 <211> 20 <212> PRT <213> Artificial sequence <220> <223> Human CD-40 signal peptide sequence <400> 7 Met Val Arg Leu Pro Leu Gln Cys Val Leu Trp Gly Cys Leu Leu Thr 1 5 10 15 Ala Val His Pro 20 <210> 8 <211> 397 <212> PRT <213> Artificial sequence <220> <223> The full-length mouse CTLA4-Ig sequence containing the signal peptide <400> 8 Met Ala Cys Leu Gly Leu Arg Arg Tyr Lys Ala Gln Leu Gln Leu Pro 1 5 10 15 Ser Arg Thr Trp Pro Phe Val Ala Leu Leu Thr Leu Leu Phe Ile Pro 20 25 30 Val Phe Ser Glu Ala Ile Gln Val Thr Gln Pro Ser Val Val Leu Ala 35 40 45 Ser Ser His Gly Val Ala Ser Phe Pro Cys Glu Tyr Ser Pro Ser His 50 55 60 Asn Thr Asp Glu Val Arg Val Thr Val Leu Arg Gln Thr Asn Asp Gln 65 70 75 80 Met Thr Glu Val Cys Ala Thr Thr Phe Thr Glu Lys Asn Thr Val Gly 85 90 95 Phe Leu Asp Tyr Pro Phe Cys Ser Gly Thr Phe Asn Glu Ser Arg Val 100 105 110 Asn Leu Thr Ile Gln Gly Leu Arg Ala Val Asp Thr Gly Leu Tyr Leu 115 120 125 Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Phe Val Gly Met Gly 130 135 140 Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser 145 150 155 160 Asp Leu Ile Ser Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro 165 170 175 Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile 180 185 190 Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile 195 200 205 Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln 210 215 220 Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln 225 230 235 240 Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu 245 250 255 Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys 260 265 270 Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys 275 280 285 Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro 290 295 300 Gln Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr 305 310 315 320 Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys 325 330 335 Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly 340 345 350 Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val 355 360 365 Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn 370 375 380 His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys 385 390 395 <210> 9 <211> 422 <212> PRT <213> Artificial sequence <220> <223> Full sequence of mouse CD40-Ig with signal peptide <400> 9 Met Val Ser Leu Pro Arg Leu Cys Ala Leu Trp Gly Cys Leu Leu Thr 1 5 10 15 Ala Val His Leu Gly Gln Cys Val Thr Cys Ile Asp Lys Gln Tyr Leu 20 25 30 His Asp Gly Gln Cys Cys Asp Leu Cys Gln Pro Gly Ser Arg Leu Thr 35 40 45 Ser His Cys Thr Ala Leu Glu Lys Thr Gln Cys His Pro Cys Asp Ser 50 55 60 Gly Glu Phe Ser Ala Gln Trp Asn Arg Glu Ile Arg Cys His Gln His 65 70 75 80 Arg His Cys Glu Pro Asn Gln Gly Leu Arg Val Lys Lys Glu Gly Thr 85 90 95 Ala Glu Ser Asp Thr Val Cys Thr Cys Lys Glu Gly Gln His Cys Thr 100 105 110 Ser Lys Asp Cys Glu Ala Cys Ala Gln His Thr Pro Cys Ile Pro Gly 115 120 125 Phe Gly Val Met Glu Met Ala Thr Glu Thr Thr Asp Thr Val Cys His 130 135 140 Pro Cys Pro Val Gly Phe Phe Ser Asn Gln Ser Ser Leu Phe Glu Lys 145 150 155 160 Cys Tyr Pro Trp Thr Ser Cys Glu Asp Lys Asn Leu Glu Val Leu Gln 165 170 175 Lys Gly Thr Ser Gln Thr Asn Val Ile Cys Gly Leu Lys Ser Arg Met 180 185 190 Arg Gly Thr Val Pro Arg Asp Cys Gly Cys Glu Pro Cys Ile Cys Thr 195 200 205 Val Pro Glu Val Ser Ser Val Ile Ile Phe Pro Pro Lys Pro Lys Asp 210 215 220 Val Leu Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val Val Asp 225 230 235 240 Ile Ser Lys Asp Asp Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp 245 250 255 Val Glu Val His Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln Leu Asn 260 265 270 Ser Ala Phe Arg Ser Val Gly Glu Leu Pro Ile Met His Gln Asp Trp 275 280 285 Leu Asn Gly Lys Glu Phe Lys Met Gln Gly Gln Gln Cys Ser Phe Pro 290 295 300 Cys Pro His Arg Glu Asn His Leu Pro Thr Pro Gln Lys Pro Lys Ala 305 310 315 320 Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp 325 330 335 Lys Val Ser Leu Thr Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile 340 345 350 Thr Val Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn 355 360 365 Thr Gln Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys 370 375 380 Leu Asn Val Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys 385 390 395 400 Ser Val Leu His Glu Gly Leu His Asn His His Thr Glu Lys Ser Leu 405 410 415 Ser His Ser Pro Gly Lys 420 <210> 10 <211> 26 <212> PRT <213> Artificial sequence <220> <223> Oncogene M signal peptide <400> 10 Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala 1 5 10 15 Leu Leu Phe Pro Ser Met Ala Ser Met Ala 20 25 <210> 11 <211> 126 <212> PRT <213> Artificial sequence <220> <223> Human CTLA-4 extracellular domain without signal peptide <400> 11 Lys Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg 1 5 10 15 Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr 20 25 30 Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu 35 40 45 Val Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr Phe Leu Asp 50 55 60 Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr 65 70 75 80 Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val 85 90 95 Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr 100 105 110 Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp 115 120 125 <210> 12 <211> 223 <212> PRT <213> Artificial sequence <220> <223> Full-length mouse CTLA-4 protein sequence <400> 12 Met Ala Cys Leu Gly Leu Arg Arg Tyr Lys Ala Gln Leu Gln Leu Pro 1 5 10 15 Ser Arg Thr Trp Pro Phe Val Ala Leu Leu Thr Leu Leu Phe Ile Pro 20 25 30 Val Phe Ser Glu Ala Ile Gln Val Thr Gln Pro Ser Val Val Leu Ala 35 40 45 Ser Ser His Gly Val Ala Ser Phe Pro Cys Glu Tyr Ser Pro Ser His 50 55 60 Asn Thr Asp Glu Val Arg Val Thr Val Leu Arg Gln Thr Asn Asp Gln 65 70 75 80 Met Thr Glu Val Cys Ala Thr Thr Phe Thr Glu Lys Asn Thr Val Gly 85 90 95 Phe Leu Asp Tyr Pro Phe Cys Ser Gly Thr Phe Asn Glu Ser Arg Val 100 105 110 Asn Leu Thr Ile Gln Gly Leu Arg Ala Val Asp Thr Gly Leu Tyr Leu 115 120 125 Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Phe Val Gly Met Gly 130 135 140 Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser 145 150 155 160 Asp Phe Leu Leu Trp Ile Leu Val Ala Val Ser Leu Gly Leu Phe Phe 165 170 175 Tyr Ser Phe Leu Val Ser Ala Val Ser Leu Ser Lys Met Leu Lys Lys 180 185 190 Arg Ser Pro Leu Thr Thr Gly Val Tyr Val Lys Met Pro Pro Thr Glu 195 200 205 Pro Glu Cys Glu Lys Gln Phe Gln Pro Tyr Phe Ile Pro Ile Asn 210 215 220 <210> 13 <211> 126 <212> PRT <213> Artificial sequence <220> <223> mouse CTLA-4 extracellular domain <400> 13 Glu Ala Ile Gln Val Thr Gln Pro Ser Val Val Leu Ala Ser Ser His 1 5 10 15 Gly Val Ala Ser Phe Pro Cys Glu Tyr Ser Pro Ser His Asn Thr Asp 20 25 30 Glu Val Arg Val Thr Val Leu Arg Gln Thr Asn Asn Asp Gln Met Thr Glu 35 40 45 Val Cys Ala Thr Thr Phe Thr Glu Lys Asn Thr Val Gly Phe Leu Asp 50 55 60 Tyr Pro Phe Cys Ser Gly Thr Phe Asn Glu Ser Arg Val Asn Leu Thr 65 70 75 80 Ile Gln Gly Leu Arg Ala Val Asp Thr Gly Leu Tyr Leu Cys Lys Val 85 90 95 Glu Leu Met Tyr Pro Pro Pro Tyr Phe Val Gly Met Gly Asn Gly Thr 100 105 110 Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp 115 120 125 <210> 14 <211> 174 <212> PRT <213> Artificial sequence <220> <223> mouse CD40 extracellular domain <400> 14 Leu Gly Gln Cys Val Thr Cys Ser Asp Lys Gln Tyr Leu His Asp Gly 1 5 10 15 Gln Cys Cys Asp Leu Cys Gln Pro Gly Ser Arg Leu Thr Ser His Cys 20 25 30 Thr Ala Leu Glu Lys Thr Gln Cys His Pro Cys Asp Ser Gly Glu Phe 35 40 45 Ser Ala Gln Trp Asn Arg Glu Ile Arg Cys His Gln His Arg His Cys 50 55 60 Glu Pro Asn Gln Gly Leu Arg Val Lys Lys Glu Gly Thr Ala Glu Ser 65 70 75 80 Asp Thr Val Cys Thr Cys Lys Glu Gly Gln His Cys Thr Ser Lys Asp 85 90 95 Cys Glu Ala Cys Ala Gln His Thr Pro Cys Ile Pro Gly Phe Gly Val 100 105 110 Met Glu Met Ala Thr Glu Thr Thr Asp Thr Val Cys His Pro Cys Pro 115 120 125 Val Gly Phe Phe Ser Asn Gln Ser Ser Leu Phe Glu Lys Cys Tyr Pro 130 135 140 Trp Thr Ser Cys Glu Asp Lys Asn Leu Glu Val Leu Gln Lys Gly Thr 145 150 155 160 Ser Gln Thr Asn Val Ile Cys Gly Leu Lys Ser Arg Met Arg 165 170 <210> 15 <211> 188 <212> PRT <213> Artificial sequence <220> <223> Human CTLA-4 full-length protein sequence without signal peptide <400> 15 Lys Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg 1 5 10 15 Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr 20 25 30 Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu 35 40 45 Val Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr Phe Leu Asp 50 55 60 Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr 65 70 75 80 Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val 85 90 95 Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr 100 105 110 Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp Phe Leu 115 120 125 Leu Trp Ile Leu Ala Ala Val Ser Ser Gly Leu Phe Phe Tyr Ser Phe 130 135 140 Leu Leu Thr Ala Val Ser Leu Ser Lys Met Leu Lys Lys Arg Ser Pro 145 150 155 160 Leu Thr Thr Gly Val Tyr Val Lys Met Pro Pro Thr Glu Pro Glu Cys 165 170 175 Glu Lys Gln Phe Gln Pro Tyr Phe Ile Pro Ile Asn 180 185 <210> 16 <211> 277 <212> PRT <213> Artificial sequence <220> <223> Human CD40 full-length protein sequence with signal peptide <400> 16 Met Val Arg Leu Pro Leu Gln Cys Val Leu Trp Gly Cys Leu Leu Thr 1 5 10 15 Ala Val His Pro Glu Pro Pro Thr Ala Cys Arg Glu Lys Gln Tyr Leu 20 25 30 Ile Asn Ser Gln Cys Cys Ser Leu Cys Gln Pro Gly Gln Lys Leu Val 35 40 45 Ser Asp Cys Thr Glu Phe Thr Glu Thr Glu Cys Leu Pro Cys Gly Glu 50 55 60 Ser Glu Phe Leu Asp Thr Trp Asn Arg Glu Thr His Cys His Gln His 65 70 75 80 Lys Tyr Cys Asp Pro Asn Leu Gly Leu Arg Val Gln Gln Lys Gly Thr 85 90 95 Ser Glu Thr Asp Thr Ile Cys Thr Cys Glu Glu Gly Trp His Cys Thr 100 105 110 Ser Glu Ala Cys Glu Ser Cys Val Leu His Arg Ser Cys Ser Pro Gly 115 120 125 Phe Gly Val Lys Gln Ile Ala Thr Gly Val Ser Asp Thr Ile Cys Glu 130 135 140 Pro Cys Pro Val Gly Phe Phe Ser Asn Val Ser Ser Ala Phe Glu Lys 145 150 155 160 Cys His Pro Trp Thr Ser Cys Glu Thr Lys Asp Leu Val Val Gln Gln 165 170 175 Ala Gly Thr Asn Lys Thr Asp Val Val Cys Gly Pro Gln Asp Arg Leu 180 185 190 Arg Ala Leu Val Val Ile Pro Ile Ile Phe Gly Ile Leu Phe Ala Ile 195 200 205 Leu Leu Val Leu Val Phe Ile Lys Lys Val Ala Lys Lys Pro Thr Asn 210 215 220 Lys Ala Pro His Pro Lys Gln Glu Pro Gln Glu Ile Asn Phe Pro Asp 225 230 235 240 Asp Leu Pro Gly Ser Asn Thr Ala Ala Pro Val Gln Glu Thr Leu His 245 250 255 Gly Cys Gln Pro Val Thr Gln Glu Asp Gly Lys Glu Ser Arg Ile Ser 260 265 270 Val Gln Glu Arg Gln 275 <210> 17 <211> 257 <212> PRT <213> Artificial sequence <220> <223> Human CD40 full-length protein sequence with signal peptide <400> 17 Glu Pro Pro Thr Ala Cys Arg Glu Lys Gln Tyr Leu Ile Asn Ser Gln 1 5 10 15 Cys Cys Ser Leu Cys Gln Pro Gly Gln Lys Leu Val Ser Asp Cys Thr 20 25 30 Glu Phe Thr Glu Thr Glu Cys Leu Pro Cys Gly Glu Ser Glu Phe Leu 35 40 45 Asp Thr Trp Asn Arg Glu Thr His Cys His Gln His Lys Tyr Cys Asp 50 55 60 Pro Asn Leu Gly Leu Arg Val Gln Gln Lys Gly Thr Ser Glu Thr Asp 65 70 75 80 Thr Ile Cys Thr Cys Glu Glu Gly Trp His Cys Thr Ser Glu Ala Cys 85 90 95 Glu Ser Cys Val Leu His Arg Ser Cys Ser Pro Gly Phe Gly Val Lys 100 105 110 Gln Ile Ala Thr Gly Val Ser Asp Thr Ile Cys Glu Pro Cys Pro Val 115 120 125 Gly Phe Phe Ser Asn Val Ser Ser Ala Phe Glu Lys Cys His Pro Trp 130 135 140 Thr Ser Cys Glu Thr Lys Asp Leu Val Val Gln Gln Ala Gly Thr Asn 145 150 155 160 Lys Thr Asp Val Val Cys Gly Pro Gln Asp Arg Leu Arg Ala Leu Val 165 170 175 Val Ile Pro Ile Ile Phe Gly Ile Leu Phe Ala Ile Leu Leu Val Leu 180 185 190 Val Phe Ile Lys Lys Val Ala Lys Lys Pro Thr Asn Lys Ala Pro His 195 200 205 Pro Lys Gln Glu Pro Gln Glu Ile Asn Phe Pro Asp Asp Leu Pro Gly 210 215 220 Ser Asn Thr Ala Ala Pro Val Gln Glu Thr Leu His Gly Cys Gln Pro 225 230 235 240 Val Thr Gln Glu Asp Gly Lys Glu Ser Arg Ile Ser Val Gln Glu Arg 245 250 255 Gln
Claims
1. Use of immunogenicity inducer mediators in the preparation of medicaments for inducing immune tolerance to immunogenic target mediators used for gene delivery in subjects, wherein: The inducer medium comprises an AAV8 vector encoding a CTLA-4 derivative, and the target medium is an AAV8 vector encoding a target gene. The CTLA-4 derivative comprises: an extracellular domain of CTLA-4, or a fragment of the extracellular domain capable of binding to at least one of CD80(B7-1) or CD86(B7-2). The drug is administered to the subject prior to the administration of the target agent to induce immune tolerance to the target agent.
2. Use according to claim 1, wherein, The inducing agent also includes an AAV8 carrier encoding a CD40 derivative.
3. Use according to claim 2, wherein, The CTLA-4 derivative and the CD40 derivative function by downregulating the immune stimulation pathway and / or by upregulating the immunosuppressive pathway.
4. Use according to claim 3, wherein, The CTLA-4 derivative downregulates the B7-CD28 immune stimulation pathway, and the CD40 derivative downregulates the CD40 and CD40L immune stimulation pathways.
5. The use according to claim 2, wherein, The CD40 derivative includes: the extracellular domain of CD40, or a fragment of the extracellular domain that can bind to CD40L (CD154).
6. The use according to claim 1, wherein, The CTLA-4 derivative further includes a half-life-extending peptide moiety.
7. The use according to claim 2, wherein, The CD40 derivative further includes a half-life-extending peptide moiety.
8. Use according to claim 6 or 7, wherein, The half-life-extending peptide moiety includes Fc.
9. The use according to claim 1, wherein, The subject did not have a pre-existing immune response to the inducer and / or the target agent.
10. The use according to claim 1, wherein, The immune tolerance is characterized in that, after administration of the inducer mediator to the subject, the antibody titer of the anti-AAV8 antibody in the subject's serum does not exceed 200, and wherein the antibody titer is defined as the dilution factor by which the subject's serum produces threshold-specific binding to the inducer mediator or the target mediator.
11. The use according to claim 1, wherein, The immune tolerance is characterized in that, after administration of the inducer mediator to the subject, the antibody titer of neutralizing antibodies in the subject's serum does not exceed 32, and wherein the antibody titer is defined as the dilution factor by which the subject's serum produces a maximum neutralization of 50% of the inducer mediator or the target mediator.
12. A kit for inducing immune tolerance in subjects to an immunogenic target agent, the kit comprising: A first pharmaceutical composition comprising a therapeutically effective amount of an inducer mediator, the inducer mediator comprising an AAV8 carrier encoding a CTLA-4 derivative, the CTLA-4 derivative comprising: an extracellular domain of CTLA-4, or a fragment of the extracellular domain capable of binding to at least one of CD80 (B7-1) or CD86 (B7-2); A second pharmaceutical composition comprising a therapeutically effective amount of the target agent, wherein the target agent is an AAV8 vector encoding a target gene.
13. The kit of claim 12, wherein, The inducing agent also includes an AAV8 carrier encoding a CD40 derivative.
14. The kit of claim 13, wherein, The CD40 derivatives include the extracellular domain of CD40 or a fragment thereof capable of binding to CD40L (CD154).
15. The kit of claim 12, wherein, The CTLA-4 derivative further includes a half-life-extending peptide moiety.
16. The kit of claim 13, wherein, The CD40 derivative further includes a half-life-extending peptide moiety.
17. The kit of claim 15 or 16, wherein, The half-life-extending peptide moiety includes Fc.
18. The kit according to claim 12 or 13, further comprising a first instruction manual for administering the first pharmaceutical composition to the subject.
19. The kit according to claim 12 or 13, further comprising a first detection kit for determining whether immune tolerance is induced in the subject after administration of the first pharmaceutical composition to the subject.
20. The kit of claim 12 or 13, further comprising a second detection kit, wherein the second detection kit comprises at least one second reagent configured to allow detection of the expression of the CTLA-4 derivative in the subject.
21. The kit of claim 18, further comprising a second instruction for administering the second pharmaceutical composition to the subject, wherein the second instruction further comprises a first sub-instruction for administering the second pharmaceutical composition to the subject after administering the first pharmaceutical composition.
22. The kit of claim 21, wherein the second instruction further comprises a second sub-instruction for repeated administration of the second pharmaceutical composition.
23. The kit according to claim 12 or 13, further comprising a third detection kit, wherein the third detection kit comprises at least one third reagent configured to allow detection of the expression of the target gene in the subject.
Citation Information
Patent Citations
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10266850B2
Efficient purification of adenovirus
US20020034735A1
Apoptosis-mimicking synthetic entities and use thereof in medical treatment
US20020086049A1
Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods
US20020168342A1
Soluble CTLA4 mutant molecules and uses thereof
US20030219863A1
